Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Initiated ART in Early HIV Infection After Having Received VRC01 or Placebo in HVTN 703/HPTN 081
Phase: NA
Conditions: HIV Infection
Sponsor: HIV Vaccine Trials Network

  
PROTOCOL 
HVTN 805/HPTN 093 
Antiretroviral analytical treatment interruption (ATI) to 
assess immunologic and virologic responses in 
participants who initiated ART in early HIV infection 
after having received VRC01 or placebo in HVTN 
703/HPTN 081 
DAIDS DOCUMENT ID 38691 
Non-IND Protocol 
CLINICAL TRIAL SPONSORED BY 
Division of AIDS (DAIDS) 
National Institute of Allergy and Infectious Diseases (NIAID) 
National Institutes of Health (NIH) 
Department of Health and Human Services (DHHS) 
Bethesda, Maryland, USA 
April 27, 2020 
HVTN 805/HPTN 093 
Version 1.0 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 2 of 153 
Contents 
1 Protocol summary ..........................................................................................................4 
1.1 
Précis ..............................................................................................................6 
1.2 
Schema ...........................................................................................................7 
1.3 
Protocol team ..................................................................................................8 
2 Background and rationale ............................................................................................10 
2.1 
Antiretroviral therapy ...................................................................................10 
2.2 
Early ART initiation is associated with delayed time to rebound and post-
treatment control ..........................................................................................10 
2.3 
Broadly neutralizing antibodies (bnAbs) .....................................................15 
2.4 
Antiretroviral analytical treatment interruption (ATI) .................................26 
2.5 
An AMP ATI ................................................................................................33 
2.6 
Ethical considerations ..................................................................................34 
2.7 
Feasibility .....................................................................................................35 
2.8 
Conclusion ....................................................................................................37 
3 Study design .................................................................................................................38 
3.1 
Hypotheses ...................................................................................................38 
3.2 
Objectives and endpoints .............................................................................38 
3.3 
ATI ...............................................................................................................41 
4 Statistical considerations ..............................................................................................45 
4.1 
Estimated accrual .........................................................................................45 
4.2 
Statistical analyses ........................................................................................46 
5 Study population ..........................................................................................................51 
5.1 
Inclusion criteria ...........................................................................................51 
5.2 
Exclusion criteria ..........................................................................................53 
5.3 
Criteria for participant early termination......................................................55 
5.4 
Study termination .........................................................................................56 
6 Study procedures ..........................................................................................................57 
6.1 
Schedule 1: Monitoring ATI ........................................................................57 
6.2 
Schedule 2: Monitoring ATI with viremia ...................................................62 
6.3 
Schedule 3: Follow-up on ART ...................................................................63 
6.4 
Interim visits .................................................................................................64 
6.5 
Early termination visit ..................................................................................65 
6.6 
Contraception status .....................................................................................65 
6.7 
Specific clinical management considerations ..............................................66 
7 Study products .............................................................................................................67 
8 Laboratory ....................................................................................................................68 
8.1 
CRS laboratory procedures ..........................................................................68 
8.2 
Assay timepoints ..........................................................................................68 
8.3 
Endpoint assays: cellular ..............................................................................68 
8.4 
Phenotyping of cell populations ...................................................................69 
8.5 
Endpoint assays: humoral .............................................................................69 
8.6 
HIV viral reservoir .......................................................................................69 
8.7 
Host genomics ..............................................................................................70 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 3 of 153 
8.8 
HIV antiretroviral resistance testing.............................................................70 
8.9 
ARV detection ..............................................................................................70 
8.10 Biohazard containment .................................................................................70 
9 Research use of stored human samples and/or data .....................................................71 
9.1 
Specimen storage and other use of specimens .............................................71 
9.2 
Exploratory studies .......................................................................................71 
10 Potential risks and benefits ..........................................................................................72 
10.1 Potential risks ...............................................................................................72 
10.2 Potential benefits ..........................................................................................72 
11 Monitoring of safety ....................................................................................................73 
11.1 Safety monitoring and oversight ..................................................................73 
11.2 Safety reporting ............................................................................................75 
12 Ethics/protection of human subjects ............................................................................77 
12.1 Informed consent process .............................................................................77 
12.2 Participant confidentiality ............................................................................78 
13 Protocol conduct ..........................................................................................................79 
13.1 Emergency communication with study participants ....................................80 
14 Acronyms and abbreviations........................................................................................81 
15 Protocol version history ...............................................................................................83 
16 Document references (other than literature citations) ..................................................84 
17 References ....................................................................................................................86 
Appendix A Sample informed consent form ....................................................................97 
Appendix B Approved birth control methods (for sample informed consent form) ......120 
Appendix C Sample consent form for use of samples and information in other studies 121 
Appendix D Tables of procedures for sample informed consent form ...........................126 
Appendix E Laboratory procedures—Schedule 1: Monitoring ATI ..............................131 
Appendix F Laboratory procedures—Schedule 2: Monitoring ATI with viremia .........135 
Appendix G Laboratory procedures—Schedule 3: Follow-up on ART .........................139 
Appendix H Procedures at CRS—Schedule 1: Monitoring ATI ....................................141 
Appendix I Procedures at CRS—Schedule 2: Monitoring ATI with viremia ...............145 
Appendix J Procedures at CRS—Schedule 3: Follow-up on ART ...............................147 
Appendix K Visit Windows ............................................................................................148 
Appendix L Protocol Signature Page .............................................................................153 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 4 of 153 
1 
Protocol summary 
Full title: 
Antiretroviral analytical treatment interruption (ATI) to 
assess immunologic and virologic responses in participants 
who initiated ART in early HIV infection after having 
received VRC01 or placebo in HVTN 703/HPTN 081 
Short title: 
HVTN 805/HPTN 093  
Sponsor: 
NIAID Division of AIDS 
Conducted by: 
HIV Vaccine Trials Network (HVTN) and HIV Prevention 
Trials Network (HPTN) 
Protocol chairs: 
Shelly Karuna, MD, MPH; Katharine Bar, MD; Simba 
Takuva, MBChB, MSc 
Sample size: 
16 - 61 
Study population: 
HVTN 703/HPTN 081 participants living with HIV who 
met criteria for transition to Schedule 2 or Schedule 3 in 
that trial  
Study design: 
An exploratory study of participants living with HIV 
undergoing an analytical treatment interruption after early 
initiation of antiretroviral therapy (ART) following HIV 
acquisition in HVTN 703/HPTN 081, where they received 
VRC01 or placebo infusions 
Study duration: 
Study duration is potentially indefinite for a participant 
maintaining extended viral control during ATI. Study 
duration for most participants is expected to be 13-18 
months. The maximum anticipated duration for any 
participant is expected to be approximately 2½ to 3 years.  
Study products: 
None. Drugs for ART and for pre-exposure prophylaxis 
(PrEP) will not be provided by the study or paid for using 
sponsor funds. Access to external funding sources for PrEP 
and ART provision is available and is detailed in the 
HVTN 805/HPTN 093 Study Specific Procedures (SSP). 
Primary hypotheses: Individuals who initiated ART early in HIV infection in 
HVTN 703/HPTN 081 will suppress plasma viremia and 
maintain CD4+ T-cell counts longer during ATI than 
historical cohorts (ie, SPARTAC African and non-African 
cohorts described in Gossez et al (1) comprising individuals 
who initiated ART early in HIV infection without other 
interventions). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 5 of 153 
Individuals who initiated ART early in HIV infection and 
also received VRC01 within 8 weeks before or after 
acquiring HIV in HVTN 703/HPTN 081 will suppress 
plasma viremia and maintain CD4+ T-cell counts longer 
during ATI than those who initiated ART early in HIV 
infection and received placebo within 8 weeks before or 
after acquiring HIV in HVTN 703/HPTN 081. 
ATI will be safe and well-tolerated in individuals who 
acquired HIV during their participation in HVTN 
703/HPTN 081. 
Primary objectives: 
To evaluate the effect of early ART initiation, with or 
without having received VRC01 in the immediate pre-HIV 
acquisition period and/or during early infection, on the time 
to meeting ART re-initiation criteria in participants 
undergoing ATI 
To evaluate the safety of ATI among HVTN 805/HPTN 
093 participants 
Secondary hypotheses: Individuals who initiated ART early in HIV infection and 
also received VRC01 within 8 weeks before or after 
acquiring HIV in HVTN 703/HPTN 081 will have 
enhanced cellular and humoral responses compared with 
those who initiated ART early in HIV infection and 
received placebo within 8 weeks of acquiring HIV in 
HVTN 703/HPTN 081. 
Individuals who initiated ART early in HIV infection and 
also received VRC01 within 8 weeks before or after 
acquiring HIV in HVTN 703/HPTN 081 will have more 
limited viral reservoirs, before and after ATI, than those 
who initiated ART early in HIV infection and received 
placebo within 8 weeks of acquiring HIV in HVTN 
703/HPTN 081. 
Secondary objectives: To evaluate the effect of early ART initiation, with or 
without having received VRC01 in the immediate pre-HIV 
acquisition period and/or during early infection, on the 
development of anti-HIV immune responses and on the 
potential association of those immune responses with time 
to meeting criteria for ART re-initiation in participants 
undergoing ATI 
To evaluate the effect of early ART initiation, with or 
without having received VRC01 in the immediate pre-HIV 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 6 of 153 
acquisition period and/or during early infection, on viral 
load in participants undergoing ATI 
To evaluate the effect of early ART initiation, with or 
without having received VRC01 in the immediate pre-HIV 
acquisition period and/or during early infection, on HIV 
reservoir size before and after ATI, and whether HIV 
reservoir measurements are associated with time to meeting 
criteria for ART re-initiation in participants undergoing 
ATI 
1.1 
Précis 
While plasma viremia rebounds rapidly in most chronically HIV-infected 
individuals upon cessation of therapy, early initiation of ART after HIV diagnosis 
has been associated with later ART-free virologic control in individuals known as 
“post-treatment controllers” (PTCs). Similarly, preclinical (eg, murine, nonhuman 
primate [NHP]) and clinical evidence suggest that the presence of broadly 
neutralizing anti-HIV-1 antibodies (bnAbs), even at a concentration, or with a 
neutralization sensitivity profile, insufficient to prevent HIV acquisition, may 
nevertheless modulate the autologous response to HIV infection in ways that help 
set the stage for later durable virologic control. There is also evidence suggesting 
that early ART initiation and the presence of bnAbs at the time of or soon after 
HIV infection may be capable of limiting the establishment of and decreasing the 
size of viral reservoirs. Whether and how these effects might act together to 
support durable viral control, and what biomarkers may predict such control, is 
unknown. 
The Antibody Mediated Prevention (AMP) studies HVTN 704/HPTN 085 and 
HVTN 703/HPTN 081, phase 2b studies assessing the ability of the CD4 binding 
site bnAb VRC01 to prevent HIV-1 infection, provide a unique opportunity to 
assess the impact of these hypothesized effects. The AMP studies currently have 
the only cohort of HIV-1–infected individuals who were diagnosed soon after 
acquisition, who initiated ART relatively soon after diagnosis, and a subset of 
whom had bnAb present at or near the time of infection. A pause in antiretroviral 
treatment—that is, an ATI—is the only way to determine whether early ART 
initiation with and without VRC01 circulating around the time of HIV acquisition, 
results in blunted, delayed, or absent viral rebound following discontinuation of 
ART, or subsequent immune control of any rebound that may be observed. If such 
an impact is observed, ATI is also the best means of assessing mechanisms and 
identifying predictive biomarkers of that impact through assessment of innate, 
cellular, and humoral markers along with characterization of the viral reservoir. 
Extensive virologic, immunologic, and safety monitoring will be conducted, and 
the trial has been formulated for consistency with recent consensus guidelines on 
the design and conduct of ATI studies (2, 3), particularly with respect to risk 
mitigation. 
The study schema is shown below. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 7 of 153 
1.2 
Schema 
 
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 8 of 153 
1.3 
Protocol team 
Protocol leadership 
Co-chairs 
Shelly Karuna 
HVTN Core, Fred Hutch 
206-667-4355 
skaruna@fredhutch.org 
Medical officers 
Randall Tressler 
DAIDS Therapeutics Research 
Program 
240-627-3072 
randall.tressler@nih.gov 
 
Katharine Bar 
Univ. of Pennsylvania 
215-573-8497 
bark@pennmedicine.upenn.edu 
 
David Burns 
DAIDS Prevention Sciences 
Program (PSP), NIAID 
301-435-8896 
burnsda@niaid.nih.gov 
 
Simba Takuva 
HVTN Core, Fred Hutch 
011-989-9754 
stakuva@hcrisa.org.za 
 
Margarita Gomez Lorenzo 
DAIDS Vaccine Research 
Program (VRP), NIAID 
240-627-3510 
gomezmm@niaid.nih.gov 
Protocol Team 
leaders 
Shelly Karuna 
HVTN Core, Fred Hutch 
206-667-4355 
skaruna@fredhutch.org 
Laboratory leads 
John Hural 
HVTN Laboratory Program, 
Fred Hutch 
206-667-1683 
jhural@fredhutch.org 
 
Phil Andrew 
HPTN LOC, FHI 360 
919.544.7040 x11213 
pandrew@fhi360.org 
 
 
Estelle Piwowar-Manning  
HPTN Laboratory Center 
Johns Hopkins University 
410-614-6736 
epiwowa@jhmi.edu 
Statistician 
Allan DeCamp 
SCHARP, Fred Hutch 
206-667-7892 
adecamp@scharp.org 
 
 
Other contributors  
Core medical 
monitor 
Shelly Karuna 
HVTN Core, Fred Hutch 
HVTN Regional 
medical liaison, 
Africa 
Simba Takuva 
HVTN Core, Fred Hutch 
Consulting 
investigators 
Tae-Wook Chun 
NIAID Laboratory of 
Immunoregulation 
HVTN Clinical safety 
specialist 
Maija Anderson 
HVTN Core, Fred Hutch 
 
Lucio Gama 
NIAID Vaccine Research Center 
HVTN Social/ 
behavioral scientist 
Michele Andrasik 
HVTN Core, Fred Hutch 
 
Catherine Orrell 
Desmond Tutu HIV Centre, 
Cape Town, South Africa 
HVTN Clinical trials 
manager 
Carissa Karg 
HVTN Core, Fred Hutch 
 
Nyaradzo Mgodi 
UZ-UCSF Collaborative 
Research Programme 
Harare, Zimbabwe 
HPTN Clinical 
research manager 
Phil Andrew 
HPTN LOC, FHI 360 
HVTN Laboratory 
representative 
Lisa Sanders 
HVTN Laboratory Program, 
Fred Hutch 
Statistical research 
associates 
Erika Rudnicki 
SCHARP, Fred Hutch 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 9 of 153 
HPTN Laboratory 
representative 
Vanessa Cummings 
HPTN Laboratory Center 
Johns Hopkins University 
 
Chenchen Yu  
SCHARP, Fred Hutch 
Regulatory affairs 
associate 
Megan Brandon 
HVTN Core, Fred Hutch 
Clinical data 
manager 
Alison Ayres 
SCHARP, Fred Hutch 
Clinic 
coordinators 
Nitesha Jeenarain 
South Africa MRC Chatsworth 
CRS 
Durban, South Africa  
SDMC Associate 
director of lab 
science 
April Randhawa 
SCHARP, Fred Hutch 
 
TBD 
Protocol 
development 
manager 
Carter Bentley 
HVTN Core, Fred Hutch 
Community 
Advisory Board 
(CAB) members 
Angy Peter 
Groote Schuur CAB 
Cape Town, South Africa 
HVTN Community 
engagement unit 
representatives 
Gail Broder  
HVTN Core, Fred Hutch 
 
Maximina Jokonya 
University of Zimbabwe College 
of Health Sciences Clinical 
Trials Research Center 
(UZCHS-CTRC) CAB 
Harare, Zimbabwe 
 
Kagisho Baepanye 
HVTN Core 
Johannesburg, South Africa 
Prevention 
research specialist 
Michelle Robinson 
HPTN LOC, FHI 360 
HPTN Community 
program associate 
Jonathan Lucas 
HPTN LOC, FHI 360 
Ethics 
representative 
Ames Dhai 
University of the Witwatersrand, 
Johannesburg, South Africa  
Community 
educator/recruiters 
Charles Chasakara 
University of Zimbabwe College 
of Health Sciences Clinical Trials 
Research Center (UZCHS-CTRC)  
Harare, Zimbabwe 
 
 
 
Ivy Kaunda 
CAPRISA-eThekwini 
Durban, South Africa 
 
 
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 10 of 153 
2 
Background and rationale 
2.1 
Antiretroviral therapy 
Antiretroviral therapy (ART) can now achieve prolonged suppression of plasma 
viremia in most HIV-infected individuals. Consequently, ART has dramatically 
improved the mortality, morbidity, quality of life, and overall clinical course of 
infected individuals. However, clinically successful suppression of HIV comes at 
a cost; long-term toxicity, drug-drug interactions, stigma, drug resistance, 
adherence challenges, and pill fatigue necessitate a continued search for effective 
alternatives for achieving durable control of HIV replication in infected 
individuals. Furthermore, ART alone has been unable to completely eradicate 
HIV; plasma viremia rebounds rapidly with reactivation of persistent viral 
reservoirs in almost all chronically HIV-infected individuals upon cessation of 
therapy (4-7). Persistence of HIV reservoirs, even with successful suppression of 
plasma viremia by ART, is a major obstacle to HIV eradication.  
Thus, one of the highest priorities for the HIV field is the search for therapeutic 
strategies that can eliminate or control HIV replication and reservoirs in the 
absence of ART. Early initiation of ART after HIV diagnosis has been associated 
with later ART-free virologic control in individuals known as “post-treatment 
controllers” (PTCs). Another potential strategy is to harness the immune system 
of people living with HIV to increase their ability to control HIV off ART; 
broadly neutralizing monoclonal antibodies (bnAbs) against HIV, present at the 
time of HIV acquisition, may help increase the immune system’s capacity to 
contribute to ART-free control. 
2.2 
Early ART initiation is associated with delayed time to rebound and 
post-treatment control 
There is a substantial body of evidence suggesting early initiation of ART is 
associated with both delayed time to rebound after ATI and durable post-
treatment control. PTCs are generally considered to be individuals who, after 
maintaining some period of viral suppression on ART, stop ART and maintain 
virologic control for a prolonged period of time, generally more than 6 to 12 
months. Investigators are also interested in shorter durations of virus suppression, 
which are captured by studies comparing time to rebound in the immediate weeks 
to months after treatment interruption. It is unclear to what degree durable post-
treatment control and more transient periods of delayed time to rebound are 
related mechanistically, but both phenomena are enriched in people living with 
HIV with early ART initiation. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 11 of 153 
2.2.1 
Delayed time to rebound 
Multiple clinical trials have shown that individuals with ART initiation during 
early infection (generally after antibody seroconversion but within ~6 months of 
infection, or Fiebig stages III-V), and to a lesser degree, during acute infection 
(generally pre-antibody seroconversion, or Fiebig stages I-II) experience delayed 
viral rebound compared to individuals starting antiretrovirals in chronic infection. 
In a metanalysis of 6 AIDS Clinical Trials Group (ACTG) trials compiling data 
from individuals who underwent ATI without intervention, Jonathan Li and 
colleagues (8) found that participants starting ART during acute infection (n = 32) 
and early infection (n = 48) maintained virus suppression at 12 weeks post-ATI at 
increased rates compared to those with ART initiation during chronic infection 
(n = 155) (9% and 15% vs 3%, respectively, p = 0.01, Fisher’s exact test) (see 
Figure 2-1). As possible mechanisms for the longer time to rebound, the study 
explored issues of size and transcriptional activity of the participants’ viral 
reservoirs. In subset analyses, participants with acute and early ART initiation 
(n = 20) were found to have less transcriptionally active virus reservoirs than 
participants with chronic ART initiation (n = 104) (cell-associated RNA (caRNA) 
levels of 92 vs 156 copies/106 CD4 T cells, p < 0.01, exact Wilcoxon) and a 
statistically non-significant trend toward smaller reservoirs, as measured by total 
HIV DNA. Notably, these 6 ACTG trials enrolled predominantly white men from 
the United States infected with clade B viruses (91% men, 77% Caucasian).  
(b) Threshold: < 200 HIV RNA copies/mL 
(c) Threshold: < 1000 HIV RNA copies/mL 
 
Figure 2-1 Virologic suppression after treatment interruption stratified by timing of ART 
initiation. (b) Cumulative percentage of participants who remained suppressed stratified by 
treatment initiated during acute, early, or chronic HIV infection at the 200 HIV ribonucleic acid 
(RNA) copies/ml and (c) 1000 HIV RNA copies/ml viral rebound thresholds. From (8), Figure 1. 
Several other studies have corroborated the effect of early ART initiation on 
delayed time to rebound. For example, Steingrover et al (9) described results from 
trials of ATI in individuals initiating ART during primary HIV infection (PHI) 
(n = 24) vs chronic HIV infection (CHI) (n = 48). Participants with early ART 
initiation rebounded later than those with chronic ART initiation (median 8 weeks 
vs 4 weeks, with viral rebound thresholds of > 50, > 500, and > 5000 copies/ml) 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 12 of 153 
(Figure 2-2). In the early ART group, 4 participants (17%) maintained virus 
suppression < 50 copies/mL at 48 weeks, while no chronic ART initiators 
maintained suppression. This European trial enrolled largely white men (87% 
men, 76% Western origin) and results are further limited by frequent use of non-
nucleoside reverse transcriptase inhibitor (NNRTI) antiretrovirals with long half-
lives and relatively infrequent sampling.  
 
Figure 2-2 Longitudinal plots of plasma HIV-1 RNA after treatment interruption. (a) The mean 
plasma HIV-1 RNA load plotted against the time in weeks after interruption of HAART (stop) for 
CHI (squares) and PHI (triangles) groups. Error bars represent 95% confidence intervals. Kaplan–
Meier plots showing the different time to plasma viral rebound for CHI and PHI groups. Rebound of 
plasma HIV-1 viral load was defined as a single measurement of plasma HIV-1 RNA above (a) 
5000 copies/ml, (b) 500 copies/ml or (c) 50 copies/ml. Differences between the groups were tested 
using the log rank test. CHI, chronic HIV infection; HAART, highly active antiretroviral therapy; PHI, 
primary HIV infection. From (9), Figure 1. 
As noted above, the literature describing viral kinetics after treatment interruption 
is limited in women and non-Westerners. A recent publication describing 
treatment interruption in the PROMISE trial provides one of the only analyses of 
young, international, post-partum women. Le et al monitored viral kinetics and 
safety after a treatment interruption in 1,076 virally suppressed, post-partum 
women (82% Black/African, 7% White, 7% Asian/Pacific Islander) (10). The vast 
majority of PROMISE participants rebounded early (median 2 weeks post-ATI); 
however, in comparison to the largely male, American cohort described above in 
the ACTG metanalysis (8), the PROMISE cohort had a significantly higher 
proportion of virally suppressed participants at 12 weeks post-ATI (25.4% vs 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 13 of 153 
6.4%, p < 0.0001). A comparison between the PROMISE women and the 
American women in the ACTG study (n = 22) demonstrated a non-significant 
trend in the same direction ( 25.4% vs 13.6%, p = 0.11). Importantly, the ATI was 
well tolerated with very few adverse events. This study is partially limited by 
missing data points, use of longer-lived NNRTI antiretrovirals, and confounding 
immunologic effects of recent pregnancy. This cohort is also missing information 
on timing of ART initiation; however, it highlights the potential role of sex and 
epidemiology (including host genetic, environmental, or virus subtype 
differences) in virologic control post-ATI.  
 
2.2.2 
Post-treatment control  
Evidence is similarly strong that early ART initiation is associated with the 
phenomenon of durable post-treatment control. While post-treatment control has 
been observed at different rates across cohorts, it is consistently more frequent in 
groups of early ART initiators (see Figure 2-3; note that follow-up of participants 
in some of these cohorts continues, hence increases in duration of virologic 
control is expected over time).  
 
Figure 2-3 Estimates of the frequency of post-treatment control and remission. Each 
data point represents an individual study, which has measured the frequency of post-treatment 
control or remission following treatment interruption among individuals who commenced ART 
during primary HIV infection (PHI). Included are analyses of the following studies: CASCADE 
(11, 12), ANRS Primo (13), VISCONTI (14, 15), SPARTAC (16, 17), CHAMP (18), ZHPI (19), 
SeaPIP (20) and NCT01859325 (21). Those which define post-treatment control (here 
considered to be > 24 months following treatment interruption) are colored green, those 
defining remission (> 4 months following treatment interruption) are shown in red. In some 
cases, a study explored both phenotypes; where possible these are disaggregated and listed 
twice, otherwise these are shown as remission. The duration of control is the time between 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 14 of 153 
treatment interruption and viral rebound, or the end of follow-up, and is plotted at the median 
value amongst controllers. The size of the point corresponds to the median duration of ART 
prior to treatment interruption amongst controllers. Where a study did not report either of these 
values, the minimum value for inclusion is used instead. From (22) Figure 1. 
The VISCONTI cohort is one the first and the best characterized groups of PTCs. 
This cohort arose from the French ANRS PRIMO study of early ART initiation, 
which identified 14 of 164 participants (9%) who maintained virus suppression 
after a median of 4.5 years of follow up (13). The 14 PTCs were subsequently 
found to have distinct characteristics from elite controllers (individuals who 
achieve virus control prior to ART initiation), including small but detectable 
latent reservoirs, few protective human leukocyte antigen (HLA) alleles, weak 
HIV-specific CD8+ T-cell responses, and more severe acute retroviral syndromes 
(ARS) (14, 18, 23-25). 
The characteristics of the VISCONTI cohort and participants with delayed time to 
rebound give some hints into the potential mechanisms underlying virus 
suppression post-ATI and why it is more frequent with early ART. In general, 
early ART initiators have smaller, less diverse, and less transcriptionally active 
reservoirs. Further, their immune systems are believed to be better preserved and 
less exhausted. A recent sub-study of the SPARTAC trial has borne out some of 
these hypotheses. 
The SPARTAC trial, which evaluated the impact of immediate vs delayed ART 
initiation after HIV diagnosis in both European and African participants, reported 
a 14% rate of post-treatment control at 1 year (16). Initial analyses suggested that 
smaller reservoirs were associated with PTC, as levels of total HIV-1 DNA prior 
to ART initiation and at ATI were associated with time to rebound. More 
recently, an in-depth analysis of the immunologic characteristics of the European 
(Subtype B virus-infected) SPARTAC PTCs has shown that measures of T-cell 
exhaustion (PD-1, Lag-3, and TIM-3) prior to ART initiation are strongly 
correlated with both levels of total HIV-1 DNA and time to rebound (26). 
Notably, no biomarkers at the time of ATI were identified that correlated with 
time to rebound. These results confirm the importance of smaller reservoirs and 
functional immune systems in post-treatment control, but do not elucidate a 
simple mechanism nor shed light on testing that can be done on ART-suppressed 
individuals to better predict their response to ATI.  
Post-treatment control has continued to be reported in clinical trials and 
observational cohorts. Like the increased frequency of delayed rebound seen in 
African women in the PROMISE study, durable post-treatment control may be 
more common among African women. A recent SPARTAC sub-study revealed 
that the African SPARTAC cohort, all females infected with non-B (primarily C) 
subtypes, was more likely than the non-African SPARTAC cohort to maintain 
virologic control at study end (HR 3.9, 95% CI 1.75-8.81, p < 0.001) (1, 17). 
Further, 5 of 22 (23%) maintained VL <400 copies for the duration of follow up 
(median 4.48 years), while none of the non-African men maintained VL < 400 for 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 15 of 153 
this duration. Of note, this frequency of post-treatment control is greater than any 
others included in the Martin et al analysis shown above in Figure 2-3.  
Gossez and colleagues reported a more in-depth analysis of the controllers, which 
is relevant to this proposal for several reasons (1). First, the cohort of African 
women studied in SPARTAC is similar to the potential participants HVTN 
805/HPTN 093, in that they were young southern African women (91% from 
South Africa, median age of 26 years [interquartile range (IQR) 21- 31.8]), 
infected with predominantly non-clade B viruses (86.5% clade C), with early 
ART initiation (median 15.5 [IQR 13.2-17.7] weeks between seroconversion to 
ART initiation). ATI was safe and well-tolerated in SPARTAC and the prolonged 
ATI experienced by the 5 African women achieving post-treatment control was 
also safe and well tolerated, with CD4 counts remaining high (median 962 cells/ul 
[IQR 840-1028]) and reservoir measures remaining stable (total DNA, median 
3.317 copies/million CD4 T cells [IQR 3.03-3.18]). Three of the 5 post-treatment 
controllers had episodes of transient viremia (ie, viral loads > 400 copies/mL, 
between 560-1690 copies/mL), supporting more permissive ART restart criteria. 
Finally, reservoir and immunologic characterizations were performed, but no 
predictor of delayed rebound or post-treatment control was identified, reinforcing 
the dearth of biomarkers and the current need for ATI to assess whether PTC will 
occur.  
2.3 
Broadly neutralizing antibodies (bnAbs) 
Over the past decade, several bnAbs have been discovered and isolated and their 
HIV-1 target sites and mechanisms of neutralization have been elucidated (27-
34). These efforts have informed the development of recombinant HIV vaccine 
immunogens designed to elicit broadly neutralizing antibodies (31, 35-39) and 
they have set the stage for an evaluation of these antibodies’ potential as tools for 
HIV-1 prevention (ie, passive immunization or antibody-mediated prevention), 
treatment, and possibly cure (40-45). 
Several early phase trials in HIV-uninfected and HIV-infected individuals 
demonstrated the safety, tolerability, antiviral activity, and PK of VRC01 (46-50) 
and in 2016 VRC01 advanced to the first bnAb prevention efficacy trials in HIV-
uninfected individuals, the Antibody-Mediated Prevention (AMP) trials HVTN 
704/HPTN 085 and HVTN 703/HPTN 081. 
2.3.1 
The HVTN 703/HPTN 081 AMP study 
HVTN 703/HPTN 081 opened in May 2016 and enrolled 1924 women (persons 
assigned female sex at birth) at risk of HIV infection. Participants were 
randomized 1:1:1 in a double-blind fashion to receive 10 mg/kg VRC01, 30 
mg/kg VRC01, or placebo. Participants receive study product via intravenous (IV) 
infusion every 8 weeks for a total of 10 infusions over 72 weeks and are then 
followed every 4 weeks to week 80, and every 8 weeks thereafter to week 104 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 16 of 153 
(51) (see Table 2-1). In addition to assessing the prevention efficacy of VRC01 
and providing further VRC01 safety and PK data, the AMP studies include 
assessment of functional activity (ie, fragment crystallizable (Fc) effector 
functions), sieve analyses, and correlates analyses. HVTN 703/HPTN 081 
completed enrollment in October 2018. 
Table 2-1 HVTN 703/HPTN 081 AMP schema 
 
 
 
Infusion schedule (Weeks) 
[A = VRC01 infusion; C = Control infusion] 
 
Treatment 
N* 
W0 
W8 
W16 
W24 
W32 
W40 
W48 
W56 
W64 
W72 
W80♦ 
W104† 
Group 
1 
VRC01  
10 mg/kg  
633 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
 
 
Group 
2 
VRC01  
30 mg/kg  
633 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
 
 
Group 
3 
Control 
634 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
 
 
* Due to the randomization scheme, the numbers of VRC01 and control recipients may differ 
slightly. 
♦ Week 80 is the last study visit for the primary endpoint analysis of prevention efficacy. 
† Week 104 is the last study visit for the co-primary endpoint analysis of safety and tolerability. 
HIV diagnostic testing is conducted every 4 weeks and is accompanied by 
collection of serum and, at up to 4 timepoints, peripheral blood mononuclear cells 
(PBMCs) for storage. Participants who acquire HIV discontinue further study 
infusions and are monitored for 24 weeks with viral loads, CD4+ T-cell counts, 
and VRC01 levels, while providing serum, plasma and PBMCs for storage, 
functional humoral assays and other assessments. HIV-infected participants are 
linked to care for ART initiation and additional clinical follow-up.  
Most HVTN 703/HPTN 081 participants initiate ART within 4 weeks of 
confirmation of HIV infection, a mean of 7 weeks after the first RNA-positive 
HIV diagnostic sample. The vast majority of participants exhibit HIV diagnostic 
patterns of RNA-positive, enzyme immunoassay (EIA)-positive, and Bio-Rad 
Geenius-negative, -indeterminate, or -positive with p31-negative at the time of 
their confirmatory HIV diagnostic sample, and initiate ART within 4 weeks of 
this time point.  
2.3.2 
bnAbs can mediate virologic control  
The mission of the HVTN and of the HPTN is to prevent HIV, and the aim of the 
AMP studies is to evaluate the prevention efficacy of the VRC01 bnAb. However, 
for those participants who acquire HIV in spite of their participation in HVTN 
703/HPTN 081, the potential impact of bnAbs beyond prevention efficacy is 
important to evaluate. Preclinical (eg, murine, NHP) and clinical (ie, human) 
evidence is mounting that anti-HIV bnAbs like VRC01 can mediate sustained 
virologic control of HIV.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 17 of 153 
For instance, in a preclinical experiment designed to assess the impact of early 
immunotherapy postacquisition, VRC01 was administered 10 days after simian-
human immunodeficiency virus (SHIV)SF162P3 inoculation (ie, immediately prior 
to projected peak viremia) in 6 rhesus macaques, while another 6 macaques 
received a combination of VRC07-523LS + PGT121, and another 6 macaques 
received ART alone from day 10. Though SHIVSF162P3 is ~10-fold less sensitive 
to VRC01 than most isolates and both VRC07-523LS and PGT121 are more 
potent than VRC01, suppression of viral replication was comparable across all 
groups prior to the development of anti-monoclonal antibody (mAb) antibodies, a 
known limitation of the NHP model for bnAb administration (see Figure 2-4) 
(52). 
 
 
Figure 2-4 Geometric mean plasma SHIV viral loads (pVL) for the untreated group and the 3 
treatment groups (n = 6 per group). The error bars represent the 95% confidence intervals at 
each time point. From (52) Figure 2B. 
In another recent study (53), macaques were infected with SHIVAD8-EO. Three 
days after infection (prior to antibody seroconversion), the animals were 
randomized to receive either a 2-week course of 10-1074 and 3BNC117 or 
standard ART. At 15 weeks postinfection, the ART group discontinued ART. Six 
of the 13 animals treated with 10-1074 and 3BNC117 exhibited prolonged 
suppression of plasma viremia long after serum levels of infused antibodies 
became undetectable; in 5 of these controller macaques, this period of suppression 
followed an initial rebound of viremia with preservation of CD4+ T cells (see 
Figure 2-5 and Figure 2-6). Although the 7 noncontroller bnAb-treated macaques 
did not fully suppress virus, 4 of those 7 maintained CD4+ T cell counts and low 
levels of viremia (105 – 385 copies/mL) without ART for 2-3 years postinfection. 
Thus, 10 of the 13 bnAb-treated macaques appeared to benefit from early 
immunotherapy. In contrast, none of the 3 ART-treated animals exhibited 
sustained suppression of plasma viremia following discontinuation of ART. No 
significant differences in HIV-specific CD8+ or CD4+ T-cell responses or anti-
gp120 binding antibody levels were observed in controller and noncontroller 
bnAb-treated macaques, but infusion of a T-cell-depleting anti-CD8β mAb in the 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 18 of 153 
6 controller animals led to depletion of CD8+ T cells and the rapid reappearance 
of plasma viremia, suggesting that the prolonged suppression of viremia observed 
in these animals resulted from potent antiviral CD8+ T-cell immunity induced by 
the short course bnAb treatment amidst low levels of viral replication (53). 
 
Figure 2-5 Establishment of controller status in bnAb-treated animals inoculated with 
SHIVAD8-EO by the intrarectal route (a-f). Plasma viral loads (black) and CD4+ T-cell levels (red) 
are shown in 3 controller (a-c) and 3 noncontroller (d-f) macaques. From (53), Figure 2. 
 
Figure 2-6 Establishment of controller status in bnAb-treated animals inoculated with 
SHIVAD8-EO by the IV route (a-g). Plasma viral loads (black) and CD4+ T-cell levels (red) are 
shown in 3 controller (a-c) and 4 noncontroller (d-g) macaques. From (53), Figure 3. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 19 of 153 
3BNC117 and 10-1074 in combination, and 3BNC117 alone, have also been 
associated with virologic control in humans. Thirteen individuals with chronic 
HIV who received 2 or 4 3BNC117 infusions, immediately prior to analytical 
treatment interruption and then separated by 3 or 2 weeks, respectively, had a 
mean time to virologic rebound of 6.7 weeks (range of 5-9 weeks) after 2 
infusions of the antibody or 9.9 weeks (range of 3-19 weeks) after 4 infusions of 
the antibody. Eleven chronically infected individuals who received 3BNC117 and 
10-1074 immediately prior to and 3 and 6 weeks after analytical treatment 
interruption had a median time to virologic rebound of 21 weeks (range 5 to > 30 
weeks) (54, 55) (see Figure 2-7).  
 
Figure 2-7 Kaplan–Meier plots summarizing time to viral rebound for the participants with HIV-
1 RNA < 20 copies per mL 2 weeks before and at the start of ATI (n = 11, left), for the participants 
sensitive to both antibodies (n = 9, center), and for the participants that showed pre-existing 
resistance to 1 of the antibodies (n = 2, right). The y axis shows the percentage of participants that 
maintain viral suppression. The x axis shows the time in weeks after start of ATI. Participants 
receiving the combination of 3BNC117 and 10-1074 are indicated by the blue line. Dotted red lines 
indicate a cohort of individuals receiving 3BNC117 alone during ATI (54) (n = 13) and dotted black 
lines indicate a cohort of participants who underwent ATI without intervention (8) (n = 52). From 
Mendoza et al (55), Figure 1c. 
2.3.3 
bnAbs modulate the autologous immune response to acute HIV 
infection 
The mechanisms underlying bnAb-mediated virologic control are unknown, but 
there are clues in experiments that highlight bnAb-associated enhancement of 
autologous cellular and humoral responses. Adoptive transfer experiments have 
demonstrated that 3BNC117 can accelerate clearance of HIV-infected cells (see 
Figure 2-8) (56).  
 
Figure 2-8 Percentage of Gag+ cells among CD3+CD8- cells in mice treated with 3BNC117 
(600 mcg) or mice treated with isotype control 5 hours after HIV-1YU2–infected cell transfer. 
From (56) Figure 2A. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 20 of 153 
Barouch et al demonstrated increased CD8+ T cell-mediated virus inhibition and 
decreased CD8+ and CD4+ T cell exhaustion in the presence of PGT121 
compared to control as well as increased titers of autologous neutralizing antibody 
in macaques receiving PGT121, 3BNC117, and b12 (see Figure 2-9 and Figure 
2-10) (57). 
 
Figure 2-9 SHIVSF162P3 and SHIVSF162P4 serum neutralizing antibody titers (ID50) in the 
macaques described in Figure 2-10 after administration of the triple PGT121, 3BNC117, and 
b12 monoclonal antibody cocktail. From (57) Extended Data Figure 2. 
  
 
Figure 2-10 Therapeutic efficacy of the triple PGT121, 3BNC117, and b12 monoclonal 
antibody cocktail. LEFT: Log inhibition of viral replication in CD8+ T-lymphocyte-dependent virus 
suppression assays after monoclonal antibody infusion. One animal had no recoverable virus at 
week 2. CENTER and RIGHT: PD-11Ki671 expression on Gag-specific CD8+ (center) and CD4+ 
(right) T lymphocytes after monoclonal antibody infusion. From (57) Figure 1f, 1g, and 1h. 
Enhanced humoral responses—specifically, elevated levels of HIV Env-specific 
antibodies—were also observed in macaques by Bolton et al (52). In this study, 
antibody titers in animals that received either VRC01 or VRC07-523LS + 
PGT121 with ART exceeded titers achieved by animals receiving ART alone (see 
Figure 2-11). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 21 of 153 
 
Figure 2-11 Geometric mean endpoint titer values for plasma reactivity to HIV-1 SF162 gp120 
(anti-HIV Env) determined by enzyme-linked immunosorbent assay (ELISA) for each group 
(n = 6) at the indicated days postinfection. Error bars represent the 95% confidence intervals; 
the dotted lines indicate the limit of detection for the assay. From (52) Figure 3B. 
Haigwood et al (58) demonstrated accelerated development of autologous 
neutralizing antibodies in macaques. Uninfected macaques were assigned to no 
immunization (n = 4) or passive immunization, 1 and 14 days after challenge, 
with either normal immunoglobulin G (IgG) (n = 6) or specific intravenous 
immunoglobulin (SIVIG) (n = 6), which is a polyclonal IgG obtained from a 
healthy SIV-infected nonprogressor animal with high-titer neutralizing activity. 
Three of the 6 animals that received SIVIG showed accelerated development of 
neutralizing antibodies, in contrast to the animals that received normal IgG or no 
IgG (see Figure 2-12). These SIVIG-associated antibodies contributed to rapid 
control of post-acute phase viremia, resulting in delayed disease onset.  
 
Figure 2-12 Scatter plot of Env-specific binding and SIVsmE660 neutralizing antibodies 
(nAbs) at weeks 2 and 12 in macaques that seroconverted. Note that some symbols overlap. 
Mean ratios are noted for each group at weeks 2 and 12, with 95% confidence intervals. From (58), 
Figure 5. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 22 of 153 
Schoofs et al (59) also observed significantly increased autologous neutralizing 
antibody breadth and potency in chronically infected viremic individuals who 
received 3BNC117 compared to controls (see Figure 2-13). 
 
Figure 2-13 Heterologous antibody responses. (A) The difference in overall area under the 
curve (AUC) (mean AUC change) per individual in TZM.bl assays against 13 heterologous viruses 
for d0 versus week 24 IgG obtained from 36 untreated viremic controls (mean sampling interval 
26.8 weeks), 15 viremic individuals infused with 3BNC117 (mean sampling interval 24.1 weeks), 
and 12 ART-treated individuals receiving 3BNC117 infusion (mean sampling interval 24.0 weeks). 
(B) The aggregated differences in AUC between d0 and week 24 IgG assayed by TZM.bl for all 
viruses and all individuals. Each dot represents a single AUC difference for a single virus from one 
individual displayed in (A). Colored bars represent the mean of all AUCs. (C) 3BNC117 antibody 
levels (ELISA, white) and TZM.bl neutralization titer against tier 2 strain Q769.d22 (green) in patient 
2A3. (D) Mean AUCs of IgGs of all individuals at d0 (gray) and week 24 (color of respective group) 
for each HIV-1 pseudovirus tested. Changes in neutralization of viremic control individuals without 
3BNC117 infusion are shown in yellow (left). Change in neutralization of 3BNC117-treated 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 23 of 153 
individuals are shown in dark blue (off ART, middle) and light blue (on ART, right). Red stars 
indicate significant p-values after Bonferroni correction (threshold p < 0.0038). From (59), Figure 2. 
Furthermore, bnAbs appear to render otherwise-ineffective autologous antibodies 
more effective. In a hu-mice model in animals lacking autologous neutralizing 
antibodies, 10-1074 administered in combination with an autologous tier-1 
neutralizing antibody (either 10-188 or 1-79) was associated with significantly 
greater reduction in viremia than 10-1074 or the autologous bnAbs alone. 
Additional experiments (data not shown) suggested that bnAbs directed viral 
evolution to variants more sensitive to autologous tier-1 nAbs, while the 
autologous nAbs also appeared to limit viral evolution away from the bnAb (see 
Figure 2-14) (60).  
 
Figure 2-14 Changes of log10 viral load (mean and standard error of the mean [SEM]) of mice 
treated with 10-1074 (gray), 10-1074 + 10-188 (blue), and 10-1074 + 1-79 (green). Significant 
differences between treatment groups were determined by using repeated measures analysis of 
variance (ANOVA) with a Bonferroni pos-hoc test. *, p < 0.05; **, p < 0.001. From (60) Figure 7D.  
The concurrent enhancement of both cellular and humoral responses, and the 
associated evidence of virologic control, calls to mind the immunologic responses 
to tumor antigens in individuals receiving cancer immunotherapy, and implicates 
immune complexes formed by bnAbs bound to circulating virus and infected cells 
(61, 62). Immune complexes act as potent immunogens, as evidenced by work in 
the HIV vaccine field. A trial of an immune complex vaccine reported that anti-
CD4bs complexes with gp120 led to conformational changes in gp120 that 
stabilized and exposed epitopes in the V3 loop, leading to enhanced antigenicity 
and immunogenicity compared to gp120 alone (63, 64). This recapitulates the 
difference in HIV acquisition without bnAbs present (ie, comparable to gp120 
alone) compared to acquisition in the presence of bnAbs bound to the gp120, 
forming immune complexes that stimulate a more effective autologous immune 
response.  
Immune complexes with infected cells and with cell-free virions undergo FcγR-
mediated uptake by antigen presenting cells (eg, dendritic cells) and efficient 
antigen processing via proteasomal and endosomal degradation, that exposes 
particularly antigenic epitopes for MHCII presentation, stimulating enhanced 
CD4+ T-cell responses and directing the immunologic response down a Th1 
pathway, with enhanced CD4+ co-stimulation, a more efficient cytokine milieu 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 24 of 153 
for antiviral control, and enhanced CD8+ T-cell responses. The consequent 
development of pools of precursor T cells, in particular, sets the stage for durable 
virologic control, as these cells proliferate in the presence of antigen later, 
producing large amounts of effector T cells that then clear HIV-infected cells and 
virions (65-67). In fact, this pathway has been demonstrated in the murine FrCasE 
retrovirus model that has many similarities to HIV infection. Treg suppression was 
also observed in this model after therapeutic bnAb administration and subsequent 
immune complex-mediated induction of an antiviral host response that preserved 
immune function and stymied disease development, demonstrating yet another 
potential contribution to the bnAb-optimized early antiviral responses that may 
ultimately yield long-term virologic control (68, 69).  
Rendering this enhancement of the innate component of the immune response 
even more effective is bnAbs’ binding and neutralization of virus—a direct 
“debulking” of viral particles and of infected cells, thus limiting the number of 
virions capable of direct infection and replication and serving to limit viral factors 
that impair dendritic cell activation and maturation. This “viral debulking” 
function of bnAbs is analogous to surgical debulking (ie, cytoreductive surgery) 
performed for some tumors, which is associated with a survival advantage that is 
attributed in part to improved autologous immune function, with lower levels of 
tumor factors that impair the host immune response to cancer.  
In summary, by forming immune complexes, modulating and enhancing 
autologous immune responses, dampening HIV replication, and exerting a sieve 
effect at acquisition and pressure in early infection, even bnAb concentrations that 
are insufficient to prevent acquisition might nevertheless work in concert with the 
autologous innate and adaptive immune response to facilitate a more effective 
response to early infection and to help set the stage for later durable virologic 
control (70-72).  
2.3.4 
bnAbs may limit establishment and decrease the size of the viral 
reservoir 
In addition to, and in part likely due to, their enhancement of innate and adaptive 
immune responses, bnAbs appear to be capable of limiting the establishment and 
decreasing the size of the viral reservoir (45, 73). An in-vitro study of cells 
obtained from chronically infected aviremic humans demonstrated bnAb binding 
of cell-free virions produced from the latent reservoir, suppression of entry of 
those virions to activated uninfected CD4+ T cells, and suppression of replication-
competent HIV in autologous CD4+ T cells (74). In a humanized mouse model, 
administration of bnAbs 4 days after infection interfered with the establishment of 
a reservoir through Fc-mediated mechanisms and, when administered with 
latency-reversal agents, decreased the size of an established viral reservoir (40). 
Administration of bnAb with ART to reduce viral load, then of a single bnAb 
alone after ART termination, was followed by functional virologic control, 
demonstrating potential synergy between bnAbs and ART for durable viral 
suppression (75). In macaques, a reduction in cell-associated viral DNA and RNA 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 25 of 153 
in PBMCs and tissues was also observed after administration of single and 
combination bnAb immunotherapy (57, 76).  
The mechanisms of these impacts on the viral reservoir are likely myriad and 
include direct neutralization of virions from reactivated cells and bnAb binding 
and Fc-mediated recruitment of cytotoxic immune cells (eg, natural killer [NK] 
cells) that kill reactivated cells, which may be significantly enhanced by immune 
complex formation as described above (40, 45, 67). BnAbs accomplish this work 
of limiting reservoir seeding, and later reducing reservoir size, not only in blood 
and interstitial fluid but also in some of the principal sites of pre-ART virus 
production and persistence, lymph nodes and gut-associated lymphoid tissue, in 
which antiretrovirals have less penetrance (77-79). In one study, a significant 
reduction of cell-associated SHIV DNA was observed in these tissues after 
administration of a single bnAb to infected macaques (57) (see Figure 2-15). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 26 of 153 
 
Figure 2-15 Therapeutic efficacy of the single monoclonal antibodies PGT121 and 3BNC117. 
a–c, Plasma viral RNA (log copies/mL) in rhesus monkeys chronically infected with SHIV-SF162P3 
after a single infusion (arrows) of PGT121 (a), 3BNC117 (b), or the control monoclonal antibody 
DEN3 (c). d–f, Proviral DNA (copies/106 cells) in PBMCs (d), lymph nodes (e) and gastrointestinal 
mucosa (f) 14 days after the monoclonal antibody infusion in the animals that received PGT121 or 
DEN3. Red bars indicate mean values. Assays for one of the DEN3-treated controls failed. g, h, 
PD-1+ Ki671+ expression on Gag-specific CD8+ (g) and CD4+ (h) T lymphocytes in the monkeys 
that received PGT121. From (57), Figure 3. 
2.4 
Antiretroviral analytical treatment interruption (ATI) 
More than 150 studies with ATIs have been conducted since the introduction of 
combination ART over 20 years ago. Nearly 100 of those were conducted in the 
first decade of the 21st century, largely seeking to mitigate the risk of ART 
toxicity, multiresistant virus, and treatment failures (80-85). Among these was the 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 27 of 153 
Strategies for Management of Antiretroviral Therapy (SMART) trial, which 
evaluated standard continuous ART (n = 2,720) vs episodic, CD4+ T cell count-
guided ART (n = 2,752). In 2006, the SMART team reported a hazard ratio (HR) 
of 2.6 (95% CI 1.9-3.7, p < 0.001) for the combined primary study endpoint of 
opportunistic disease or death from any cause when comparing episodic ART 
with standard continuous ART. Of note, the trial enrolled participants with CD4+ 
counts of > 350 and with any ART history, did not exclude participants with 
chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, monitored 
participants every 2 months in the first year and then every 4 months thereafter, 
and re-initiated ART in the episodic arm only when CD4+ T-cell counts dipped 
below 250 cells/mL. There were no virologic criteria for re-initiating ART, and 
the median duration of the first ATI in the episodic ART group was 16.8 months 
(81). 
A subset analysis of the SMART data revealed that all serious adverse events 
(SAEs) in the trial occurred when CD4+ T cell counts were below 300 cells/mL. 
This subset analysis was restricted to 16 weeks of treatment interruption, 
participants with CD4+ T-cell counts > 400 cells/mL, ART re-initiation at CD4+ 
T-cell count of 350, and participants with no evidence of hepatitis B, hepatitis C, 
or diabetes at study entry. In participants meeting these criteria, no deaths and no 
renal or hepatic events were observed; 2 cardiac events were observed, one in 
each study group; and there was no difference in AIDS-related events (0.005% in 
the continuous ART group and 0.002% in the episodic treatment group) (86). 
These findings of no mortality or treatment-interruption-associated morbidity in 
this SMART subset are consistent with observations reported for several 
concurrent and subsequent treatment interruptions (all smaller than SMART; 
approximately half were randomized clinical trials like SMART) that similarly 
limited eligibility for and duration of treatment interruption, re-initiated ART at 
higher CD4+ cell counts, and monitored participants more frequently (84, 87-92).  
Treatment interruption designs post-SMART, including the design for HVTN 
805/HPTN 093, reflect lessons learned from SMART to mitigate the risks of 
treatment interruptions. Recent consensus guidelines on the design and conduct of 
analytical treatment interruptions further codify these risk mitigation measures 
and the current concept is aligned with these guidelines (see Figure 2-16, (2, 3)) 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 28 of 153 
 
Figure 2-16 Consensus recommendations of the July 9, 2018 forum held at the Ragon 
Institute of MGH, MIT and Harvard, Cambridge, MA, USA. From (3). 
Specifically, the eligibility criteria recommended in Julg et al (3) and proposed by 
the HVTN 805/HPTN 093 team help ensure that the risks of hepatic, renal, and 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 29 of 153 
cardiac morbidity and mortality observed in SMART are substantially reduced, as 
individuals are only eligible for treatment interruption if they have no active or 
chronic hepatitis B, no active hepatitis C, no evidence of other significant liver 
disease, no significant or unstable cardiac or cerebrovascular disease, and no 
evidence of HIV-related renal disease or moderate-to-severe reduction in 
estimated glomerular filtration rate (eGFR). 
Eligibility and ART re-initiation criteria and the frequency and type of monitoring 
also reduce the risks of HIV-related morbidity and mortality observed in the 
SMART trial. These safety features include eligibility only after an extended 
period of virologic suppression on ART; requirement that volunteers on NNRTI-
based ART regimens switch to short-acting antiretrovirals (Protease Inhibitor 
[PI]- or Integrase Strand Transfer Inhibitor [INSTI]-based ART regimens) in 
order to prevent emergence of ART-resistant HIV; requirement that volunteers 
have neither a history of AIDS-defining illness nor of specified HIV-associated 
conditions; eligibility only at higher baseline CD4+ T-cell counts; ART re-
initiation for any symptomatic HIV disease, CD4+ T-cell counts < 350 cells/mL, 
or HIV RNA ≥ 1,000 copies/mL for 4 weeks; and initial monitoring weekly and 
then biweekly, including CD4+ T-cell counts, viral load, and psychosocial 
experiences. 
The evidence that post-SMART changes in ATI trial design have, in fact, limited 
the risks of treatment interruption, is growing. For example, Huiting et al (93) 
demonstrated that among 22 participants who initiated ART in early HIV 
infection and then underwent a 16-week treatment interruption followed by re-
initiation of ART, there were no significant differences between pre- and 
post-ATI CD4+ or CD8+ T-cell counts or percentage and no significant 
differences in reservoir markers, including HIV DNA, cell-associated RNA, and 
replication-competent HIV (see Figure 2-17).  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 30 of 153 
Figure 2-17 Kinetics of HIV reservoirs and immunologic parameters prior to and following 
ATI and re-initiation of ART. The frequency of CD4+ T cells carrying HIV DNA and cell-
associated viral RNA was measured prior to (pre-ATI) and following ATI (ATI) and upon re-initiation 
of ART (post-ATI). The frequency and cell count of CD4+ and CD8+ T cells are shown at the pre-
ATI, ATI, and post-ATI timepoints. Statistical significance was tested with Wilcoxon signed rank 
test. *p < 0.05, **p < 0.01, ****p < 0.0001, NS, not significant. Adapted from (93) Figure 1. 
Bar et al (48) reported on 24 chronically infected participants in 2 cohorts; in one 
cohort (A5340), participants had been taking ART for 3.8-6.0 years (median 4.7) 
and in the other (15-I-0140) participants had been taking ART for 7.7-13.3 years 
(median 10.0). All participants received VRC01, followed by an ATI, which 
ended upon confirmation of viral rebound. Median time to viral rebound was 4 
weeks in the A5340 trial and 5.6 weeks in the 15-I-0140 trial. VRC01 slightly 
delayed plasma viral rebound compared with historical controls but did not 
sustain viral suppression. No safety issues were observed in either cohort. 
Clarridge et al (94) reported on the 10 chronically infected participants in the 15-
I-0140 cohort who received VRC01 immediately before and during ATI (median 
of 8 weeks, range 3-17 weeks). The length of the treatment interruption was 
governed by the time to meeting ART re-initiation criteria, which included a 
decrease of > 30% from the baseline CD4+ T-cell count or an absolute CD4+ T-
cell count < 350 cells/mL, sustained (≥ 4 weeks) plasma viremia > 1,000 
copies/mL, any HIV-related symptoms, or pregnancy (48, 94). During treatment 
interruption, total HIV DNA in CD4+ T cells increased significantly from 
preinterruption levels and all participants rebounded, with median peak viremia of 
30,950 copies/mL observed (range 340 - 273,221). By 6-12 months post-ATI, 
reservoir size, including the proportion of near full-length, genome-intact proviral 
sequences and structurally defective proviral sequences, and immune markers of 
exhaustion and activation returned to pre-ATI levels; CD4+, CD8+ (including 
activated CD8+), B, and NK cell levels also returned to pre-ATI levels; and there 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 31 of 153 
was no evidence of emergence of antiretroviral drug resistance mutations in intact 
proviral DNA sequences.  
Similar findings were reported by Salantes et al  (95) among 14 chronically 
infected individuals who received VRC01 immediately prior to and during 
treatment interruption (median of 6 weeks, range 3-14 weeks) in A5340. The 
length of the treatment interruption was governed by the time to meeting ART re-
initiation criteria, which included CD4+ T-cell count < 350 cells/mL or a return of 
HIV viremia defined as HIV RNA ≥ 200 copies/mL followed by HIV RNA ≥ 
1,000 copies/mL or 3 consecutive measurements of ≥ 200 copies/mL. No 
significant changes in pre or postinterruption reservoir size or composition were 
observed by quantitative polymerase chain reaction (PCR), cell-associated RNA 
or quantitative viral outgrowth assay (QVOA). Perhaps most relevant to HVTN 
805/HPTN 093, these findings remained true for participants with very small and 
relatively less heterologous reservoirs pre-ATI (eg, participant 7 in Figure 2-18). 
 
Figure 2-18 Quantitative measures of reservoir change. Pre-ATI and post-ATI values (obtained 
at study entry and more than 6 months after viral suppression following ART re-initiation, 
respectively) of total HIV-1 DNA in CD4+ T cells (A), caRNA in CD4+ T cells (B), and the frequency 
of resting CD4+ T cells bearing replication-competent virus (infectious units per million [IUPM]) (C) 
are shown for each A5340 participant. Total DNA is not shown for participant A06, because the 
values were below detectable levels at both timepoints. P-values shown in A–C indicate the 
significance of the within-participant changes and were determined by Wilcoxon signed-rank test. 
From (95), Figure 2. 
Strongin et al (96) assessed reservoir measures in 12 early- and chronic-treated 
participants across 4 ACTG studies that included ATI. Participants had at least 1 
year of suppressive ART prior to treatment interruption that lasted a median of 12 
weeks. No change in integrated HIV DNA was observed between baseline, pre-
ATI samples and samples 6 months after ART re-initiation. In a shorter-term ATI, 
with a median duration of approximately 4 weeks, Papasavvas et al  (97) 
demonstrated similar findings among 23 chronically-treated, ART-suppressed 
individuals. As expected, treatment interruption was accompanied by decreases in 
CD4+ T cells and increases in HIV viral load, markers of T-cell activation (eg, 
HLA-DR and CD38 co-expression), and levels of cellular HIV DNA (total DNA 
and 2-LTR [long terminal repeat] circles in PBMCs) and cellular RNA (by PCR). 
However, upon re-initiation of ART, viral re-suppression was achieved at a 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 32 of 153 
median of 13 weeks and levels of CD4+ T cells, T-cell activation markers, and 
cellular HIV DNA and RNA returned to baseline, pre-ATI levels. 
A recent meta-analysis offers further reassurance of the safety of ART treatment 
interruption with respect to rates of adverse events experienced by participants in 
trials with treatment interruptions. The meta-analysis included 7,104 participants 
across 22 studies with varying ATI designs, allowing for comparisons of 
outcomes across trials with different eligibility criteria, treatment interruption 
duration, follow-up intervals and ART re-initiation criteria. The overall rate of 
adverse experiences (AEs) during ATIs longer than 4 weeks’ duration was 3% 
(95% CI 0%-7%) and was lower in studies with monitoring ≤ every 2 weeks (0%; 
95% CI 0%-1%) than in studies with less frequent follow-up (6%; 95% CI 2%-
13%; p-value for interaction = 0.01). Among the studies reporting new viral 
resistance mutations emerging during ATI, a 3% (95% CI 0%-8%) rate of such 
mutations was observed, with a higher rate in studies with less frequent 
monitoring (9%; 95% CI 3%-16%) compared to the rate observed in trials with 
more frequent (≤ every 2 weeks) monitoring (0%; 95% CI 0%-1%; p = 0.03). Of 
note, the analysis was unable to discern which ART regimens preceded ATI in all 
of these trials, thus limiting their ability to account for trials with NNRTI switch 
periods to reduce the risk of the development of viral drug resistance mutations. 
Baseline CD4+ T-cell count was also associated with outcomes, with baseline 
CD4+ T cells > 500 cells/mcL associated with the fewest AEs (0%; 95% CI 0%-
3%) (98, 99). 
The authors conclude that treatment interruption can be conducted safely—with 
no lasting negative impact on clinical, immunologic, immune activation or 
virologic parameters—when appropriately designed with frequent monitoring and 
appropriate duration, eligibility and re-initiation criteria. The cited authors of the 
meta-analysis and assessments of ATI impacts described above specifically note 
that appropriate re-initiation criteria should allow for viral spikes (ie, without re-
initiating ART prematurely) that may be necessary to elicit the ART-free, 
virologic suppression potential of immunomodulatory interventions, like bnAbs 
(18, 21, 93, 98-100). 
The mitigation of risk in treatment interruptions relies on the optimal 
implementation of eligibility assessment, monitoring, timely ART re-initiation, 
and other risk mitigation practices. An assessment of site capacity to implement 
these aspects of the treatment interruption design—for example, capacity for 
weekly and biweekly clinic visits, including retention and adherence metrics thus 
far, and access to ART for timely re-initiation, including metrics of initial ART 
uptake—was completed prior to the determination of participating sites. Ongoing 
monitoring of the implementation of these risk mitigation measures will be in 
place throughout the trial’s conduct. However, even with these measures, 
treatment interruptions do still entail risk and promise no anticipated benefit. 
These points must be made clear in an informed consent process for individuals 
contemplating any interruption in their antiretroviral therapy.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 33 of 153 
A pause in antiretroviral therapy—with careful eligibility criteria, frequent 
clinical and laboratory monitoring, and clear criteria for ART re-initiation—is a 
safe and acceptable strategy to evaluate the efficacy of VRC01 in this population 
of antiretroviral-treated HIV-infected adults. Current and prior studies of immune-
based therapy, including a subgroup analysis of the SMART study, support the 
value, safety and acceptability of interruptions in antiretroviral therapy to assess 
virologic efficacy in this context (21, 48, 54, 86, 93, 101-105). In addition, while 
there remains uncertainty regarding how best to measure latent HIV reservoirs, 
several recent studies of participants undergoing similar short-term interruptions 
in antiretroviral therapy have noted no persistent changes in the size of the latent 
reservoir of infected CD4+ T cells following re-suppression by ART, based on the 
measures currently thought to reflect HIV reservoir size (21, 93-99). Specifically, 
ATI with intensive monitoring evaluating time to viral rebound has been 
advanced as a careful approach to provide insight regarding novel therapeutic 
approaches to control HIV off ART (79, 106, 107). 
2.5 
An AMP ATI  
AMP participants who acquired HIV are unique: they were diagnosed with HIV 
soon after acquisition due to monthly HIV diagnostics on-study; they initiated 
ART soon after diagnosis due to AMP-facilitated linkage to ART; and those 
randomized to receive VRC01 had circulating bnAb at the time of acquisition due 
to the q8-week frequency of infusion and VRC01 PK. This sets the stage for 
formation of immune complexes of VRC01 bound to free virions or HIV-infected 
cells which, as detailed above, can modulate the immune response and, thus, the 
course of infection. This cohort offers a singular opportunity to assess the 
potential impact of very early immunotherapy on the immunologic and virologic 
trajectory of infection, a contribution that recent preclinical and clinical data 
suggests could meaningfully enhance our understanding of HIV pathogenesis and 
illuminate potential host defenses, and means of enhancing them, that previous 
HIV preventive, therapeutic, or curative interventions have heretofore not 
identified or successfully engaged. 
A pause in antiretroviral treatment is the only way to determine if the presence of 
VRC01 at the time of, or shortly after, acquisition of HIV results in a blunted, 
delayed, or absent plasma viral rebound off ART, or subsequent control of 
rebound that may be observed. If such an impact on viral rebound is observed, 
ATI is also the best means of assessing mechanisms and predictive biomarkers of 
that impact through a detailed assessment of innate, cellular, and humoral markers 
along with characterization of the viral reservoir. 
Recent research has suggested that viral rebound may be predicted by duration of 
infection, length of ART suppression, CD4+ T-cell nadir, total HIV DNA and 
cell-associated HIV RNA, among others; but samples and validation of these 
potential predictors are limited and there is no consensus biomarker predictive of 
durable viral suppression (8, 77, 108). Identification of reliably predictive 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 34 of 153 
biomarkers could inform future therapeutic and cure trial design and guide 
allocation of limited resources, advancing promising therapies more efficiently, 
and limiting exposure of trial participants to ineffective interventions. The AMP 
trial has pre and postinfection serum and limited PBMC samples on each 
participant, including samples obtained ≤ 4 weeks from the time of acquisition 
and pre-ART. Thus, across currently available and proposed samples, ATI among 
AMP participants provides a unique opportunity to contribute to the exploration 
and validation of biomarkers, many observed in the preclinical studies described 
in Section 2.3.2 through 2.3.4 above, that may predict the virologic and 
immunologic course of infection among bnAb and placebo recipients. 
2.6 
Ethical considerations 
In the last 2 decades of treatment interruption conduct, an ethical framework for 
the conduct of such studies has evolved. There is general agreement that the risks 
of treatment interruption must be minimized; the trial must provide valuable data 
to answer an important question; and there must be no other methods entailing 
less risk that could answer that question (109, 110).  
While ethicists have noted that “in general, the risks of the ATI itself, when 
closely monitored, are considered to be low,” risk mitigation is an essential part of 
the design of any treatment interruption. Risk mitigation includes but is not 
limited to: adoption of appropriate eligibility criteria; efforts to enhance potential 
participant benefits; community engagement in the design and implementation of 
the trial; frequent participant monitoring, balanced with considerations of 
participant burden; and a sound informed consent process. The informed consent 
process should acknowledge the risks and the lack of anticipated individual 
benefits, the fact that treatment interruptions are not recommended in clinical 
care, and the fact that ART guidelines recommend lifelong treatment (109, 110). 
Each of these recommendations has been adopted by the HVTN 805/HPTN 093 
Protocol Team. The HVTN 805/HPTN 093 informed consent process and Sample 
Informed Consent Form (SICF) include all points noted above and include 
elements demonstrated to improve the quality of informed consent in not only 
HIV research but also other fields (see Section 12.1). Trial design, including 
eligibility and ART re-initiation criteria, ATI duration, and monitoring frequency, 
are modeled on the most recent consensus guidelines for treatment interruption 
design (see Figure 2-16 above) (2, 3). The HVTN 805/HPTN 093 Protocol Team 
will implement not only rigorous counseling for participants on reducing HIV 
transmission risk to their partners but also a program for PrEP provision to 
participants’ partners while the participant is enrolled; HIV genotyping (not 
standard of care in many AMP regions, unless first-line ART options have been 
exhausted); and accelerated, physician-led ART (re-initiation) access for 
participants in regions where ART stock-outs, public nurse-led care, and a 
window of several weeks between meeting ART re-initiation criteria and ART 
initiation could pose challenges for participants. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 35 of 153 
As all potential participants in HVTN 805/HPTN 093 would come from the 
parent HVTN 703/HPTN 081 study, early engagement of investigators and 
community representatives in several communities where HVTN 703/HPTN 081 
was conducted has already been initiated and is ongoing. These consultations with 
community stakeholders and investigators include an overview of the history and 
current context of treatment interruption, including potential risks and region-
specific considerations. They also provide an opportunity for dialogue about the 
immunologic hypotheses and design for HVTN 805/HPTN 093 and began laying 
a foundation of authentic stakeholder engagement in the earliest weeks of 
development of this study. See Section 2.7 below for further details. 
2.7 
Feasibility 
 
The HVTN 805/HPTN 093 team has the significant advantage of data and 
experience from the AMP Study to inform an assessment of the feasibility of 
HVTN 805/HPTN 093, appreciating that while this concept is significantly 
different from the parent AMP Study, all participants for HVTN 805/HPTN 093 
will be from the AMP cohort at sites and in communities now familiar to the 
AMP and HVTN 805/HPTN 093 teams. AMP accrual and retention rates, early 
termination rates, data quality and safety have been excellent by any standard, 
perhaps particularly so considering the demanding nature of the 2 AMP trials 
(HVTN 704/HPTN 085 and HVTN 703/HPTN 081) that, together, enrolled 4,625 
participants for 2 years of monthly clinic visits and q8-weekly IV infusions (111, 
112). In over 35,000 IV infusions administered to date, no procedural 
complications (eg, local IV site infection,) have been observed; 2/3 of participants 
receive VRC01 and very low rates of infusion reactions have been observed, all of 
which have been medically managed exceptionally well (111, 113).  
While overall performance in AMP has been exceptional, the HVTN 805/HPTN 
093 team also considered site-specific performance and other considerations in 
determining which sites will implement HVTN 805/HPTN 093. Considerations 
include: site-specific retention performance; timeliness and accuracy of safety 
data submission; access to potentially eligible participants; site capacity for 
frequent clinic visits and close clinical monitoring of participants; access to and 
capacity for close partnership with primary HIV care, including timely ART re-
initiation; and site willingness to participate, including receptivity of site 
investigators, community representatives, and regulatory authorities.  
Partnership with regional investigator, regulatory, and community representatives 
for the development of HVTN 805/HPTN 093 has already begun in earnest and is 
ongoing.  
A symposium with sub-Saharan African investigators, regulatory and public 
health representatives, and community representatives, including representatives 
from local Community Advisory Boards (CABs), was held in August 2019 in 
Cape Town, South Africa, with co-sponsorship by the South African Medical 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 36 of 153 
Research Council (SAMRC). Attendees were engaged and were supportive of 
contributing to the global HIV cure and remission research agenda, including with 
rigorously-designed ATIs like HVTN 805/HPTN 093, with some participants 
stating, “We need this,” “This is for our communities,” and “This [an AMP ATI] 
is a first step.” Understanding and engagement was also evident in attendee 
questions and dialogue throughout the consultation. 
Early in development in early 2019, the HVTN 805/HPTN 093 team also solicited 
and received input and support from sub-Saharan African AMP investigators, 
policy makers, basic and clinical scientists, and from the AMP Community 
Working Group (AMP CWG), whose members include community educators, 
recruiters, and CAB members from each AMP site. Several forums throughout 
2019 also provided opportunities for additional discussion and feedback regarding 
HVTN 805/HPTN 093 with AMP Protocol Team and site representatives (eg, 
investigators, clinic coordinators) and AMP CWG members.  
Community engagement and site readiness, as described above, are necessary but 
not sufficient to support the conduct of HVTN 805/HPTN 093. AMP participant 
willingness to participate in the ATI is a crucial additional feasibility 
consideration. Again, interim data from AMP provides some insight here.  
A mixed-methods AMP sub-study enrolled 300 participants—50 AMP 
participants from each of 6 sites based throughout the US. Upon exiting the AMP 
Study, each participant took part in a brief survey and a 60-minute interview 
regarding their demographics, understanding of bnAbs, and any enrollment or 
retention barriers and facilitators they experienced. In an interim analysis, about a 
quarter of participants expressed concerns about the AMP Study time 
commitment or the experimental nature of the VRC01 product and the associated 
uncertainty regarding its efficacy. All participants expressed a strong sense of 
appreciation for and positive identification with their clinical research site. For 
example, one participant noted: “I’m going to volunteer for clinical research, 
especially if it’s research that’s going to affect the community that I’m part of” 
and another enthused “I’m such a big fan of [the CRS] that any research study 
that they pretty much put forward, I’m like interested in, or definitely highly 
support.” Several participants cited the additional medical care they received at 
the clinic as a facilitator of ongoing study participation: “[staff member name] 
took on this role of like a secondary primary care physician for me. In addition to 
the care I was getting at my doctor’s office, I also felt like I was getting another 
set of eyes on me. I just felt cared for.” Another observed “I liked how I got tested 
so often, and they were there to help me with any concerns I had, whether in 
regard to the infusion or to getting tested for other STDs or STIs.” 
While the scope of the sub-study is limited to the US, anecdotal evidence from 
sites around the world, coupled with the exceptional accrual and retention 
observed in the AMP studies to date (112), suggests that the experience 
participants have with their HVTN and HPTN AMP sites, globally, is a strongly 
positive motivator for continued engagement with their site. Furthermore, many 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 37 of 153 
sites retain engagement with their participants through various means even post-
AMP and have the ability, prespecified in site-specific AMP consent forms 
approved by their Institutional Review Boards/Ethics Committees (IRBs/ECs), to 
reach out to participants after they’ve exited the trial to inquire about their interest 
in possible future research. 
Thus, HVTN 805/HPTN 093 as described herein is thought to be feasible thanks 
in large part to the selection of sites for AMP and their conduct of the study, 
including their relationships with site participants and their community and 
regulatory partners. 
2.8 
Conclusion 
The AMP ATI is uniquely positioned to test for ART-free virologic control and to 
enhance understanding of the immunologic (ie, host) and virologic mechanisms 
and biomarkers of control among individuals who acquired HIV in the presence 
of circulating bnAb. Here, we have an opportunity to translate the intriguing 
preclinical observations in SHIV-infected primates (53) to humans. This trial will 
extend early clinical observations, explore potential mechanisms, validate 
biomarkers of control, and discern whether AMP participants who became HIV-
infected while on trial may become “post-bnAb controllers,” capable of early 
ART- and/or bnAb-induced immunologic responses that change the course of 
their infection. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 38 of 153 
3 
Study design 
3.1 
Hypotheses 
3.1.1 
Primary hypotheses 
• Individuals who initiated ART early in HIV infection in HVTN 703/HPTN 
081 will suppress plasma viremia and maintain CD4+ T-cell counts longer 
during ATI than historical cohorts (ie, SPARTAC African and non-African 
cohorts described in Gossez et al (1) comprising individuals who initiated 
ART early in HIV infection without other interventions). 
• Individuals who initiated ART early in HIV infection and also received 
VRC01 within 8 weeks before or after acquiring HIV in HVTN 703/HPTN 
081 will suppress plasma viremia and maintain CD4+ T-cell counts longer 
during ATI than those who initiated ART early in HIV infection and received 
placebo within 8 weeks before or after acquiring HIV in HVTN 703/HPTN 
081. 
• ATI will be safe and well-tolerated in individuals who acquired HIV during 
their participation in HVTN 703/HPTN 081. 
3.1.2 
Secondary hypotheses 
• Individuals who initiated ART early in HIV infection and also received 
VRC01 within 8 weeks before or after acquiring HIV in HVTN 703/HPTN 
081 will have enhanced cellular and humoral responses compared with those 
who initiated ART early in HIV infection and received placebo within 8 
weeks of acquiring HIV in HVTN 703/HPTN 081. 
• Individuals who initiated ART early in HIV infection and also received 
VRC01 within 8 weeks before or after acquiring HIV in HVTN 703/HPTN 
081 will have more limited viral reservoirs, before and after ATI, than those 
who initiated ART early in HIV infection and received placebo within 8 
weeks of acquiring HIV in HVTN 703/HPTN 081. 
3.2 
Objectives and endpoints 
3.2.1 
Primary objectives and endpoints 
Primary objective 1 
• To evaluate the effect of early ART initiation, with or without having received 
VRC01 in the immediate pre-HIV acquisition period and/or during early 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 39 of 153 
infection on the time to meeting ART re-initiation criteria in participants 
undergoing ATI 
Primary endpoint 1 
• Time to meeting criteria for ART re-initiation 
• Frequency of sustained post-treatment HIV control, defined as ≥ 24 weeks off 
ART without meeting ART re-initiation criteria 
Primary objective 2 
• To evaluate the safety of ATI among HVTN 805/HPTN 093 participants 
Primary endpoint 2 
• Laboratory measures of safety, adverse events (AEs), SAEs, and rates of 
discontinuation 
3.2.2 
Secondary objectives and endpoints 
Secondary objective 1 
• To evaluate the effect of early ART initiation, with or without having received 
VRC01 in the immediate pre-HIV acquisition period and/or during early 
infection on the development of anti-HIV immune responses and on the 
potential association of those immune responses with time to meeting criteria 
for ART re-initiation in participants undergoing ATI 
Secondary endpoints 1 
• Response rate, magnitude, and polyfunctionality of HIV-specific CD4+ and 
CD8+ T-cell responses as measured by flow cytometry 
• Magnitude and breadth of neutralizing antibody (nAb) responses against 
autologous and heterologous HIV isolates, as measured by TZM-bl 
neutralization assay  
• Non-neutralizing, FcγR-mediated antibody effector functions such as 
antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent 
cellular phagocytosis (ADCP), and virion capture 
• Frequency of dendritic cell activation and maturation markers, as measured by 
flow cytometry or other cell phenotyping assays 
• Frequency of T- and B-cell activation and exhaustion markers, as measured by 
flow cytometry or other cell phenotyping assays 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 40 of 153 
Secondary objective 2 
• To evaluate the effect of early ART initiation, with or without having received 
VRC01 in the immediate pre-HIV acquisition period and/or during early 
infection on viral load in participants undergoing ATI 
Secondary endpoint 2 
• Cumulative incidence of participants with viral load ≥ 200 at weeks 8, 16, and 
24 
Secondary objective 3 
• To evaluate the effect of early ART initiation, with or without having received 
VRC01 in the immediate pre-HIV acquisition period and/or during early 
infection on HIV reservoir size before and after ATI, and whether HIV 
reservoir measurements are associated with time to meeting criteria for ART 
re-initiation in participants undergoing ATI 
Secondary endpoint 3 
• Frequency of CD4+ T cells carrying intact and/or total pro-viral HIV DNA, 
replication competent virus, and/or cell-associated HIV RNA  
3.2.3 
Exploratory objectives 
Exploratory objective 1 
• To assess participant and potential participant motivations, perceptions and 
tolerance for ATIs, for prolonged viremia, and for trial requirements (eg, ART 
switches, barrier protection for all sexual activity) 
Exploratory objective 2 
• To assess social benefits (eg, altruism) and negative social impacts, including 
but not limited to anxiety regarding being off ART and becoming viremic 
again and fear of inadvertent HIV transmission to partners 
Exploratory objective 3 
• To assess participant and potential participant decision-making quality, 
including perception of being informed, clarity and support in decision 
making and satisfaction with their choice regarding participation 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 41 of 153 
Exploratory objective 4 
• To evaluate the effect of VRC01 received in the immediate pre-HIV 
acquisition period and/or during early infection on viral kinetics in 
participants undergoing ATI 
Exploratory objective 5 
• To determine whether characteristics of the transmitted/founder (T/F) viruses, 
rebound virus(es), and/or baseline viral reservoirs, including relative VRC01 
sensitivity or resistance, are associated with virologic control or the 
development of anti-HIV immunity among individuals who acquired HIV 
during their participation in HVTN 703/HPTN 081 
Exploratory objective 6 
• To assess whether host genetics (eg, HLA type, CCR5 heterozygosity) and 
sex assigned at birth are associated with time to meeting ART re-initiation 
criteria among VRC01 or placebo recipients who acquired HIV during their 
participation in HVTN 703/HPTN 081 
Exploratory objective 7 
• To qualitatively characterize the immune responses and reservoir 
characteristics of controllers and non-controllers in this cohort and to compare 
these to immune responses and reservoir characteristics of historical cohorts 
(ie, SPARTAC African and non-African cohorts, described in Gossez et al (1), 
comprising individuals who initiated ART early in HIV infection without 
other interventions) 
3.3 
ATI  
For all participants, ATI begins with cessation of ART in Schedule 1, Monitoring 
ATI. Participants on ATI (ie, Schedule 1 or 2) who do not meet criteria for 
moving to the next visit schedule (ie, viral rebound or re-initiating ART) should 
continue on their current ATI visit schedule, including extended visits (as 
appropriate) until such time as they move to the next visit schedule or are 
terminated from the study. Schedule 1 and Schedule 2 extended visits occur 
quarterly and are designated as Visits Type A and Type B, with procedures 
specified for each visit type, in the laboratory and clinical procedures tables (see 
Appendix E, Appendix F, Appendix H, Appendix I, and Appendix K). For 
participants who meet criteria for reinitiating ART but decline to do so, see 
Section 3.3.4.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 42 of 153 
3.3.1 
Transition from Schedule 1, Monitoring ATI to Schedule 2, ATI 
monitoring with viremia  
For participants on Schedule 1, Monitoring ATI, the following virologic criterion 
will trigger a transition to Schedule 2, ATI monitoring with viremia: 
• Confirmed VL ≥ 200 copies/mL (ie, on 2 consecutive samples). 
A confirmatory sample should be drawn at the next visit (within approximately 1-
2 weeks) following the first VL result ≥ 200 copies/mL (see HVTN 805/HPTN 
093 SSP for details).  
3.3.2 
Transition from Schedule 1, Monitoring ATI to Schedule 3, Follow-up 
on ART 
For participants on Schedule 1, Monitoring ATI, any of the following non-
virologic criteria will trigger ART re-initiation and transition to Schedule 3, 
Follow-up on ART: 
• Confirmed CD4+ T-cell count < 350 cells/mm3 (ie, on 2 consecutive samples) 
• Any HIV-related syndrome (eg, ARS, an opportunistic infection) 
• Pregnancy or breastfeeding 
• ART re-initiation requested by participant 
• ART re-initiation requested by primary HIV care provider or clinical research 
site (CRS) Investigator of Record (IoR) (eg, if deemed medically necessary) 
A confirmatory sample should be drawn at the next visit (within approximately 1-
2 weeks) following the first CD4+ T-cell count < 350 cells/mm3 (see HVTN 
805/HPTN 093 SSP for details).  
3.3.3 
Transition from Schedule 2, ATI monitoring with viremia, to Schedule 
3, Follow-up on ART 
For participants on Schedule 2, Monitoring ATI with viremia, the following 
virologic criteria will trigger ART re-initiation and transition to Schedule 3, 
Follow-up on ART. 
From the Week 0 visit to the Week 24 visit in Schedule 2:  
• Viral load remains ≥ 1,000 copies/mL for ≥ 4 consecutive weeks AND viral 
load has not dropped 0.5 log from the previous week 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 43 of 153 
This ART re-initiation criterion applies irrespective of missed visits and must take 
account of VL results ≥ 1,000 copies/mL experienced by a participant while on 
Schedule 1. Furthermore, assessing whether participants meet this criterion may 
require additional visits beyond those scheduled from Week 8 (Visit 48) to Week 
24 (Visit 56) in Schedule 2. Ideally, these additional visits will be conducted 
weekly. These additional visits will be treated as interim visits (for more details, 
see the HVTN 805/HPTN 093 SSP).  
After the Week 24 visit in Schedule 2, the ART re-initiation criterion is:  
• Confirmed viral load ≥ 200 copies/mL (ie, on 2 consecutive samples). 
A confirmatory sample should be drawn at the next visit (within approximately 1-
2 weeks) following the first VL result ≥ 200 copies/mL (see HVTN 805/HPTN 
093 SSP for details).  
The above virologic ART re-initiation criteria are shown schematically in Figure 
3-1. 
 
 
Figure 3-1 Virologic criteria for transition from Schedule 2 to Schedule 3 (ie, ART re-
initiation) 
In addition, at any time during Schedule 2, any of the following non-virologic 
criteria will trigger prompt ART re-initiation and transition to Schedule 3, Follow-
up on ART: 
• Confirmed CD4+ T-cell count < 350 cells/mm3 (ie, on 2 consecutive samples) 
• Any HIV-related syndrome (eg, ARS, an opportunistic infection) 
• Pregnancy or breastfeeding 
• ART re-initiation requested by participant 
• ART re-initiation requested by primary HIV care provider or CRS IoR (eg, if 
deemed medically necessary). 
A confirmatory sample should be drawn at the next visit (within approximately 1-
2 weeks) following the first CD4+ T-cell count < 350 cells/mm3 (see HVTN 
805/HPTN 093 SSP for details).  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 44 of 153 
3.3.4 
Participants who decline to re-initiate ART 
When ART re-initiation criteria are met, CRS staff will strongly recommend that 
the participant restart ART. Participants who decline to do so should be urged to 
continue clinic visits per the schedule they are in at that time (eg, Schedule 1 or 
Schedule 2) until such time as the participant re-initiates ART, at which time they 
should transition to Schedule 3. Monitoring such participants may require 
additional visits. Ideally, these visits will be conducted weekly. These additional 
visits will be treated as interim visits. For details, see the HVTN 805/HPTN 093 
SSP. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 45 of 153 
4 
Statistical considerations 
4.1 
Estimated accrual 
Recruitment will target participants who received VRC01 or placebo and became 
HIV-infected during participation in HVTN 703/HPTN 081. 
We calculate the expected trial size under different scenarios for the percentage of 
enrolled participants out of the total number of endpoint infected cases from 
HVTN 703/HPTN 081; scenarios include 25%, 50%, and 75%. Given an 
assumption of a common prevention efficacy at each dose (PE10 and PE30), the 
expected trial size will depend on different levels of PE. Under the null hypothesis 
(PE10 = PE30 = 0%), the total expected number of endpoint infections among 
placebo recipients is 26 and VRC01 recipients is 54 (Table 4-3 in the parent 
protocol HVTN 703/HPTN 081); therefore, we assume a trial size of 7, 13, or 20 
placebo recipients and 14, 27, or 41 VRC01 recipients depending on the 
enrollment ratio. Under the alternative hypothesis (PE10 = PE30 = 60%), the total 
expected number of endpoint infections among placebo recipients is 35 and 
VRC01 recipients is 28 (Table 4-3 in the parent protocol); therefore, under the 
different enrollment ratio scenarios, we assume a trial size of 9, 18, or 26 placebo 
recipients and 7, 14, or 21 VRC01 recipients. These 6 sample size scenarios 
represent estimated upper and lower bounds for sample size given the expected 
number of endpoint infections under the null and alternative hypotheses 
respectively, as well as various scenarios for the percentage of eligible 
participants who will ultimately enroll in HVTN 805/HPTN 093. 
4.1.1 
Power to evaluate time to ART re-initiation criteria 
Using data from the placebo arm of a therapeutic vaccine study which enrolled 
early treated patients (21), we modeled the time T (in weeks) to meet re-initiation 
criteria as a Weibull distribution with survival function P(T > t) = exp[-(λt)p], 
where λ = exp(-2.932) = 0.053 and p = 2.014. From these parameters, we 
estimated the median time to meet re-initiation criteria as 15.6 weeks in the AMP 
placebo recipients. We can express the treatment effect in terms of either the HR 
θ or the factor β by which treatment increases the median time to meet re-
initiation criteria; β and θ are related by β = θ-1/p. 
We model censoring of time to restart criteria using an exponential model and a 
maximum follow-up time of 72 weeks, where follow-up is censored at a rate of 
20% per year due to either study termination or re-initiation of ART before 
reaching the restart criteria. Power for a 40%, 50%, 60%, and 70% reduction in 
hazard under different prevention efficacy scenarios are shown in Table 4-1. 
These hazard reductions correspond to 29%, 41%, 58%, and 82% increases in the 
median time to meet restart criteria. Therefore, if VRC01 increases the median 
time to restart criteria 58% and the enrollment rate is 50%, then under the parent 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 46 of 153 
study null hypothesis power to detect a difference in time to restart criteria is 72% 
while under the alternative hypothesis power is 62%. 
Table 4-1 Power under different prevention efficacy results, different enrollment rates and 
different treatment effects, expressed as either reduction in hazard or percent increase in 
median time to meet re-initiation criteria 
Enrollment Rate 
Null hypothesis 
Alternative hypothesis 
25% 
50% 
75% 
25% 
50% 
75% 
Expected number of placebos 
7 
13 
20 
9 
18 
26 
Expected number of VRC01 
14 
27 
41 
7 
14 
21 
Reduction in hazard 
% Increase in 
median time to 
meet re-initiation 
criteria 
 
40% 
29% 
20% 
31% 
44% 
16% 
27% 
36% 
50% 
41% 
31% 
49% 
67% 
23% 
42% 
57% 
60% 
58% 
46% 
72% 
89% 
35% 
62% 
81% 
70% 
82% 
65% 
90% 
98% 
52% 
85% 
95% 
4.1.2 
Sample size considerations for safety 
The goal of the safety evaluation for this study is to identify safety concerns 
associated with ATI. The ability of the study to detect SAEs (see Section 4.2.3.1) 
can be expressed by the true event rate above which at least 1 SAE would likely 
be observed and the true event rate below which no events would likely be 
observed. Under the enrollment rate and PE scenarios described in Section 4.1, 
Table 4-2 shows the true event rate such that there is a 90% chance of observing 
at least 1 event (or no events) among three groups; 1) the placebo recipients only, 
2) the VRC01 recipients only, or 3) all enrolled participants. 
Table 4-2 True event rates above which at least 1 SAE (or below which no events) would 
likely be observed in a group of size n participants. Event rates are computed separately for 
various values of n given by the range and midpoint for the estimated number of participants 
among 3 groups; 1) the placebo recipients only, 2) the VRC01 recipients only, or 3) all enrolled 
participant based on the enrollment scenarios described in Section 4.1. 
 
Placebo recipients 
VRC01 recipients 
All enrolled 
n 
7 
17 
26 
7 
24 
41 
16 
39 
61 
At least 1 event 
28.0% 
12.7% 
8.5% 
28.0% 
9.1% 
5.5% 
13.4% 
5.7% 
3.7% 
No events 
1.5% 
0.6% 
0.4% 
1.5% 
0.4% 
0.3% 
0.7% 
0.3% 
0.2% 
4.2 
Statistical analyses 
Analyses for primary endpoints will be performed using SAS and R. All other 
descriptive and inferential statistical analyses will be performed using SAS, 
StatXact, or R statistical software. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 47 of 153 
No formal multiple comparison adjustments will be employed for multiple safety 
endpoints or secondary endpoints. However, multiplicity adjustments will be 
made for certain laboratory assays, as discussed below, when the assay endpoint 
is viewed as a collection of hypotheses (eg, testing multiple peptide pools to 
determine a positive response). 
4.2.1 
Analysis variables 
The analysis variables consist of baseline participant characteristics, safety, and 
laboratory outcomes for primary- and secondary-objective analyses. 
4.2.2 
Baseline comparability 
Groups defined by the parent protocol treatment arms will be compared for 
baseline participant characteristics using descriptive statistics. 
4.2.3 
Primary virologic analysis 
In this study we either compare placebo recipients from HVTN 703/HPTN 081 
with historical controls (ie, SPARTAC cohorts described in Gossez et al (1)) or 
we condition on HIV-infection with the intention of comparing virologic 
outcomes by randomized treatment assignment from HVTN 703/HPTN 081.  
When comparing outcomes by treatment assignment among infected AMP 
participants, we are conditioning on a postrandomization event, HIV-infection. 
Consequently, a two-sample test for a difference in outcome is subject to 
postrandomization selection bias. A direct comparison of virologic outcomes 
between treatment groups, which measures the “net treatment effect,” does not 
have a causal interpretation (114). As an example of the type of bias that can 
occur, suppose VRC01 protects against mild viruses but is not effective against 
virulent viruses. If this were true, we might see longer time to re-initiation criteria 
in VRC01 recipients than placebo recipients whereas, if we restricted only to 
those participants infected with a virulent HIV strain, we might see shorter time to 
re-initiation criteria in the VRC01 group. Therefore, a two‐sample test comparing 
time to re-initiation criteria between treatment groups could give a misleading 
impression that VRC01 shortens viral suppression time during ATI while the 
causal interpretation of this hypothetical example would be that for virulent 
viruses, VRC01 increases viral suppression time during ATI compared to placebo. 
Approaches will be taken to ensure robust and unbiased results. Implementation 
of targeted minimum loss-based estimation (TMLE) methods, used to address the 
objectives in the following sections, will be fully prespecified in the statistical 
analysis plan (SAP) to ensure objective and reproducible inference. 
When comparing by treatment assignment among AMP cases, each analysis will 
be done pooling the VRC01 recipients versus placebo recipients with 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 48 of 153 
supplemental analyses done separately for each dose group versus the placebo 
recipients.  
4.2.3.1 
Time to ART re-initiation criteria 
The primary outcome is the time from the start of treatment interruption until the 
participant meets criteria to re-initiate ART.  
For a comparison of the placebo group to historical controls a Cox proportional 
hazards model with the indicator of AMP placebo group versus historical control 
group will be used to estimate the cumulative incidence in each group, as well as 
the HR, all with 95% confidence intervals and associated 2-sided p-values, where 
the model controls for baseline covariates thought to potentially predict both HIV-
1 infection and the instantaneous hazard of meeting the ART re-initiation criteria. 
This is needed for controlling for potential selection bias given that analyzed 
treatment groups are not randomized. Plots of the estimated cumulative incidence 
will be shown by treatment group. 
A Cox proportional hazards model with the indicator of assignment to a mAb 
group versus the control group will be used to estimate the cumulative incidence 
in each of the infected VRC01 and infected placebo groups, as well as the HR, all 
with 95% confidence intervals and associated 2-sided p-values, where the model 
controls for baseline covariates thought to potentially predict both HIV-1 
infection and the instantaneous hazard of meeting the ART re-initiation criteria. 
This is needed for controlling for potential postrandomization selection bias given 
that analyzed treatment groups are selected postrandomization. Plots of the 
estimated cumulative incidence will be shown by treatment group. 
As a supportive analysis of this hypothesis, TMLE may be used to estimate 
cumulative incidences of the primary efficacy endpoint over time for the pooled 
mAb arm and the control arm. Iterative mean-based TMLE is used for this 
analysis as described by Benkeser et al (115). The Super Learner (116) is used to 
generate initial estimates of the conditional censoring distribution and the iterated 
conditional means. This analysis will use TMLE as implemented in the R package 
survtmle available on CRAN (117). 
4.2.3.2 
Frequency of sustained post-treatment HIV control 
The same covariate adjusted model used to estimate cumulative incidence of 
meeting the re-initiation criteria for ART over time, described in the previous 
section, will be used to compare the rates of failure to maintain HIV control at 24 
weeks between the placebo group and historical controls and between the 2 
treatment groups. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 49 of 153 
4.2.4 
Secondary analyses of immune responses, reservoir measurements 
and viral load 
Analyses of immune responses and reservoir measurements will be descriptive 
using appropriate plotting techniques for describing measurements at a fixed time 
point (eg, boxplots and barplots) or longitudinally (eg, spaghetti plots) separately 
by treatment group. In addition, if enough samples are assayed we plan to do 
inferential and descriptive analyses as described in the following sections. 
4.2.4.1 
Evaluate the difference in anti-HIV immune responses or reservoir size 
between VRC01 and placebo recipients 
TMLE will be used to estimate mean endpoints in each of the infected VRC01 
and infected placebo groups, as well as the mean difference, all with 95% 
confidence intervals and associated 2-sided p-values, where the TMLE controls 
for all baseline covariates thought to potentially predict both HIV-1 infection and 
one of the secondary endpoints under study. This is needed for controlling for 
potential postrandomization selection bias given that analyzed treatment groups 
are selected postrandomization. 
4.2.4.2 
Assess whether anti-HIV immune responses or reservoir size are 
associated with time to meeting ART re-initiation criteria 
Cox regression will be used to estimate cumulative incidence over time for groups 
defined by levels of immune response or reservoir size for each treatment group. 
4.2.4.3 
Time to viral load > 200 
Secondary endpoint 2 is time until the participant has a viral load > 200. The same 
methodology used to assess time to ART re-initiation criteria will be used for this 
endpoint. In this analysis we will compare cumulative incidence at week 8 in each 
of the infected VRC01 and infected placebo groups supplemented by a sensitivity 
analysis based on cumulative incidence at weeks 8, 16, and 24. 
4.2.5 
Primary safety analysis 
4.2.5.1 
AEs and SAEs 
AEs will be summarized using Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class and preferred terms. Tables will show by 
treatment arm the number and percentage of participants experiencing an AE 
within a System Organ Class or within preferred term category by severity or by 
relationship to treatment interruption. For the calculations in these tables, a 
participant with multiple AEs within a category will be counted once under the 
maximum severity or the strongest recorded causal relationship to treatment 
interruption. Formal statistical testing comparing arms is not planned since 
interpretation of differences must rely heavily upon clinical judgment. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 50 of 153 
4.2.5.2 
Local laboratory values 
Box plots of local laboratory values will be generated for baseline values and for 
values measured during the course of the study by treatment arm and visit. Each 
box plot will show the first quartile, the median, and the third quartile. Outliers 
(values outside the box plot) will also be plotted. If appropriate, horizontal lines 
representing boundaries for abnormal values will be plotted. 
For each local laboratory measure, summary statistics will be presented by 
treatment arm and timepoint, as well as changes from baseline for postenrollment 
values. In addition, the number (percentage) of participants with local laboratory 
values recorded as meeting Grade 2 AE criteria or above as specified in the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events will be tabulated by treatment arm for each timepoint after initiation of 
treatment interruption. Reportable clinical laboratory abnormalities without an 
associated clinical diagnosis will also be included in the tabulation of AEs 
described above. 
4.2.5.3 
Reasons for discontinuation of ATI and early study termination 
The number and percentage of participants who discontinue ATI and who 
terminate from the study early will be tabulated by reason and treatment arm. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 51 of 153 
5 
Study population  
Participants for this trial will be recruited from among former HVTN 703/HPTN 
081 (NCT02568215) study participants who met criteria for transition to Schedule 
2 or Schedule 3 in that study and who meet the following inclusion/exclusion 
criteria.  
Investigators should always use good clinical judgment in considering a 
volunteer’s overall fitness for trial participation. Some volunteers may not be 
appropriate for enrollment even if they meet all inclusion/exclusion criteria. 
Medical, psychiatric, occupational, or other conditions may make evaluation of 
safety difficult, or may make volunteers unable to comply with the requirements 
of participation. For these reasons, some volunteers may be poor candidates for 
retention. 
5.1 
Inclusion criteria  
1. Estimated date of HIV-1 acquisition within 8 weeks of (ie, before or after) 
having received an HVTN 703/HPTN 081 infusion (see HVTN 805/HPTN 093 
SSP) 
2. Initiated ART within 28 weeks of HVTN 703/HPTN 081 date of HIV-1 
diagnosis 
3. Receiving continuous ART for at least 1 year  
• ART interruptions of up to 7 days in duration and ≥ 90 days prior to 
enrollment are acceptable.  
• Within- and between-class changes in ART within the previous year are 
acceptable. 
4. If on an NNRTI, willingness and ability to switch to a PI- or INSTI-containing 
regimen for at least 4 weeks prior to ART interruption 
5. Willingness to interrupt ART for up to 24 weeks or up to the time of meeting 
ART re-initiation criteria (Section 3.3) 
6. Willingness to re-initiate ART upon meeting study ART re-initiation criteria 
7. Willingness to use barrier protection (ie, male or female condoms) for all 
sexual activity during the ATI and until confirmation of viral suppression 
following ART re-initiation 
8. Willingness for CRS staff to contact primary HIV care provider to exchange 
information regarding HVTN 805/HPTN 093 and participant medical history 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 52 of 153 
9. Site investigator anticipates that a fully active alternative ART regimen could 
be constructed and would be available in the event of virologic failure on the 
participant’s current ART regimen.  
10. Access to a participating CRS and willingness to adhere to study visit schedule 
and to be followed for the planned duration of the study 
11. Ability and willingness to provide informed consent 
12. Assessment of understanding: volunteer demonstrates understanding of this 
study; completes a questionnaire prior to enrollment with verbal demonstration of 
understanding of all questionnaire items answered incorrectly. 
13. Agrees not to enroll in another study of an investigational research agent for the 
duration of the participant’s trial participation 
Laboratory Inclusion Values 
Immunology/Virology 
14. HIV-1 infection, with reactive HIV-1 antibody and any Multispot or Geenius 
HIV-1/HIV-2 results, documented by the HVTN 703/HPTN 081 HIV diagnostic 
algorithm 
15. Plasma HIV-1 RNA ≥ 1,000 copies/mL by any assay, prior to initiating ART 
16. CD4+ T-cell count ≥ 450 cells/mm3 obtained within 90 days prior to enrollment 
17. One plasma HIV-1 RNA below the lower limit of quantitation (LLOQ) 
collected at each of the following: 
• at screening, within 90 days prior to enrollment; and 
• greater than 9 months prior to the screening HIV-1 RNA 
Note: Sites must have results from locally available assays that are approved as 
standard-of-care by their regional governing bodies. 
Hematology 
18. Hemoglobin (Hgb) ≥ 10.0 g/dL  
19. Absolute neutrophil count (ANC) ≥ 750 cells/mm3 
20. Platelets ≥ 100,000 cells/mm3 
Chemistry 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 53 of 153 
21. Alanine aminotransferase (ALT) < 2.5 times the institutional upper limit of 
normal and direct bilirubin within the institutional range of normal 
22. eGFR > 60 mL/min/1.73m2 
Reproductive Status 
23. Volunteers capable of becoming pregnant: negative serum or urine beta human 
chorionic gonadotropin (β-HCG) pregnancy test performed at the screening visit 
and prior to enrollment. Persons who are NOT capable of becoming pregnant due 
to having reached menopause (no menses for 1 year) or having undergone total 
hysterectomy or bilateral oophorectomy or tubal ligation (verified by medical 
records) are not required to undergo pregnancy testing. 
24. Reproductive status: A volunteer who is capable of becoming pregnant must 
agree to consistently use effective contraception (ie, IUD or hormonal; see 
Appendix B and HVTN 805/HPTN 093 SSP) for sexual activity that could lead to 
pregnancy from at least 21 days prior to enrollment through confirmation of viral 
suppression following ART re-initiation.  
25. Volunteers capable of becoming pregnant must also agree not to seek 
pregnancy through alternative methods, such as artificial insemination or in 
vitro fertilization, until after confirmation of viral suppression following ART re-
initiation. 
5.2 
Exclusion criteria  
1. Any plasma HIV-1 RNA ≥ LLOQ (LLOQ: 75, 50, 40, or 20 copies/mL) within 
12 months prior to enrollment 
• 
NOTE: Two “blips” (ie, plasma HIV-1 RNA > LLOQ) < 400 copies/mL are 
allowed if preceded and followed by values < LLOQ and if the blips occur 
more than 6 months prior to enrollment. 
Note: Sites must have results from locally available assays that are approved as 
standard-of-care by their regional governing bodies. 
2. History of AIDS-defining illnesses or US Centers for Disease Control (CDC) 
Category C events per the current list on the CDC website (see HVTN 
805/HPTN 093 SSP) 
3. Autoimmune disease, including Type I diabetes mellitus (Not excluded from 
participation: Volunteer with mild, stable and uncomplicated autoimmune disease 
that does not require consistent immunosuppressive medication and that, in the 
judgment of the site investigator, is likely not subject to exacerbation and likely 
not to complicate AE assessments). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 54 of 153 
4. Immunosuppressive medications received within 6 months before enrollment 
(Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] 
topical corticosteroids for mild, uncomplicated dermatologic condition; or [4] a 
single course of oral/parenteral prednisone or equivalent at doses < 60 mg/day and 
length of therapy < 11 days with completion at least 30 days prior to enrollment) 
5. Blood products received within 120 days before planned ART interruption 
6. Investigational research agents, other than experimental vaccine(s) (See 
Exclusion Criterion #7), received within 30 days before planned ART interruption 
7. HIV or non-HIV experimental vaccine(s) received within the last 1 year. 
Exceptions may be made by the HVTN 805/HPTN 093 Protocol Safety Review 
Team (PSRT) for vaccines that have subsequently undergone licensure by the 
FDA or by the national regulatory authority where the volunteer is enrolling. For 
volunteers who have received control/placebo in an experimental vaccine trial, the 
HVTN 805/HPTN 093 PSRT will determine eligibility on a case-by-case basis. 
For volunteers who have received an experimental vaccine(s) greater than 1 year 
ago, eligibility for enrollment will be determined by the HVTN 805/HPTN 093 
PSRT on a case-by-case basis. 
8. Licensed live attenuated vaccines received within 30 days before planned ART 
interruption (eg, measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; 
varicella; yellow fever; live attenuated influenza vaccine) 
9. Licensed vaccines that are not live attenuated vaccines received within 14 days 
before planned ART interruption (eg, tetanus, pneumococcal, hepatitis A or B, 
influenza) 
10. Significant unstable cardiac or cerebrovascular disease (eg, angina, congestive 
heart failure [CHF], recent cerebrovascular accident [CVA], or myocardial 
infarction [MI]) 
11. Positive Hepatitis B surface antigen (HBsAg) or positive HCV RNA (Not 
exclusionary: positive HCV Ab with negative HCV RNA) 
12. Pregnant or breastfeeding 
13. Clinically significant medical condition, physical examination findings, 
clinically significant abnormal laboratory results, or past medical history with 
clinically significant implications for current health. A clinically significant 
condition or process includes but is not limited to: 
• A process that would affect the immune response; 
• A process that would require medication that affects the immune response; 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 55 of 153 
• Any contraindication to repeated blood draws, including inability to establish 
venous access; 
• A condition that requires active medical intervention or monitoring to avert 
grave danger to the volunteer’s health or well-being during the study period; 
or 
• Any condition specifically mentioned among the exclusion criteria. 
14. Any medical, psychiatric, occupational, or other condition that, in the 
judgment of the investigator, would interfere with, or serve as a contraindication 
to, protocol adherence, assessment of safety, or a volunteer’s ability to give 
informed consent 
15. Any medical, psychiatric, occupational, or other condition that, in the 
judgment of the investigator, could be exacerbated by events associated with 
protocol participation, which include: ATI, low-level viremia, subsequent viral 
rebound, and ART re-initiation 
16. HIV dementia or other neurologic disease that, in the judgment of the 
investigator, would be a contraindication to study participation 
17. Psychiatric condition that precludes compliance with the protocol. 
Specifically excluded are persons with psychoses within the past 3 years, ongoing 
risk for suicide, or history of suicide attempt or gesture within the past 3 years. 
18. Malignancy (Not excluded from participation: Volunteer who has had 
malignancy excised surgically and who, in the investigator’s judgment, has a 
reasonable assurance of sustained cure, or who is unlikely to experience 
recurrence of malignancy during the period of the study) 
19. Current untreated or incompletely treated active tuberculosis disease or 
current latent tuberculosis infection (Not excluded from participation: 
Volunteer who has latent tuberculosis infection and is undergoing treatment, with 
at least one month of treatment completed) 
20. Untreated or incompletely treated syphilis, gonorrhea, or chlamydia 
infection 
5.3 
Criteria for participant early termination 
• Pregnancy or breastfeeding (see Section 6.7.1) 
 
• 
Declared intention to become pregnant or begin breastfeeding before 
confirmation of viral suppression following ART re-initiation 
• Request by the participant to withdraw 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 56 of 153 
• Request of the primary HIV care provider  
• Participant starts ART switch but is not virally suppressed after approximately 
12 weeks (see Section 6.1.3). 
• Participant is judged by the investigator to be at significant risk of failing to 
comply with the provisions of the protocol so as to cause to harm to self or 
seriously interfere with the validity of the study results. 
• Participant relocates and remote follow-up or transfer to another CRS is not 
possible. (Note: Remote follow-up is allowable only after confirmation of 
viral suppression after ART re-initiation; see Ab Manual of Operations (MOP) 
and HVTN 805/HPTN 093 SSP for further detail.) 
• CRS determines that the participant is lost to follow-up. 
• Investigator decides, in consultation with Protocol Team leadership, to 
terminate participation (eg, if participant exhibits inappropriate behavior 
toward clinic staff). 
• Any condition where termination from the study is required by applicable 
regulations 
5.4 
Study termination 
This study may be terminated early by the determination of the HVTN 805/HPTN 
093 PSRT, a pertinent national regulatory authority, NIH, or the Office for 
Human Research Protections (OHRP). In addition, the conduct of this study at an 
individual Network CRS may be terminated by the determination of the IRB/EC 
and any applicable RE. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 57 of 153 
6 
Study procedures 
For all study visits, unless otherwise specified, participants will come to their 
assigned CRS.  
6.1 
Schedule 1: Monitoring ATI 
6.1.1 
Screening 
Screening may occur over the course of several contacts/visits. All inclusion and 
exclusion criteria must be assessed within 8 weeks (56 days) prior to enrollment, 
unless otherwise specified in the eligibility criteria (Section 5). 
After signing informed consent, volunteers will undergo the following 
procedures, as shown in Appendix E and Appendix H: 
• Assessment of Understanding 
• Medical history, including: 
o current psychiatric status and history 
o assessment of routine clinically-indicated vaccinations (note: must be 
completed prior to ATI initiation (see Section 5.2) 
• Complete physical examination 
• Assessment of concomitant medications 
• HIV transmission risk behavior assessment and counseling 
• Contraception status assessment (for participants who are capable of 
becoming pregnant and who are sexually active in a way that could lead to 
pregnancy; see 6.6 and Appendix B) 
• Decision aid 
• Blood collection for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o HBsAg and hepatitis C serology 
o QuantiFERON TB test  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 58 of 153 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
o Syphilis testing 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause (no menses for 1 year), or having undergone 
hysterectomy or bilateral oophorectomy or tubal ligation [verified by medical 
records], are not required to undergo pregnancy testing) 
• Gonorrhea/chlamydia testing by urine or cervical/vaginal swab  
• Trichomonas testing by cervical/vaginal swab 
• Tuberculin skin test (TST; only if QuantiFERON TB test not available) 
6.1.2 
Enrollment 
• Participants undergoing an “ART switch” will be considered enrolled on the 
first day of the new ART medication. 
• Participants who do not undergo an “ART switch” will be considered enrolled 
at the initiation of ATI (Day 0). 
6.1.3 
ART Switch 
ART switch 
Participants taking NNRTI-based ART regimens are required to switch to a PI- or 
INSTI-based regimen at least 4 weeks before beginning ATI and must 
demonstrate viral suppression (ie, < LLOQ) on the new regimen before beginning 
ATI. 
At the clinic visit initiating the ART switch, the participant will undergo the 
following procedures (see Appendix E and Appendix H): 
• Targeted (ie, symptom directed) physical examination, including weight and 
vital signs 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• HIV transmission risk behavior assessment and counseling 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 59 of 153 
• Contraception status assessment (for participants who are capable of 
becoming pregnant and who are sexually active in a way that could lead to 
pregnancy; see Section 6.6 and Appendix B) 
• Decision-making assessment 
• Psychosocial assessment 
• Blood collection for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause (no menses for 1 year), or having undergone 
hysterectomy or bilateral oophorectomy or tubal ligation [verified by medical 
records], are not required to undergo pregnancy testing) 
Post-ART switch contact 
The site will make arrangements to contact the participant approximately 2 weeks 
after initiation of the new ART regimen to assess tolerability of the ART switch 
and willingness to continue. This contact may be conducted over the phone or in 
person; see HVTN 805/HPTN 093 SSP for details.  
ATI qualification visit 
Four weeks or more after initiation of the new ART regimen, participants 
undergoing an ART switch will return for a clinic visit during which they will 
undergo the following procedures (see Appendix E and Appendix H): 
• Targeted (ie, symptom directed) physical examination, including weight and 
vital signs 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• HIV transmission risk behavior assessment and counseling 
• Contraception status assessment (for participants who are sexually active in a 
way that could lead to pregnancy; see Appendix B) 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 60 of 153 
• Blood collection for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause (no menses for 1 year), or having undergone 
hysterectomy or bilateral oophorectomy or tubal ligation [verified by medical 
records], are not required to undergo pregnancy testing) 
The procedures for the ATI qualification visit should be repeated as appropriate 
until viral suppression (ie, < LLOQ) is demonstrated. In general, ATI should be 
initiated approximately 2 weeks after the ATI qualification visit at which samples 
are collected that demonstrate viral suppression on the new ART regimen. 
Any participant who is not virally suppressed at the ATI qualification visit will be 
retested on a weekly basis until virally suppressed. If not virally suppressed by 
approximately 12 weeks from the start of the ART switch, the participant should 
be referred to re-initiate their previous NNRTI-containing regimen, will not 
proceed to the ATI, and will be terminated from the study. 
6.1.4 
ATI  
For all participants, initiation of ATI is defined as Day 0.  
While on Schedule 1, participants will undergo the following procedures, as 
specified in Appendix E and Appendix H: 
• Complete physical examination OR Targeted (ie, symptom directed) physical 
examination, including weight and vital signs 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• ART re-initiation assessment 
• HIV transmission risk behavior assessment and counseling 
• Contraception status assessment (for participants who are capable of 
becoming pregnant and who are sexually active in a way that could lead to 
pregnancy; see Section 6.6 and Appendix B) 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 61 of 153 
• Decision-making assessment 
• Psychosocial assessment 
• Social impact assessment 
• Social impact assessment questionnaire 
• Blood collection per Appendix E for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
o Syphilis testing 
o ARV detection 
o Intracellular cytokine staining (ICS) 
o Immune cell phenotyping 
o Neutralizing antibodies (nAb) 
o Fragment crystallizable receptor (FcR)-mediated effector functions 
o HIV reservoir assessment 
o Blood hormone levels (estradiol and progesterone) 
o Serum, plasma, and PBMC storage 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause (no menses for 1 year), or having undergone 
hysterectomy or bilateral oophorectomy or tubal ligation [verified by medical 
records], are not required to undergo pregnancy testing) 
• Gonorrhea/chlamydia testing by urine or cervical/vaginal swab 
• Trichomonas testing by cervical/vaginal swab 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 62 of 153 
6.2 
Schedule 2: Monitoring ATI with viremia 
As soon as participants demonstrate viral load ≥ 200 copies/mL, they will 
transition to Schedule 2, during which they will continue ATI while viremia is 
monitored. At Schedule 2 timepoints specified in Appendix F and Appendix I, 
participants will undergo the following procedures: 
• Complete physical examination OR targeted (ie, symptom directed) physical 
examination, including weight and vital signs 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• ART re-initiation assessment 
• HIV transmission risk behavior assessment and counseling 
• Contraception status assessment (for participants who are capable of 
becoming pregnant and who are sexually active in a way that could lead to 
pregnancy; see Section 6.6 and Appendix B). 
• Decision-making assessment 
• Psychosocial assessment 
• Social impact assessment 
• Social impact assessment questionnaire 
• Blood collection for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
o Syphilis testing 
o ARV detection 
o ICS 
o Immune cell phenotyping 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 63 of 153 
o Neutralizing antibodies (nAb) 
o FcR-mediated effector functions 
o Blood hormone levels (estradiol and progesterone) 
o Serum, plasma, and PBMC storage 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause [no menses for 1 year] or having undergone hysterectomy 
or bilateral oophorectomy [verified by medical records], are not required to 
undergo pregnancy testing). 
• Gonorrhea/chlamydia testing by urine or cervical/vaginal swab 
• Trichomonas testing by cervical/vaginal swab 
6.3 
Schedule 3: Follow-up on ART  
After ART re-initiation criteria are met (see Sections 3.3.2 and 3.3.3), participants 
will transition to Schedule 3 once ART is re-initiated (see Appendix G and 
Appendix J). In Schedule 3, if virologic resuppression has not been achieved by 
Week 12, participants may continue with biweekly visits until viral resuppression 
is achieved. These additional visits will be treated as interim visits (see HVTN 
805/HPTN 093 SSP).  
At Schedule 3 timepoints specified in Appendix G and Appendix J, participants 
will undergo the following procedures: 
• Complete physical examination OR targeted (ie, symptom directed) physical 
examination, including weight and vital signs 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• HIV transmission risk behavior assessment and counseling 
• Contraception status assessment (for participants who are capable of 
becoming pregnant and who are sexually active in a way that could lead to 
pregnancy; see Section 6.6 and Appendix B). 
• Decision-making assessment 
• Psychosocial assessment 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 64 of 153 
• Social impact assessment 
• Social impact assessment questionnaire 
• Blood collection for: 
o HIV PCR viral load 
o CD4+ and CD8+ T-cell counts 
o Hgb, ANC, platelets 
o ALT, direct bilirubin, eGFR 
o Syphilis testing 
o HIV genotypic antiretroviral resistance 
o Viral isolation and sequencing 
o ICS 
o Immune cell phenotyping 
o Neutralizing antibodies (nAb) 
o FcR-mediated effector functions 
o HIV reservoir assessment 
o Serum, plasma, and PBMC storage 
• Urine pregnancy test (persons not of reproductive potential due to having 
reached menopause [no menses for 1 year] or having undergone hysterectomy 
or bilateral oophorectomy [verified by medical records], are not required to 
undergo pregnancy testing). 
• Gonorrhea/chlamydia testing by urine or cervical/vaginal swab 
• Trichomonas testing by cervical/vaginal swab 
6.4 
Interim visits 
Confirmatory VL samples and confirmatory CD4+ T cell samples may be drawn 
at interim visits (see Sections 3.3.1, 3.3.2, and 3.3.3). At interim visits for this 
purpose, the following clinical procedures will be performed: 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 65 of 153 
• Targeted physical exam 
• Assessment of concomitant medications 
• Intercurrent illness/adverse experiences (AEs) 
• ART re-initiation assessment 
• HIV transmission risk behavior assessment and counseling 
• Social impact assessment 
Additional procedures may be performed at the discretion of the clinician.  
For additional information on interim visits, including interim visits for other 
reasons, see the HVTN 805/HPTN 093 SSP. 
6.5 
Early termination visit 
At an early termination visit for a participant on Schedule 1 or 2, CRS staff should 
consider performing procedures specified for Extended Visit Type A (see 
Appendix E, Appendix F, Appendix H, and Appendix I). Such participants will be 
urged to re-initiate ART under the care of their primary HIV care provider (see 
HVTN 805/HPTN 093 SSP for additional details).  
At an early termination visit for a participant on Schedule 3, CRS staff should 
consider performing laboratory procedures specified for Week 40 (Visit 91) and 
clinic procedures specified for Week 52 (Visit 92) (see Appendix G and Appendix 
J; see HVTN 805/HPTN 093 SSP for additional details).  
6.6 
Contraception status 
Contraception status is assessed and documented at every scheduled clinic visit 
from screening through confirmation of viral resuppression following ART re-
initiation for a participant who is capable of becoming pregnant and who is 
sexually active in a way that could cause that participant to become pregnant. 
Prior to enrollment and until viral resuppression is confirmed following ART re-
initiation, staff will ask participants to verbally confirm their use of adequate 
contraceptive methods (see Appendix B). A participant who is sexually active in a 
way that could cause that participant to become pregnant should be reminded at 
all scheduled clinic visits of the importance of using effective contraception (ie, 
IUD or hormonal) in addition to barrier protection (ie, condoms) to prevent HIV 
transmission to sexual partner(s) and should be referred to specific counseling, 
information, and advice as needed. This reminder should be documented in the 
participant’s study record. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 66 of 153 
Infertility—including having reached menopause (no menses for 1 year) or having 
undergone hysterectomy, bilateral oophorectomy, or tubal ligation—must be 
documented in the participant’s study record. 
6.7 
Specific clinical management considerations 
6.7.1 
Pregnancy or breastfeeding 
Volunteers who are pregnant or breastfeeding are not eligible to participate in this 
study. Participants who become pregnant or are breastfeeding during the ART 
switch will not be allowed to interrupt ART and will be terminated from the study 
immediately. Participants who become pregnant or are breastfeeding during the 
ATI phase will re-initiate ART as soon as possible. Post-ATI follow-up will 
continue per Schedule 3 for up to 24 weeks after viral re-suppression is confirmed 
following ART re-initiation. 
Participants who become pregnant or begin breastfeeding while on Schedule 3 (ie, 
after ART re-initiation) will continue per Schedule 3 for up to 24 weeks after viral 
re-suppression is confirmed. 
If a participant completes the study or chooses to discontinue from the study 
before the pregnancy ends, then CRS staff should request permission to contact 
the participant regarding pregnancy outcomes at the end of the pregnancy. If 
obtained, pregnancy outcomes will be recorded on a CRF at the end of the 
pregnancy. All pregnancies must be reported to the Antiretroviral Pregnancy 
Registry.  
6.7.2 
Acute retroviral syndrome (ARS) 
ARS is a rare diagnosis to be made by a CRS clinical IoR or designee or a 
primary HIV care provider. The HVTN 805/HPTN 093 PSRT should be 
consulted on possible ARS diagnosis. Participants with this diagnosis will re-
initiate ART as soon as possible. 
Signs and symptoms that may support a diagnosis of ARS include, but are not 
limited to, unintentional weight loss > 5% of pre-ATI body weight, otherwise 
unexplained persistent fever [> 38⁰C], persistent night sweats, persistent diarrhea, 
oral candidiasis, and generalized lymphadenopathy. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 67 of 153 
7 
Study products 
There are no study products. Drugs for ART and PrEP will not be provided by the 
study or paid for using sponsor funds. Access to external funding sources for 
PrEP and ART provision is available. Procedures for accessing external funding 
sources for PrEP and ART provision are detailed in the HVTN 805/HPTN 093 
SSP.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 68 of 153 
8 
Laboratory  
8.1 
CRS laboratory procedures 
The HVTN 805/HPTN 093 Site Lab Instructions and HVTN 805/HPTN 093 SSP 
provide further guidelines for operational issues concerning the clinical and 
processing laboratories. These documents include guidelines for general specimen 
collection, special considerations for phlebotomy, specimen labeling, whole blood 
processing, HIV screening/diagnostic testing, and general screening and safety 
testing. 
Tube types for blood collection are specified in Appendix E. Appendix F, and 
Appendix G. For tests performed locally, the local lab may assign appropriate 
tube types. 
In specific situations, the blood collection tubes may be redirected to another 
laboratory or may require study-specific processing techniques. In these cases, 
laboratory special instructions will be posted on the protocol-specific section of 
the HVTN website. 
Of note, all assays described below with the exception of HIV antiretroviral 
resistance testing are performed as research assays and are not approved for use in 
medical care. Results from these assays are not made available to participants or 
medical professionals to guide treatment decisions. 
8.2 
Assay timepoints 
Endpoint assays for immunologic and virologic responses will be performed on a 
subset of participants to be determined by the outcome of primary objectives and 
endpoints. 
8.3 
Endpoint assays: cellular 
8.3.1 
Intracellular cytokine staining (ICS) assay 
Flow cytometry will be used to examine HIV-specific CD4+ and CD8+ T-cell 
responses following stimulation of PBMCs with synthetic HIV peptides that span 
the HIV-1 viral proteins. ICS parameters will include cytokines such as interferon 
gamma (IFN-γ), interleukin (IL)-2, and TNF-α, and may include other cytokines 
(such as cytokines relevant to Th2 and Th17 responses) to identify T cells of 
specific functionality. Data will be reported as percentages of CD4+ and CD8+ T 
cells responding to a specific peptide pool. Additional cell surface markers, 
cytokines, or functional markers may also be analyzed. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 69 of 153 
8.4 
Phenotyping of cell populations 
Phenotyping of dendritic cells, monocytes, NK cells, B cells, T cells, or other 
leukocytes for lineage, maturation, and activation markers by flow cytometry may 
be performed on PBMCs. Data will be reported as percent of cells positive for 
each marker at the various timepoints. 
8.5 
Endpoint assays: humoral 
8.5.1 
Neutralizing antibody assay 
HIV-1–specific nAb assays will be performed on serum samples from study 
participants. The TZM-bl assay will test neutralization of the autologous 
transmitted/founder virus and a panel of heterologous tier 2 viruses (118, 119). 
Autologous neutralization escape may also be assessed at the discretion of the 
HVTN Laboratory Center, contingent on the results of the nAb assays. 
8.5.2 
Antibody-dependent cellular cytotoxicity (ADCC) 
ADCC activity may be assessed using serum samples from study participants. For 
the Luciferase-based cytotoxicity assay, participant sera are incubated with 
infectious molecular clone (IMC)-infected cells and percent killing is measured 
by evaluating the reduction in the luminescence signal after incubation of 
infected-target and effector cells in presence of serum Ab.  
8.5.3 
Antibody-dependent cellular phagocytosis (ADCP) 
To assess the ability of antibodies to engage cellular FcR for potential antiviral 
function, ADCP may be measured using serum samples from study participants. 
ADCP is measured by assessing the ability of antibodies to mediate monocyte 
phagocytosis of HIV-1 antigen coated fluorescent beads by flow cytometry (120, 
121). An array of antigens or viruses may also be analyzed at the discretion of the 
HVTN Laboratory Center, which may be contingent on the results of the primary 
antigens or viruses. 
8.5.4 
Virion capture  
The ability of purified IgG from participant serum to mediate infectious virion 
capture will be measured by infectious virion capture assay (IVCA). The test uses 
a Protein G column-based capture of Ig-virion immune complexes. 
8.6 
HIV viral reservoir 
Changes in the HIV reservoir will be quantitated in CD4+ T cells purified from 
PBMCs at designated timepoints, using testing methods such as the Intact Proviral 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 70 of 153 
DNA Assay (IPDA), Tat/rev Induced Limiting Dilution Assay (TILDA), assays 
detecting replication-competent virus-bearing cells (eg, virus outgrowth assays), 
and/or measures of total proviral DNA. Cell-associated HIV-RNA may be 
quantitated as a measure of the transcriptionally active reservoir. 
8.7 
Host genomics 
HLA and CCR5 genotyping may be performed on samples from this study or 
HVTN 703/HPTN 081 using cryopreserved PBMC. Other genes, including 
those associated with immune responses (eg, immunoglobulin or T-cell receptor 
genes) or HIV-1 disease progression may also be assessed. 
8.8 
HIV antiretroviral resistance testing 
HIV antiretroviral resistance testing will be performed by RNA sequencing for 
resistance mutations in participants whose plasma viremia shows limited 
suppression after ART re-initiation.  
8.9 
ARV detection  
Blood specimens will be collected during treatment interruption for ARV 
detection and drug level testing. ARV drug levels may be assessed at the 
discretion of the protocol team for participants who have not met virologic and 
non-virologic criteria for transition from monitoring ATI (Schedule 1) to 
monitoring ATI with viremia (Schedule 2) or for ART re-initiation (from 
Schedule 2 to Schedule 3). Assay methods may include HPLC-mass 
spectrometry, reverse-phase HPLC coupled with tandem mass spectrometry, or 
another similar method. 
8.10 
Biohazard containment 
As the transmission of HIV and other blood-borne pathogens can occur through 
contact with contaminated needles, blood, and blood products, appropriate 
precautions will be employed by all personnel in the drawing of blood and 
shipping and handling of all specimens for this study, as currently recommended 
by the CDC and the NIH or other applicable agencies. 
All dangerous goods materials, including Biological Substances, Category A or 
Category B, must be transported according to instructions detailed in the 
International Air Transport Association Dangerous Goods Regulations. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 71 of 153 
9 
Research use of stored human samples and/or data 
9.1 
Specimen storage and other use of specimens 
The HVTN and HPTN store specimens from all study participants indefinitely, 
unless a participant requests that specimens be destroyed or if required by 
IRB/EC, or RA. 
Other use of specimens is defined as studies not covered by the protocol or the 
informed consent form for the main study (see Appendix A and Appendix C). 
This research may relate to HIV, vaccines, antibodies, the immune system, and 
other diseases. This could include genetic testing and, potentially, genome-wide 
studies. This research is done only to the extent authorized in each study site’s 
informed consent form, or as otherwise authorized under applicable law. Other 
research on specimens (“other use”) will occur only after review and approval by 
the Networks, the IRB/EC of the researcher requesting the specimens, and the 
IRBs/ECs/REs of the CRSs if required. 
As part of consenting for the study, participants document their initial decision to 
allow or not allow their specimens to be used in other research, and they may 
change their decision at any time. The participant’s initial decision about other 
use of their specimens, and any later change to that decision, is recorded by their 
CRS in a Web-based tool that documents their current decisions for other use of 
their specimens. The Networks will only allow other research to be done on 
specimens from participants who allow such use. 
CRSs must notify HVTN Regulatory Affairs if institutional or local governmental 
requirements pose a conflict with or impose restrictions on specimen storage or 
other use of specimens. 
9.2 
Exploratory studies 
Samples may be used for other testing and research related to furthering the 
understanding of HIV, immunology, antibodies, or vaccines. In addition, 
cryopreserved samples may be used to perform additional assays to support 
standardization and validation of existing or newly developed methods. 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 72 of 153 
10 
Potential risks and benefits 
10.1 
Potential risks 
10.1.1 
Risks of ATI 
The risks from a closely monitored ATI are minimal in this study population. 
There is a theoretical risk that such an interruption could lead to the development 
of HIV drug resistance (122). This may be a particular concern for individuals 
taking NNRTIs. However, this potential risk is substantially mitigated by the 
procedures described in Section 6.1.1. Given the study population as restricted by 
the eligibility criteria, the frequency of immunological and virologic monitoring, 
and the criteria for restarting ART, it is extremely unlikely that such an ART 
interruption will lead to the development of any opportunistic infections or AIDS-
defining conditions. 
Rarely, viremic rebound may be associated with ARS (see Section 6.7.2). 
During the ATI phase, participants may transmit HIV infection if they do not 
adhere to safer sex practices. 
10.1.2 
Phlebotomy 
Drawing blood may be associated with discomfort, bruising, local hematoma 
formation and, on rare occasions, infections, lightheadedness, and fainting. 
The amount of blood drawn for research purposes will be within regulatory limits 
(see 21 CFR 630.15). 
10.2 
Potential benefits 
Study participants should expect no direct health benefits from study 
participation. Knowledge gained in this study may aid in development of better 
interventions against HIV. 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 73 of 153 
11 
Monitoring of safety 
11.1 
Safety monitoring and oversight 
11.1.1 
HVTN 805/HPTN 093 PSRT 
The HVTN 805/HPTN 093 PSRT is composed of the following members: 
• DAIDS medical officer representatives 
• Protocol chairs 
• Protocol Team leaders 
• Core medical monitor 
• Clinical safety specialist 
• Regional medical liaison 
The Protocol Team clinic coordinator, clinical data manager, clinical trial 
manager, clinical research manager, and others may also be included in HVTN 
805/HPTN 093 PSRT meetings. 
The clinician members of HVTN 805/HPTN 093 PSRT are responsible for 
decisions related to participant safety. 
The PSRT will review laboratory parameters (HIV-RNA, CD4+ T-cell count), 
adverse events, and a summary of the distribution of time to meeting ART re-
initiation criteria twice a month. Once the final participant achieves viral 
resuppression in Schedule 3, the PSRT may consider holding less frequent 
reviews (ie, monthly). 
The PSRT will also review the distribution of time to meeting ART re-initiation 
criteria in the first 20 HVTN 805/HPTN 093 participants and assess whether the 
distribution is comparable to that observed in an NIH intramural therapeutic HIV 
vaccine study that enrolled HIV-infected participants who initiated ART early 
with similar ART re-initiation criteria to those proposed here. Based on the NIH 
intramural therapeutic HIV vaccine study results, we expect that the median time 
to meeting ART re-initiation criteria in HVTN 805/HPTN 093 will be at ATI 
week 15 and that the 75th percentile for time to meeting ART re-initiation criteria 
will be around week 12-18. If the spread in the distribution time to meeting ART 
re-initiation criteria is less than expected, then the HVTN 805/HPTN 093 PSRT, 
in consultation with the NIAID Data and Safety Monitoring Board (DSMB), will 
consider strategies for modifying the study (eg, to alter the eligibility criteria) 
with the aim to further enrich for potential controllers. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 74 of 153 
The HVTN 805/HPTN 093 PSRT will also monitor specifically for failure to re-
suppress or to demonstrate a 2-log viral load reduction within 12 weeks after ART 
re-initiation. Any such failure and/or any AE ≥ Grade 4 deemed related to the 
study procedures will be reviewed by the HVTN 805/HPTN 093 PSRT promptly 
and, if indicated, by the NIAID DSMB to evaluate whether and how the study 
should be modified. 
11.1.2 
NIAID DSMB 
The NIAID DSMB assesses the study conduct during the trial and may give 
advice to the HVTN 805/HPTN 093 Protocol Team leadership.  
Approximately 6 months after enrollment of the first participant or after the 10th 
participant has completed 12 weeks of ATI (whichever comes first), an interim 
review of the study will occur. The DSMB will review accrual; retention; AE 
summaries, including all reported AEs ≥ Grade 3 and all STIs; summaries of the 
time to meeting ART re-initiation criteria; and longitudinal summaries of HIV-1 
RNA and CD4+ T-cell count. Subsequent DSMB reviews will occur at least 
annually while participants remain on study. A DSMB may also be convened if a 
reason is identified by the DAIDS MO, study Co-chairs, or study statisticians in 
consultation with the HVTN 805/HPTN 093 Protocol Team leadership. 
11.1.3 
Roles and responsibilities in safety monitoring  
The roles and responsibilities of the Statistical and Data Management Center 
(SDMC) in relation to safety monitoring include: 
• Maintaining a central database management system for clinical data; 
• Providing reports of clinical data to appropriate groups such as the HVTN 
805/HPTN 093 PSRT and NIAID DSMB (see Section 11.1.2); 
The roles and responsibilities of the HVTN CSS, HVTN RML, or HVTN Core 
designee in relation to safety monitoring include: 
• Daily monitoring of clinical data; 
• Querying CRSs for additional information regarding reported clinical data; 
and 
• Providing support to the HVTN 805/HPTN 093 PSRT. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 75 of 153 
11.2 
Safety reporting 
11.2.1 
Submission of safety forms to SDMC 
CRS staff must submit all safety forms (eg, AEs, local lab results, concomitant 
medications) before the end of the next business day, excluding federal or bank 
holidays. The forms should not be held in anticipation of additional information at 
a later date. If additional information is received at a later date, the forms should 
be updated and resubmitted before the end of the next business day after receiving 
the new information. For the case of a longer CRS holiday closure, CRS staff 
must submit the data by the end of the 5th day (local time) after receiving the 
information even if this day is a holiday.  
For example: If the CRS becomes aware of an AE on Thursday (Day 0), the CRS 
must submit the data by the end of the next business day, on Friday. If there is a 
longer CRS holiday closure, then this AE must be reported no later than the end 
of the fifth day, Monday (Day 4). If Monday is a holiday as well, all safety forms 
still need to be submitted by the end of Monday (Day 4). 
11.2.2 
Serious adverse event (SAE) 
An SAE is an AE that results in one or more of the following outcomes: 
• Death 
• A life-threatening (ie, an immediate threat to life) event 
• Requires in-patient hospitalization or prolongation of an existing 
hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• A congenital anomaly/birth defect 
• A medically important event (medical and scientific judgment should be 
exercised in deciding whether expedited reporting is appropriate in such 
situations, such as important medial events that may not be immediately life 
threatening or result in death or hospitalization, but which may jeopardize the 
individual or may require intervention to prevent one of the outcomes listed 
above.) 
11.2.3 
AE reporting 
An AE is any untoward medical occurrence in a clinical investigation participant, 
including an abnormal laboratory finding, symptom, or disease temporally 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 76 of 153 
associated with the individual’s participation in the research, whether or not 
related to the research. 
The study intervention for which adverse event attribution reporting is required is 
ATI. 
At designated visits, information regarding AEs will be elicited by appropriate 
questioning and examinations and will be documented in the medical record and 
in the electronic database. 
All AEs are graded according to the Division of AIDS (DAIDS) Table for 
Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 
2.1, July 2017, available on the DAIDS Regulatory Support Center (RSC) website 
at https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-
tables, except: 
• Unintentional Weight Loss is required to be reported as an AE only if it is 
considered to be potentially deleterious to the participant’s health (see HVTN 
805/HPTN 093 SSP); and 
• Creatinine is required to be reported as an AE only if it is gradable per the 
increase from local lab upper limit of normal (ULN) parameter. Do not grade 
elevated creatinine based on the change from the baseline parameter. 
• eGFR is required to be reported as an AE only if it is gradable per reported 
value or if dialysis is needed. Do not grade decreased eGFR based on the 
change from the baseline parameter (see HVTN 805/HPTN 093 SSP).  
All AEs are reported to the SDMC on the appropriate CRF. 
Sites are expected to notify HVTN clinical safety staff of any serious safety 
concern requiring their attention. Telephone numbers and email addresses are 
found on the protocol home page on the HVTN Members’ site 
(https://members.hvtn.org/protocols/hvtn805-hptn093). Concerns requiring 
immediate attention should be communicated by calling the clinical safety phone. 
In the case of email notification, clinical safety staff will reply within one 
business day. 
In addition, CRS investigators are required to submit AE information in 
accordance with IRB/EC and any applicable RE requirements. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 77 of 153 
12 
Ethics/protection of human subjects 
12.1 
Informed consent process 
Informed consent is a process where information is presented to enable persons to 
voluntarily decide whether or not to participate in a clinical trial. It is an ongoing 
conversation between the prospective or enrolled research participant and the 
researchers that begins before consent is given and continues through the 
decision-making process and until the end of the participant’s involvement in the 
research. Discussions about the research will provide essential information about 
the study and include: purpose, duration, experimental procedures, alternatives, 
risks, and benefits. Participants will be given the opportunity to ask questions and 
to have them answered.  
The participant will sign the informed consent document prior to undergoing any 
research procedures. The participant may withdraw consent at any time 
throughout the course of the study. A copy of the informed consent document will 
be given to participants for their records. Documentation of the signing of the 
consent form will be retained in the participant’s medical record. The rights and 
welfare of participants will be protected by emphasizing to them that the quality 
of their medical care will not be adversely affected if they decline to participate in 
this study. These rights and responsibilities are further elaborated upon in the 
Participants Bill of Rights and Responsibilities developed by the HVTN and 
HPTN for their jointly conducted trials. 
The HVTN 805/HPTN 093 SICF is modeled on previously-approved treatment 
interruption consent forms and, specifically, emphasizes the cautionary points 
noted above (see Section 2.6) with respect to the uncertainties, risks and lack of 
anticipated individual benefits; the fact that treatment interruptions are not 
recommended in clinical care; and the fact that ART guidelines recommend 
lifelong treatment. While the SICF is a crucial starting point, the quality of 
informed consent also relies on the process and other tools employed to 
supplement that document. With respect to these supplementary measures the 
team is building upon each Network’s longstanding efforts to build rigorous 
informed consent into trial implementation (123). These efforts begin with the 
community engagement described above (see Section 2.7) and go on to include: 
drafting of the SICF by and with local community representatives who reflect the 
target population and the sites that will be conducting the study; review of 
translated materials by local staff and community representatives who are native 
speakers of each language to help ensure accuracy and appropriateness; the 
provision of a Frequently Asked Questions information sheet; the development 
and use of visual aids to convey some concepts, such as blood draw volumes; the 
development of materials and processes to engage sexual partners, if participants 
and their partners so choose; the use of an Assessment of Understanding and re-
review of any misunderstandings as part of the initial and ongoing informed 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 78 of 153 
consent process; and ongoing community engagement throughout the trial, 
including local education and engagement activities, CAB meetings and study-
specific stakeholder meetings, among other forums. 
For HVTN 805/HPTN 093, the team will develop additional tools to facilitate 
optimal informed consent and decision-making. Specifically, the team will 
develop decision aids, such as those found to improve the quality of shared 
decision making and consent in preference-sensitive healthcare decisions (124, 
125) and will partner with participant advocates—nonteam members, ideally 
peers, familiar with the AMP Study, treatment interruption, and the HVTN 
805/HPTN 093 study—who could work with the AMP participant to further 
facilitate optimal decision-making regarding potential HVTN 805/HPTN 093 
participation. The latter model has been used, for example, in the setting of organ 
transplantation between HIV-positive donors and recipients (126, 127). Clinic 
staff will also be in consultation with each participant’s primary HIV care 
provider, as needed, to ensure their understanding and ability to support the 
participants. Any such materials developed for participants will be submitted for 
review and approval to the IRB/EC prior to using with participants.  
12.2 
Participant confidentiality 
All records will be kept confidential to the extent provided by federal, state, and 
local law. Study monitors and other authorized representatives of the Sponsor 
may inspect all documents and records required to be retained by the investigator, 
including but not limited to medical records. Records will be kept locked and all 
computer entry and networking programs will be done with coded numbers only. 
Clinical information will not be released without written permission of the 
participant, except as necessary for monitoring by IRB, NIH/NIAID/DAIDS or 
the sponsor’s designee, OHRP, or another regulatory authority. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 79 of 153 
13 
Protocol conduct 
This protocol and all actions and activities connected with it will be conducted in 
compliance with Good Clinical Practice (GCP) (ICHe6), the HVTN and HPTN 
network-specific Manuals of Operations, and DAIDS Clinical Research Policies 
and Standard Procedures Documents, including procedures for the following: 
• Protocol registration, activation, and implementation; 
• Informed consent, screening, and enrollment; 
• Study participant reimbursement; 
• Clinical and safety assessments; 
• Safety monitoring and reporting; 
• Data collection, documentation, transfer, and storage; 
• Participant confidentiality; 
• Study follow-up and close-out; 
• Quality control; 
• Protocol monitoring and compliance; 
• Advocacy and assistance to participants regarding negative social impacts 
associated with the trial; 
• Risk reduction counseling;  
• Specimen collection, processing, and analysis;  
• Exploratory and ancillary studies and sub-studies, and 
• Destruction of specimens. 
Any policies or procedures that vary from DAIDS, HVTN, or HPTN standards or 
require additional instructions will be described in the HVTN 805/HPTN 093 
SSP.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 80 of 153 
13.1 
Emergency communication with study participants 
As in all clinical research, this study may generate a need to reach participants 
quickly to avoid imminent harm, or to report study findings that may otherwise 
concern their health or welfare.  
When such communication is needed, the CRS will request that its IRB/EC and 
any applicable RE expedite review of the message. If this review cannot be 
completed in a timeframe consistent with the urgency of the required 
communication, the site should contact the participant first, and then notify the 
IRB/EC and any applicable RE of the matter as soon as possible. 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 81 of 153 
14 
Acronyms and abbreviations 
ACTG 
AIDS Clinical Trials Group 
ADCC 
antibody-dependent cellular cytotoxicity 
ADCP 
antibody-dependent cellular phagocytosis 
AE 
adverse experience 
AIDS 
acquired immune deficiency syndrome 
AMP 
antibody mediated prevention 
ANC 
absolute neutrophil count 
ARS 
acute retroviral syndrome 
ART 
antiretroviral therapy 
ATI 
analytical treatment interruption 
AUC 
area under the curve 
bnAb 
broadly neutralizing antibody 
CAB 
community advisory board 
caRNA 
cell associated RNA 
CBC 
complete blood count 
CDC 
(U.S.) Centers for Disease Control and Prevention 
CHI 
chronic HIV infection 
CRF 
case report form 
CRS 
clinical research site 
DAIDS 
Division of AIDS 
DNA 
deoxyribonucleic acid 
DSMB 
Data and Safety Monitoring Board 
EAE 
adverse event requiring expedited reporting 
EC 
ethics committee 
eGFR 
estimated glomerular filtration rate 
EIA 
enzyme immunoassay 
ELISA 
enzyme-linked immunosorbent assay 
Fc 
fragment crystallizable 
FcγR 
fragment crystallizable gamma receptor 
FcR 
fragment crystallizable receptor 
HAART 
highly active antiretroviral therapy 
HBsAg 
Hepatitis B surface antigen 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
Hgb 
hemoglobin 
HIV 
human immunodeficiency virus 
HPTN 
HIV Prevention Trials Network 
HVTN 
HIV Vaccine Trials Network 
ICS 
intracellular cytokine staining 
IgG 
immunoglobulin G 
INSTI 
integrase strand transfer inhibitor 
IoR 
investigator of record 
IQR 
interquartile range 
IRB 
institutional review board 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 82 of 153 
LLOQ 
lower limit of quantitation 
LOC 
leadership operations center 
mAb 
monoclonal antibody 
mcL 
microliter 
nAb 
neutralizing antibody 
NHP 
nonhuman primate 
NIAID 
National Institute of Allergy and Infectious Diseases 
NK 
natural killer (cells) 
NNRTI 
nonnucleoside reverse transcriptase inhibitor 
NIH 
National Institutes of Health 
OHRP 
Office of Human Research Protection 
PBMC 
peripheral blood mononuclear cells 
PCR 
polymerase chain reaction 
PHI 
primary HIV infection 
PI 
protease inhibitor 
PK 
pharmacokinetic 
PrEP 
pre-exposure prophylaxis 
PSRT 
Protocol Safety Review Team 
PTC 
post-treatment controller 
RNA 
ribonucleic acid 
SAE 
serious adverse event 
SDMC 
statistics and data management center 
SHIV 
simian/human immunodeficiency virus 
SICF 
sample informed consent form 
SIVIG 
specific intravenous immunoglobulin 
SMART 
Strategies for Management of Antiretroviral Therapy 
SSP 
study specific procedures 
TMLE 
targeted minimum loss-based estimation 
VL 
viral load 
VQA 
Virology Quality Assurance 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 83 of 153 
15 
Protocol version history 
Date: April 27, 2020 
Protocol version: 1.0 
Protocol modification: NA 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 84 of 153 
16 
Document references (other than literature 
citations) 
Other documents referred to in this protocol, and containing information relevant 
to the conduct of this study, include: 
• Antiretroviral Pregnancy Registry. Available at http://www.apregistry.com/. 
• Assessment of Understanding. Accessible through the HVTN protocol-
specific website. 
• Division of AIDS (DAIDS) Clinical Research Policies and Standard 
Procedures Documents. Available at 
https://www.niaid.nih.gov/research/daids-clinical-research-policies-standard-
procedures  
• Division of AIDS Protocol Registration Manual. Available at 
https://www.niaid.nih.gov/sites/default/files/prmanual.pdf  
• Division of AIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events. Version 2.1, dated March 2017. Available at 
https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-
tables 
• The Manual for Expedited Reporting of Adverse Events to DAIDS. Version 
2.0, January 2010. Available at https://rsc.niaid.nih.gov/clinical-research-
sites/manual-expedited-reporting-adverse-events-daids 
• HVTN Certificate of Confidentiality. Accessible through the HVTN website. 
• HVTN 805/HPTN 093 Study Specific Procedures. Accessible through the 
HVTN protocol-specific website. 
• Ab Manual of Operations. Accessible through the HVTN website. 
• HVTN Manual of Operations. Accessible through the HVTN website. 
• Dangerous Goods Regulations (updated annually), International Air Transport 
Association. Available for purchase at 
http://www.iata.org/publications/dgr/Pages/index.aspx  
• International Conference for Harmonisation of Technical Requirements for 
pharmaceuticals for Human Use (ICH) E6 (R2), Integrated Addendum to ICH 
E6(R1): Guideline for Good Clinical Practice: Section 4.8, Informed Consent 
of Trial Subjects. Available at 
https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 85 of 153 
• HVTN 805/HPTN 093 Participants’ Bill of Rights and Responsibilities. 
Accessible through the HVTN website. 
• NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical 
Research. Available at http://grants1.nih.gov/grants/guide/notice-files/NOT-
OD-01-053.html 
• Requirements for Source Documentation in DAIDS Funded and/or Sponsored 
Clinical Trials. Available at  
https://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/Pages/Cl
inicalSite.aspx  
• Title 21, Code of Federal Regulations, Part 50. Available at 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFR
Part=50 
• Title 45, Code of Federal Regulations, Part 46. Available at 
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html 
See Section 17 for literature cited in the background and statistics sections of this 
protocol. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 86 of 153 
17 
References 
1. 
Gossez M, Martin GE, Pace M, Ramjee G, Premraj A, Kaleebu P, et al. Virological 
remission after antiretroviral therapy interruption in female African HIV seroconverters. 
AIDS. 2019;33(2):185-97. 
2. 
Treatment Action Group. Community Recommendations for Clinical Research 
Involving Antiretroviral Treatment Interruptions in Adults Nov 2018 [Available from: 
http://www.treatmentactiongroup.org/sites/default/files/community_recs_clinical_research_fi
nal.pdf. 
3. 
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. 
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-
report of a consensus meeting. Lancet HIV. 2019;6(4):e259-e68. 
4. 
Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication 
and cure. AIDS. 2012;26(10):1261-8. 
5. 
Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of 
an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl 
Acad Sci U S A. 1997;94(24):13193-7. 
6. 
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. 
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. 
Science. 1997;278(5341):1295-300. 
7. 
Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. 
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. 
Science. 1997;278(5341):1291-5. 
8. 
Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the 
expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 
2016;30(3):343-53. 
9. 
Steingrover R, Pogany K, Fernandez Garcia E, Jurriaans S, Brinkman K, 
Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption 
depends on time of initiation of highly active antiretroviral therapy. AIDS. 
2008;22(13):1583-8. 
10. 
Le CN, Britto P, Brummel SS, Hoffman RM, Li JZ, Flynn PM, et al. Time to viral 
rebound and safety after antiretroviral treatment interruption in postpartum women compared 
with men. AIDS. 2019;33(14):2149-56. 
11. 
Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, et al. 
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close 
to HIV seroconversion. Arch Intern Med. 2012;172(16):1252-5. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 87 of 153 
12. 
Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, Morrison C, et al. Virological 
Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary 
HIV Infection. J Acquir Immune Defic Syndr. 2017;74(2):126-33. 
13. 
Goujard C, Girault I, Rouzioux C, Lecuroux C, Deveau C, Chaix ML, et al. HIV-1 
control after transient antiretroviral treatment initiated in primary infection: role of patient 
characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001-9. 
14. 
Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, 
et al. Post-treatment HIV-1 controllers with a long-term virological remission after the 
interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 
2013;9(3):e1003211. 
15. 
Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et 
al. Long-term immunovirologic control following antiretroviral therapy interruption in 
patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598-601. 
16. 
Stohr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, et al. Duration of 
HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates 
with time on therapy. PLoS One. 2013;8(10):e78287. 
17. 
Martin GE, Gossez M, Williams JP, Stohr W, Meyerowitz J, Leitman EM, et al. Post-
treatment control or treated controllers? Viral remission in treated and untreated primary HIV 
infection. AIDS. 2017;31(4):477-84. 
18. 
Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, et al. The Control 
of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers 
Identified From 14 Clinical Studies. J Infect Dis. 2018;218(12):1954-63. 
19. 
Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, et al. 
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-
1 DNA and plasma HIV-1 RNA. Antivir Ther. 2011;16(4):535-45. 
20. 
Maenza J, Tapia K, Holte S, Stekler JD, Stevens CE, Mullins JI, et al. How often 
does treatment of primary HIV lead to post-treatment control? Antivir Ther. 2015;20(8):855-
63. 
21. 
Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, et 
al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected 
individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 
2017;9(419). 
22. 
Martin GE, Frater J. Post-treatment and spontaneous HIV control. Curr Opin HIV 
AIDS. 2018;13(5):402-7. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 88 of 153 
23. 
Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, et al. HIV-1 proviral 
landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 
2018;128(9):4074-85. 
24. 
Goulder P, Deeks SG. HIV control: Is getting there the same as staying there? PLoS 
Pathog. 2018;14(11):e1007222. 
25. 
Rouzioux C, Hocqueloux L, Saez-Cirion A. Posttreatment controllers: what do they 
tell us? Curr Opin HIV AIDS. 2015;10(1):29-34. 
26. 
Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, et al. 
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat 
Commun. 2015;6:8495. 
27. 
Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, et al. Antibody 
specificities associated with neutralization breadth in plasma from human immunodeficiency 
virus type 1 subtype C-infected blood donors. J Virol. 2009;83(17):8925-37. 
28. 
Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, et al. A limited 
number of antibody specificities mediate broad and potent serum neutralization in selected 
HIV-1 infected individuals. PLoS Pathog. 2010;6(8):e1001028. 
29. 
Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated 
during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009;15(8):866-
70. 
30. 
Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's 
pathways. Immunol Rev. 2013;254(1):225-44. 
31. 
Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, 
structures, and B cell ontogenies. Immunity. 2012;37(3):412-25. 
32. 
McCoy LE, Burton DR. Identification and specificity of broadly neutralizing 
antibodies against HIV. Immunol Rev. 2017;275(1):11-20. 
33. 
Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in 
Vaccine Design. Annu Rev Immunol. 2016;34:635-59. 
34. 
Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad 
and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811-7. 
35. 
Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A 
Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012;12(4):396-407. 
36. 
Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current 
approaches and future directions. Curr Opin Immunol. 2010;22(3):358-66. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 89 of 153 
37. 
Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary 
titans. Proc Natl Acad Sci U S A. 2005;102(42):14943-8. 
38. 
Fauci AS. An HIV Vaccine: Mapping Uncharted Territory. JAMA. 2016;316(2):143-
4. 
39. 
Haynes BF, Mascola JR. The quest for an antibody-based HIV vaccine. Immunol 
Rev. 2017;275(1):5-10. 
40. 
Halper-Stromberg A, Nussenzweig MC. Towards HIV-1 remission: potential roles 
for broadly neutralizing antibodies. J Clin Invest. 2016;126(2):415-23. 
41. 
Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, et al. Activation and lysis 
of human CD4 cells latently infected with HIV-1. Nat Commun. 2015;6:8447. 
42. 
Sloan DD, Lam CY, Irrinki A, Liu L, Tsai A, Pace CS, et al. Targeting HIV 
Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that 
Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog. 2015;11(11):e1005233. 
43. 
Caskey M, Klein F, Nussenzweig MC. Broadly Neutralizing Antibodies for HIV-1 
Prevention or Immunotherapy. N Engl J Med. 2016;375(21):2019-21. 
44. 
Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. 
Immunol Rev. 2017;275(1):313-23. 
45. 
Ananworanich J, McSteen B, Robb ML. Broadly neutralizing antibody and the HIV 
reservoir in acute HIV infection: a strategy toward HIV remission? Curr Opin HIV AIDS. 
2015;10(3):198-206. 
46. 
Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et 
al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human 
monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289-301. 
47. 
Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic 
effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 
infection. Sci Transl Med. 2015;7(319):319ra206. 
48. 
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. 
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J 
Med. 2016;375(21):2037-50. 
49. 
Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, et al. 
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal 
antibody, in healthy adults. MAbs. 2017:1-9. 
50. 
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, et al. Safety, 
pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 90 of 153 
doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: 
Results of a phase 1 randomized trial. PLoS Med. 2017;14(11):e1002435. 
51. 
Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, et al. Basis 
and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-
Concept Efficacy Trials. Stat Commun Infect Dis. 2017;9(1). 
52. 
Bolton DL, Pegu A, Wang K, McGinnis K, Nason M, Foulds K, et al. Human 
Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human 
Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. J 
Virol. 2016;90(3):1321-32. 
53. 
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, et al. 
Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559. 
54. 
Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. HIV-1 
antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. 
Nature. 2016;535(7613):556-60. 
55. 
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination 
therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 
2018;561(7724):479-84. 
56. 
Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, et 
al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against 
HIV-1 in vivo. Science. 2016;352(6288):1001-4. 
57. 
Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Therapeutic 
efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected 
rhesus monkeys. Nature. 2013;503(7475):224-8. 
58. 
Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, et al. 
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the 
development of neutralizing antibodies. J Virol. 2004;78(11):5983-95. 
59. 
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, et al. 
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against 
HIV-1. Science. 2016;352(6288):997-1001. 
60. 
Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Jr., Halper-Stromberg A, et al. 
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape 
variants. J Exp Med. 2014;211(12):2361-72. 
61. 
Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-FcgammaR interactions in IgG-
mediated microbial neutralization. J Exp Med. 2015;212(9):1361-9. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 91 of 153 
62. 
DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor 
Vaccinal Effect. Cell. 2015;161(5):1035-45. 
63. 
Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA, Simon RE, et al. The use of 
immune complex vaccines to enhance antibody responses against neutralizing epitopes on 
HIV-1 envelope gp120. Vaccine. 2009;28(2):352-60. 
64. 
Kumar R, Tuen M, Liu J, Nadas A, Pan R, Kong X, et al. Elicitation of broadly 
reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune 
complex vaccines. Vaccine. 2013;31(46):5413-21. 
65. 
Villinger F, Mayne AE, Bostik P, Mori K, Jensen PE, Ahmed R, et al. Evidence for 
antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen 
processing and cross presentation in SIV-infected rhesus macaques. J Virol. 2003;77(1):10-
24. 
66. 
Lambour J, Naranjo-Gomez M, Piechaczyk M, Pelegrin M. Converting monoclonal 
antibody-based immunotherapies from passive to active: bringing immune complexes into 
play. Emerg Microbes Infect. 2016;5(8):e92. 
67. 
Hua CK, Ackerman ME. Increasing the Clinical Potential and Applications of Anti-
HIV Antibodies. Front Immunol. 2017;8:1655. 
68. 
Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, Hengartner H. On 
immunological memory. Annu Rev Immunol. 1996;14:333-67. 
69. 
Pelegrin M, Naranjo-Gomez M, Piechaczyk M. Antiviral Monoclonal Antibodies: 
Can They Be More Than Simple Neutralizing Agents? Trends Microbiol. 2015;23(10):653-
65. 
70. 
Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, et al. The 
natural killer cell response and tumor debulking are associated with prolonged survival in 
recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor 
lysates. Oncoimmunology. 2013;2(3):e23401. 
71. 
Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-
cell defects. Nat Rev Immunol. 2004;4(12):941-52. 
72. 
Drakes ML, Stiff PJ. Regulation of Ovarian Cancer Prognosis by Immune Cells in the 
Tumor Microenvironment. Cancers (Basel). 2018;10(9). 
73. 
Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. 
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent 
reservoirs in humanized mice. Cell. 2014;158(5):989-99. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 92 of 153 
74. 
Chun TW, Murray D, Justement JS, Blazkova J, Hallahan CW, Fankuchen O, et al. 
Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad 
Sci U S A. 2014;111(36):13151-6. 
75. 
Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich 
TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing 
antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 
2013;110(41):16538-43. 
76. 
Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. 
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses 
viraemia. Nature. 2013;503(7475):277-80. 
77. 
Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral 
persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu 
Rev Immunol. 2000;18:665-708. 
78. 
Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, et al. 
Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med. 
2017;23(11):1271-6. 
79. 
Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, 
et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in 
lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A. 
2015;112(10):E1126-34. 
80. 
Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided 
structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa 
(Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981-9. 
81. 
Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, 
Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of 
antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96. 
82. 
Team DT. Fixed duration interruptions are inferior to continuous treatment in African 
adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22(2):237-47. 
83. 
Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, et al. A 
randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral 
therapy for the treatment of HIV infection in Uganda. PLoS One. 2010;5(4):e10307. 
84. 
Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, et al. 
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral 
therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011;6(6):e21450. 
85. 
Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral 
treatment interruption in HIV-infected individuals. AIDS. 2019;33(5):773-91. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 93 of 153 
86. 
Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short-term 
antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy. 
J Med Virol. 2012;84(6):885-9. 
87. 
Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, 
Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with 
continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. 
Lancet. 2006;368(9534):459-65. 
88. 
Investigators ST, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. Short-course 
antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3):207-17. 
89. 
Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, et al. 
Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV 
treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur 
Wiesch and van Lunzen. J Infect Dis. 2013;208(2):363. 
90. 
Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, et al. 
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A 
Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Acquir Immune Defic 
Syndr. 2016;72(1):31-8. 
91. 
Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, et al. A randomized 
therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in 
HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009;27(43):6088-94. 
92. 
Levy Y, Thiebaut R, Montes M, Lacabaratz C, Sloan L, King B, et al. Dendritic cell-
based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated 
with control of viral load. Eur J Immunol. 2014;44(9):2802-10. 
93. 
Huiting ED, Gittens K, Justement JS, Shi V, Blazkova J, Benko E, et al. Impact of 
treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who had 
initiated antiretroviral therapy during the early phase of infection. J Infect Dis. 2019. 
94. 
Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, et al. 
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV 
reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 
2018;14(1):e1006792. 
95. 
Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, et al. HIV-1 latent 
reservoir size and diversity are stable following brief treatment interruption. J Clin Invest. 
2018;128(7):3102-15. 
96. 
Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, et al. 
Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. 
J Virol. 2018;92(12). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 94 of 153 
97. 
Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, et al. Analytical 
antiretroviral therapy interruption does not irreversibly change preinterruption levels of 
cellular HIV. AIDS. 2018;32(13):1763-72. 
98. 
Stecher M, Claßen A, Klein F, Lehmann C, Gruell H, Platten M, et al. Systematic 
Review And Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving 
Antiretroviral Therapy: Implications for Future HIV Cure Trials. Clinical Infectious 
Diseases. 2019. 
99. 
Hardy WD. Analytical Treatment Interruptions (ATIs) and HIV Cure Research 
Seizing the Opportunity, While Maintaining Safety and Respect. Clinical Infectious 
Diseases. 2019. 
100. 
Michael NL. Clinical trial design: The nobility of randomization. Sci Transl Med. 
2017;9(419). 
101. 
Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A dendritic cell-
based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl 
Med. 2013;5(166):166ra2. 
102. 
Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Jr., Coombs RW, et al. 
Evidence that intermittent structured treatment interruption, but not immunization with 
ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS 
Clinical Trials Group 5068. J Infect Dis. 2006;194(5):623-32. 
103. 
Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, et al. Safety 
and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral 
therapy during acute/early HIV-1 infection. PLoS ONE. 2010;5(5):e10555. 
104. 
Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. 
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-
infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 
core protein. J Infect Dis. 2010;202(5):705-16. 
105. 
Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher K, Jupimai T, et al. Ethics 
of treatment interruption trials in HIV cure research: addressing the conundrum of 
risk/benefit assessment. J Med Ethics. 2018;44(4):270-6. 
106. 
Li JZ, Smith DM, Mellors JW. The need for treatment interruption studies and 
biomarker identification in the search for an HIV cure. AIDS. 2015;29(12):1429-32. 
107. 
Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. 
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell 
transplantation: report of 2 cases. Ann Intern Med. 2014;161(5):319-27. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 95 of 153 
108. 
Hill AL, Rosenbloom DI, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, et 
al. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral 
Therapy Interruption Trials for HIV. PLoS Pathog. 2016;12(4):e1005535. 
109. 
Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, et al. 
Interrupting antiretroviral treatment in HIV cure research: scientific and ethical 
considerations. J Virus Erad. 2017;3(2):82-4. 
110. 
Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. Curr Opin 
HIV AIDS. 2018;13(5):422-7. 
111. 
Edupuganti S, Mgodi N, Karuna S, Andrew P, Kochar N, deCamp A, et al. Antibody 
Mediated Prevention: Proof-of-Concept, Randomized, Blinded, Placebo-controlled Trials to 
Assess Safety and Efficacy of VRC01 to Prevent HIV-1 (P05.18LB). R4P, October 21-25, 
2018, Madrid, Spain. 
112. 
Andrew P, Andrasik M, Thommes E, deCamp A, Kochar N, Karg C, et al. Retention 
in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent 
HIV in Women, MSM & Transgender (TG) People (P05.17LB). R4P, October 21-25, 2018, 
Madrid, Spain. 
113. 
Takuva S, Karuna S. HVTN 703/HPTN 081 & HVTN 704/HPTN 085 Antibody 
Mediated Prevention (AMP) Trials: Infusion Reactions Update. HVTN Sub-Saharan Africa 
Regional Meeting, 21-22 February 2018. Cape Town, South Africa. 
114. 
Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal 
vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59(3):531-41. 
115. 
Benkeser D, Carone M, Gilbert PB. Improved estimation of the cumulative incidence 
of rare outcomes. Stat Med. 2018;37(2):280-93. 
116. 
van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 
2007;6:Article25. 
117. 
Benkeser D, Hejazi N. survtmle: Compute Targeted Minimum Loss-Based Estimates 
in Right-Censored Survival Settings [R package]. 2018 [Available from: https://cran.r-
project.org/web/packages/survtmle/index.html. 
118. 
DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. 
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited 
neutralizing antibodies. J Virol. 2014;88(5):2489-507. 
119. 
Seaman M, Janes H, Hawkins N, Grandpre L, Devoy C, Giri A, et al. Tiered 
Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of 
Neutralizing Antibodies. J Virol. 2010;84(3):1439-52. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 96 of 153 
120. 
Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, et al. Antibody-
Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and 
Subclasses. PLoS Pathog. 2016;12(8):e1005817. 
121. 
Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A 
robust, high-throughput assay to determine the phagocytic activity of clinical antibody 
samples. J Immunol Methods. 2011;366(1-2):8-19. 
122. 
Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, et al. 
Antiretroviral resistance associated with supervised treatment interruptions in treated acute 
HIV infection. AIDS. 2003;17(7):1086-9. 
123. 
Woodsong C, Karim QA. A model designed to enhance informed consent: 
experiences from the HIV prevention trials network. Am J Public Health. 2005;95(3):412-9. 
124. 
O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW, 
Sepucha KR, et al. Toward the 'tipping point': decision aids and informed patient choice. 
Health Aff (Millwood). 2007;26(3):716-25. 
125. 
Pope TM. Certified Patient Decision Aids: Solving Persistent Problems with 
Informed Consent Law. J Law Med Ethics. 2017;45(1):12-40. 
126. 
Steel JL, Gordon EJ, Dulovich M, Kingsley K, Tevar A, Ganesh S, et al. Transplant 
advocacy in the era of the human immunodeficiency virus organ policy equity act. Clin 
Transplant. 2018;32(7):e13309. 
127. 
Durand CM, Segev D, Sugarman J. Realizing HOPE: The Ethics of Organ 
Transplantation From HIV-Positive Donors. Ann Intern Med. 2016;165(2):138-42. 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 97 of 153 
Appendix A 
Sample informed consent form 
Title: Antiretroviral analytical treatment interruption (ATI) to assess immunologic 
and virologic responses in participants who initiated ART in early HIV infection 
after having received VRC01 or placebo in HVTN 703/HPTN 081 
Protocol number: HVTN 805/HPTN 093 
Site: [Insert site name] 
Thank you for your interest in our research study. Please read this consent form or 
ask someone to read it to you. If you decide to join the study, we will ask you to 
sign or make your mark on this form. We will offer you a copy to keep. We will 
ask you questions to see if we have explained everything clearly. You can also 
ask us questions about the study. 
Research is not the same as treatment or medical care. The purpose of a research 
study is to answer scientific questions. These answers can help find new 
medicines, treatments, vaccines, and knowledge about how the human body 
works.  
You are being invited to take part in this study because you got infected with HIV 
while you were enrolled in the AMP Study and started HIV treatment (also 
known as “ART” or anti-retroviral treatment) soon after the diagnosis, and 
because your viral load (the amount of HIV in your blood) has been kept at a very 
low level or “undetectable” for at least the past year. We will enroll people who 
got the study antibody and people who got placebo. Since the AMP Study is still 
blinded, we don’t know whether you got the study antibody or not.  
We expect that between 16 and 61 people will join this study. 
Key information 
These are some of the things you should know about this study: 
• One purpose of the study is to learn whether starting HIV treatment soon after 
diagnosis might help you control HIV after you interrupt your HIV treatment. 
• A second purpose of the study is to learn whether having the AMP Study 
antibody in a person’s body might help the immune system control HIV better 
if that person gets HIV.  
• A third purpose is to learn if it is safe for people to interrupt their HIV 
treatment in a carefully monitored research study. 
• If you are eligible and choose to join, we will ask you to interrupt your HIV 
treatment.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 98 of 153 
• After you interrupt taking HIV treatment, you will have regular clinic visits to 
carefully track your HIV and your health. If your viral load goes up to 200 or 
higher, you will continue to stay off your HIV treatment, and we will check on 
your health more often.  
• If your viral load goes up to 1,000 or more and stays that high for 4 weeks, or 
if your CD4 count drops below 350, or if you show any symptoms of HIV-
related illness, you will restart taking HIV treatment. If your viral load at the 
end of 6 months is 200 or higher, you will restart taking HIV treatment. If 
your immune system maintains control of your HIV for the entire 6 months, 
you may choose to keep going without taking HIV treatment for as long as 
your viral load remains below 200 and you don’t meet the other restart criteria 
within this study. 
• Once you restart taking HIV treatment, you will have follow-up visits for up 
to a year to see how your body responds to restarting HIV treatment and to 
make sure that your viral load returns to very low or undetectable levels. 
• At clinic visits we will give you physical exams, ask about your physical and 
mental health, and collect blood for laboratory tests. 
• Interrupting your HIV treatment is an experimental procedure that is only 
used in carefully monitored research. It is not recommended as part of routine 
healthcare for people living with HIV. Healthcare guidelines recommend that 
people living with HIV take HIV treatment for the rest of their lives. Some of 
the risks when you interrupt HIV treatment include having a high viral load 
and acute retroviral syndrome, having a low CD4 count, transmitting HIV to 
your partner(s), developing HIV drug resistance, and having to switch to a 
new HIV treatment, which could have additional side effects. The study is 
designed to make it unlikely that any of these things will happen. 
• There may also be risks we don’t know about, even serious ones, including 
death.  
• There is no direct benefit to you from being in the study. 
• Whether to join this study is your choice. You do not have to join, and you are 
free to leave at any time. Your choice will not affect the care you receive at 
this clinic. 
The rest of this form provides a more complete description of this study. Please 
read it carefully and ask questions at any time. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 99 of 153 
Why is this study being done? 
Researchers know that when people interrupt their HIV treatment, their viral load 
usually goes up quickly, and they must restart taking their treatment. This quick 
increase does not always happen. Very rarely, for only a few people, it stays low, 
or even undetectable for many months.  
We do not expect this study to benefit you directly, even if you received the study 
antibody in the AMP study. You should not expect to control the virus while you 
are off of your HIV treatment. 
Researchers think that starting HIV treatment soon after being diagnosed with 
HIV may improve how the body’s immune system responds to HIV and may keep 
the viral load low. Small studies in people have shown that people who start HIV 
treatment early are more likely to be able to control HIV after interrupting HIV 
treatment than people who started HIV treatment later. Researchers want to know 
how and why this happens. 
Researchers also think that having an anti-HIV antibody like the one used in the 
AMP Study in the body at the time when HIV infection happens may improve 
how the body’s immune system responds to HIV. This could happen even if the 
antibody didn’t prevent HIV acquisition. 
Animal studies suggest that having an anti-HIV antibody in the body at the time 
of HIV infection may help the immune system keep viral load low for a longer 
period of time without taking HIV treatment. Researchers want to find out if this 
will happen in people. And if it happens in people, researchers want to know how 
and why this happens. 
1. We are doing this study to answer several questions. 
• Are people who start HIV treatment soon after diagnosis likely to keep HIV 
under control after interrupting HIV treatment? If so, for how long? 
• Are people who got the study antibody in the AMP Study more likely to keep 
HIV under control for a longer period of time without taking HIV treatment 
than people who got the placebo? 
• Is it safe for people to interrupt taking their HIV treatment in this carefully 
monitored research study? 
• Do people who got the study antibody in the AMP Study and got HIV develop 
and maintain an immune system that is more capable of controlling HIV viral 
load than people who got the placebo and get HIV? 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 100 of 153 
• Do people who got the study antibody or placebo in the AMP Study and get 
HIV have a difference in the number of cells that are infected with HIV but do 
not reproduce before and after interrupting their HIV treatment?  
2. To answer these questions, study participants will interrupt use of HIV 
treatment. 
Interrupting HIV treatment is an experimental procedure that is only used in 
carefully monitored research. It is not recommended as part of routine healthcare 
for people living with HIV. Healthcare guidelines recommend that people living 
with HIV take HIV treatment for the rest of their lives. We will tell you more 
about the risks of interrupting your HIV treatment in Section 19 of this form. 
During the time that you do not take your HIV treatment we will check your 
health and HIV frequently to minimize the chance of harm to you. If your viral 
load goes up, your CD4 count goes down, you show signs of HIV-related illness, 
or you and/or your primary healthcare worker decide to, you will restart taking 
your HIV treatment right away.  
Joining the study 
3. It is completely up to you whether or not to join the study. 
Take your time in deciding. If it helps, talk to people you trust, such as your 
primary HIV care provider, friends or family. We will be happy to help you 
explain this study to anyone you wish. If you decide not to join this study, or if 
you leave it after you have joined, your other care at this clinic and the benefits or 
rights you would normally have will not be affected. 
You cannot be in this study while you are in another study where you get a study 
product. Being in more than one study may not be safe. 
If you choose not to join this study, you may be able to join another study. 
4. If you want to join the study, we will screen you to see if you are eligible. 
Screening involves a physical exam, checking your mental health, an HIV test, 
and asking about your health history. A physical exam may include, but is not 
limited to: 
• Checking your weight, temperature and blood pressure, 
• Looking in your mouth and throat, 
• Listening to your heart and lungs, and 
• Feeling your abdomen (stomach and liver). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 101 of 153 
We will also do blood and urine tests. These tests tell us about some aspects of 
your health, such as how healthy your kidneys, liver, and immune system are. We 
will also test you for hepatitis B, hepatitis C, tuberculosis (TB), gonorrhea, 
chlamydia, syphilis, and Trichomonas. We will ask you about medications you 
are taking. If you can become pregnant, we will test you for pregnancy. If you are 
pregnant, you cannot join the study.  
We will communicate with your primary healthcare worker to coordinate your 
care during this study. We will check to make sure your HIV has been well 
controlled by your HIV treatment for at least one year.  
We will ask if you are willing to use condoms every time you have sex for an 
extended period of time during the study, until you restart your HIV treatment and 
your viral load returns to being very low or undetectable. This is to protect your 
partner(s). 
We will review the screening results with you. The screening results may show 
you are not eligible to join the study, even if you want to.  
5. If we find that you have a health problem during screening or during the 
study, we will tell you about the care that we can give here for free. 
For the care that we cannot give, we will explain how we will help you get care 
elsewhere. We will not pay for care for health problems that are unrelated to the 
study. 
Site: Appendix B, Approved contraception methods (for sample informed consent 
form), contains supplemental information. If you want to include Appendix B in this 
consent form, paste it below. 
6. If you can become pregnant, you must agree to use effective contraception to 
join this study. 
Current HIV treatment guidelines recommend using HIV treatment during 
pregnancy to prevent transmission to the baby. Since you will interrupt your HIV 
treatment in this study, you should not become pregnant. In addition to using 
condoms every time you have sex to prevent HIV transmission to your partner, 
we will ask you to use contraception as well. Effective contraception can include 
an IUD or hormone-based contraception. 
If you become pregnant or start breastfeeding before you interrupt your HIV 
treatment, you will have to leave the study immediately. 
If you become pregnant or start breastfeeding after you interrupt your HIV 
treatment, you will have to restart taking it, but you can remain in the study. If 
you become pregnant or start breastfeeding after you have restarted your HIV 
treatment, you will continue taking it. In both these situations, we would like you 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 102 of 153 
to come for clinic visits for up to 6 months after your HIV viral load returns to 
very low or undetectable. 
The study staff would like to obtain information from you about the outcome of 
the pregnancy (even if it is after your participation in the study ends). If you are 
taking your HIV treatment when you become pregnant, your pregnancy will be 
reported to an international database that collects information about pregnancies 
in people using HIV treatments. This report will not use your name or other 
information that could be used to identify you. 
Being in the study 
If you meet the study requirements and want to join, here is what will happen. 
7. We will make sure you are on the right HIV treatment for this study. 
You may have to change some of the HIV treatment you are taking. If you are 
taking HIV treatment that stays in the blood for a long time even after you stop 
taking it, we will have you switch to a different HIV treatment for at least one 
month before you interrupt all of your HIV treatment. We will provide this new 
treatment to you for free. This is to reduce the already small chance that you may 
develop drug resistance. Drug resistance means the HIV treatment you have been 
taking might not control your HIV when you restart it. We will check on you after 
about 2 weeks to see how you are doing on the new HIV treatment. If you have 
any problems after starting the new HIV treatment, please let us know. 
We will ask you to come to the clinic about 4 weeks after starting the new HIV 
treatment to see if it is controlling your HIV. If it is not, we will ask you to come 
to the clinic weekly for up to 12 weeks (about 3 months) until your HIV is 
controlled. 
If the new HIV treatment does not bring your HIV viral load to very low or 
undetectable within about 3 months, you will not able to continue with the rest of 
the study. 
8. If you join the study, we will collect some basic information. 
We will record your medical history and give you a physical examination, 
including checking your weight and vital signs. We will ask about other 
medications you are taking and about any illnesses you may have. We will also 
collect blood and urine samples, and if you can become pregnant, we will give 
you a pregnancy test. We will test you for gonorrhea and chlamydia using urine or 
a cervical/vaginal swab. We will test you for syphilis using a blood sample and 
for Trichomonas using a cervical/vaginal swab. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 103 of 153 
9. In Part 1 of the study, you will interrupt your HIV treatment. 
After you interrupt your HIV treatment, for the first 8 weeks (about 2 months) 
you will visit the clinic every week (8 visits). For the next 16 weeks (months 2-6), 
you will visit the clinic every 2 weeks (8 visits). For the next 6 months, if you are 
still in Part 1 of the study, you will visit the clinic about every month (7 visits). 
One reason for these frequent clinic visits is to carefully track your HIV and your 
health. 
At these visits we will ask about anything new in your medical history and give 
you a brief physical exam. We will collect blood. When we collect blood, the 
amount will depend on the lab tests we need to do. It will be some amount 
between 6 mL and 130 mL (a little more than 1 teaspoon and a little less than ½ 
cup). Your body will make new blood to replace the blood we take out. 
We will check to make sure you are using condoms for all sexual activity. 
If you can become pregnant, we will check to make sure you are using effective 
contraception. We will also give you a pregnancy test.  
We will test you for gonorrhea and chlamydia at some visits using urine or a 
cervical/vaginal swab. At these times we will also test you for Trichomonas using 
a cervical/vaginal swab. 
Some of the blood we collect will be used for lab tests to check your general 
health (including syphilis testing) and to check your immune system. Estrogen 
and progesterone may affect the immune system, so we will check the amount of 
those hormones in your blood. We will also check to see if you still have any HIV 
treatment in your blood.  
We will review the results of these procedures tests with you at your next visit, or 
sooner if necessary. If any of the results are important to your health, we will tell 
you. 
Some of the blood collected at each visit will be used to test your viral load and 
your CD4 count. If your viral load goes up to 200 or higher, you will move to Part 
2 of the study.  
If any of the following happens, you will restart your HIV treatment as soon as 
possible and move to Part 3 of the study.  
• Your CD4 count drops below 350, 
• You show any symptoms of HIV-related illness, 
• You decide to restart your HIV treatment, or  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 104 of 153 
• Your primary healthcare worker or the doctor at the study clinic decides that 
you should restart your HIV treatment. 
If none of these things happens, a person can stay in Part 1 for a year or longer. 
Most people will be in Part 1 of the study for less than 6 months.  
If you meet the restart criteria but choose not to restart ART, we will ask you to 
continue Part 1 clinic visits. We may need to see you for additional visits to check 
your safety. If you restart your HIV treatment you will move to Part 3. 
10. Here is what will happen in Part 2 of the study. 
In Part 2, you will continue to stay off your HIV treatment. When you start Part 2, 
for the first 8 weeks (about 2 months), you will visit the clinic every week (9 
visits). For the next 28 weeks (months 2-8), you will visit the clinic every 2 weeks 
(14 visits). After that, if you still have not met the criteria to restart your HIV 
treatment, for the next 4 months, you will visit the clinic once a month (4 visits). 
One reason for these frequent clinic visits is to carefully track your HIV and your 
health. 
At these visits we will ask about anything new in your medical history. At the first 
visit in Part 2, we will give you a complete physical exam. At all other visits in 
Part 2 we will give you a brief physical exam. We will collect blood. When we 
collect blood, the amount will depend on the lab tests we need to do. It will be 
some amount between 6 mL and 120 mL (a little more than 1 teaspoon and a little 
less than ½ cup). Your body will make new blood to replace the blood we take 
out. 
We will check to make sure you are using condoms for all sexual activity. 
If you can become pregnant, we will check to make sure you are using effective 
contraception. We will also give you a pregnancy test.  
We will test you for gonorrhea and chlamydia at some visits using urine or a 
cervical/vaginal swab. At these times we will also test you for Trichomonas using 
a cervical/vaginal swab. 
Some of the blood we collect will be used for lab tests of your general health 
(including syphilis testing) and to check your immune system. Estrogen and 
progesterone may affect the immune system, so we will check the amount of 
those hormones in your blood. We will also check to see if you have any HIV 
treatment in your blood.  
We will review the results of these procedures and tests with you at your next 
visit, or sooner if necessary. If any of the results are important to your health, we 
will tell you. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 105 of 153 
Some of the blood collected at each visit will be used to test your viral load and 
your CD4 count.  
During the first 24 weeks (about 6 months) in Part 2, if any of the following 
happens, you will restart your HIV treatment as soon as possible and move to Part 
3 of the study.  
• Your viral load goes up to 1,000 or higher and stays there for 4 weeks without 
dropping very quickly, 
• Your CD4 count drops below 350, 
• You show any symptoms of HIV-related illness, 
• You decide to restart your HIV treatment, or 
• Your primary HIV care provider or the doctor at the study clinic decides that 
you should restart your HIV treatment. 
After 24 weeks (6 months), if any of the following happens, you will restart your 
HIV treatment as soon as possible and move to Part 3 of the study. 
• Your viral load is 200 or higher, 
• Your CD4 count drops below 350, 
• You show any symptoms of HIV-related illness, 
• You decide to restart your HIV treatment, or 
• Your primary healthcare worker or the doctor at the study clinic decides that 
you should restart your HIV treatment. 
If you do not meet these restart criteria, you can stay in Part 2 of the study for as 
long as your viral load stays below 200. Most people will be in Part 2 for a few 
weeks to a few months. Some people may stay in Part 2 for a year or longer. If 
you meet the restart criteria but choose not to restart ART, we will ask you to 
continue Part 2 clinic visits. We may need to see you for additional visits to check 
your safety. If you restart your HIV treatment you will move to Part 3. 
11. After you restart taking HIV treatment, you will have follow-up clinic visits 
for about another year. This is Part 3 of the study. 
This follow-up period is to see how your body responds to restarting your HIV 
treatment and to make sure that your HIV returns to very low or undetectable 
levels. For most people, we expect that your viral load will drop within about 12 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 106 of 153 
weeks (about 3 months). If it does not, we will ask you to come to the clinic every 
2 weeks until your HIV is controlled. 
Once you restart taking HIV treatment, for the first 12 weeks (about 3 months) 
you will have clinic visits every 2 weeks (7 visits). For the next 16 weeks (about 4 
months), you will have clinic visits once a month (4 visits). For the next 24 weeks 
(about 6 months) you will have 2 visits scheduled 3 months apart. At these visits 
we will ask about anything new in your medical history and give you a brief 
physical exam. We will collect blood. When we take blood, the amount will 
depend on the lab tests we need to do. It will be some amount between 6 mL and 
225 mL (a little more than 1 teaspoon and a little less than 1 cup). 
At some visits, we will test you for gonorrhea and chlamydia using urine or a 
cervical/vaginal swab. At these times we will also test you for Trichomonas using 
a cervical/vaginal swab. We will also do a blood test for syphilis.  
We will review the results of these procedures and tests with you at your next 
visit, or sooner if necessary. If any of the results are important to your health, we 
will tell you. 
You will still need to use condoms every time you have sex until we have 
confirmed that your viral load has returned to very low or undetectable levels. If 
you can become pregnant, we will check to make sure you are using effective 
contraception until we have confirmed that your viral load has returned to very 
low or undetectable levels. We will also give you a pregnancy test at some visits.  
12. If you stay in Part 1 or Part 2 of the study for more than a year, you will have 
visits every 3 months. 
At these visits we will ask about anything new in your medical history and give 
you a brief physical exam. We will collect blood. Some of that blood gets used for 
viral load and CD4 testing.  
At some visits, we will test you for gonorrhea and chlamydia using urine or a 
cervical/vaginal swab. At these times we will also test you for Trichomonas using 
a cervical/vaginal swab. At these same visits, we will test you for syphilis using 
blood samples.  
We will review the results of these tests with you at your next visit, or sooner if 
necessary. If any of the results are important to your health, we will tell you. 
We will continue to check to make sure you are using condoms every time you 
have sex. 
Also, if you can become pregnant, we will check to make sure you are using 
effective contraception. We will also give you a pregnancy test at each visit.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 107 of 153 
If you meet the restart criteria at any time, you will restart your HIV treatment and 
move to Part 3 of the study as described above in Section 11. If you choose not to 
restart your treatment, we will strongly urge you to continue clinic visits on the 
same schedule you have been on. We may need to see you for additional visits to 
check your safety. If you restart your HIV treatment you will move to Part 3. 
13. Most participants will be in the study about 13-18 months. 
This depends on whether you need to switch your HIV treatment when you enroll 
and how long it takes before you meet the criteria to restart your HIV treatment. If 
your immune system controls your HIV for a long time without treatment, then 
you might be in the study longer. The longest we expect anyone to be in the study 
is about 3 years. 
14. We will test your samples to see how your immune system is functioning.  
We will send your samples (without your name) to labs approved by the HVTN 
and the HPTN for this study, which are located in the United States and South 
Africa. In rare cases, some of your samples may be sent to labs approved by the 
HVTN and HPTN in other countries for research related to this study. 
Some of the blood we collected previously in the AMP Study or that we collect in 
this study might be used for genetic testing in this study. Your genes are passed to 
you from your birth parents. They affect how you look and how your body works. 
Differences in genes can explain why some people get a disease and others don’t. 
The genetic testing that might be done in this study involves only some of your 
genes related to how your immune system works to fight HIV. The testing will 
not involve all of your genes (your genome). We want to understand whether your 
genes affect your ability to control HIV in combination with whether or not you 
got the AMP Study antibody. 
In some cases, researchers may take cells from your samples and grow more of 
them over time, so that your samples can continue to contribute to this study. 
These tests done on your samples are for research purposes, not to check your 
health. The labs will not give the results to you or this clinic because their tests 
are not approved for use in making health care decisions. These labs are only 
approved to do research tests. 
When your samples are no longer needed for this study, the HVTN will continue 
to store them. 
Site: Delete next section if using separate consent for use of samples and information 
in other studies. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 108 of 153 
15. When samples are no longer needed for this study, the HVTN and HPTN 
may want to use them in other studies and share them with other 
researchers.  
These samples are called “extra samples”. The HVTN and HPTN will only allow 
your extra samples to be used in other studies if you agree to this. You will mark 
your decision at the end of this form. If you have any questions, please ask. 
Do I have to agree? No. You are free to say yes or no, or to change your mind 
after you sign this form. At your request, the HVTN and HPTN will destroy all 
extra samples that they have. Your decision will not affect your being in this 
study or have any negative consequences here.  
Where are the samples stored? Extra samples are stored in a secure central place 
called a repository. Your samples will be stored in the HVTN repository in the 
South Africa. 
How long will the samples be stored? There is no limit on how long your extra 
samples will be stored. [Site: Revise the previous sentence to insert limits if your 
regulatory authority imposes them.] 
Will I be paid for the use of my samples? No. Also, a researcher may make a new 
scientific discovery or product based on the use of your samples. If this happens, 
there is no plan to share any money with you. The researcher is not likely to ever 
know who you are. 
Will I benefit from allowing my samples to be used in other studies? Probably not. 
Results from these other studies are not given to you, this clinic, or your doctor. 
They are not part of your medical record. The studies are only being done for 
research purposes. 
Will the HVTN or HPTN sell my samples and information? No, but the HVTN 
and HPTN may share your samples with other researchers. Once we share your 
samples and information, the HVTN and HPTN may not be able to get them back. 
How do other researchers get my samples and information? When a researcher 
wants to use your samples and information, their research plan must be approved 
by the HVTN and HPTN. Also, the researcher’s institutional review board (IRB) 
or ethics committee (EC) will review their plan. [Site: If review by your 
institution’s IRB/EC/RE is also required, insert a sentence stating this.] IRBs/ECs 
protect the rights and well-being of people in research. If the research plan is 
approved, the HVTN will send your samples to the researcher’s location.  
What information is shared with HVTN, HPTN, or other researchers? The 
samples and information will be labeled with a code number. The key to the code 
will stay at this clinic. It will not be shared with the HVTN, other researchers or 
with anyone else who does not need to know your name. Your name will not be 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 109 of 153 
part of the information. However, some information that The HVTN and HPTN 
share may be personal, such as your race, ethnicity, sex, health information from 
the study, and HIV status. The HVTN and HPTN may share information about 
the study product you received and how your body responded to the AMP study 
product.  
What kind of studies might be done with my extra samples and information? The 
studies will be related to HIV, vaccines, monoclonal antibodies, the immune 
system, and other diseases.  
Researchers may also do genetic testing on your samples.  
In some cases, researchers may take cells from your samples and grow more of 
them over time, so that they can continue to do research with them. 
If you agree, your samples could also be used for genome wide studies. In these 
studies, researchers will look at all your genes (your genome). The researchers 
compare the genomes of many people, looking for common patterns of genes that 
could help them understand diseases. The researchers may put the information 
from the genome-wide studies into a protected database so that other researchers 
can access it. Usually, no one would be able to look at your genome and link it to 
you as a person. However, if another database exists that also has information on 
your genome and your name, someone might be able to compare the databases 
and identify you. If others found out, it could lead to discrimination or other 
problems. The risk of this happening is extremely small. 
Who will have access to my information in studies using my extra samples?  
People who may see your information are: 
• Researchers who use your extra samples and information for other research, 
• Government agencies that fund or monitor the research using your extra 
samples and information, 
• Any regulatory agency that reviews clinical trials, 
• The researcher’s Institutional Review Board or Ethics Committee, or 
• The people who work with the researcher/ 
All these people will do their best to protect your information. The results of any 
new studies that use your extra samples and information may be published. No 
publication will use your name or identify you personally. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 110 of 153 
16. We will reimburse you [Site: Insert compensation] for each study visit you 
complete. 
This amount is to cover the costs of [Site: Insert text] 
Site: Insert any costs to participants (eg, contraception costs for participants who 
could become pregnant). 
You do not have to pay anything to be in this study. 
17. We will do our best to protect your private information. 
Your study records and samples will be kept in a secure location. We will label all 
of your samples and most of your records with a code number, not your name or 
other personal information. However, it is possible to identify you, if necessary. 
We will not share your name with the lab that does the tests on your samples, or 
with anyone else who does not need to know your name. 
Clinic staff will have access to your study records. Your records may also be 
reviewed by groups who watch over this study to see that we are protecting your 
rights, keeping you safe, and following the study plan. These groups include: 
• The US National Institutes of Health and its study monitors, 
• [Insert name of local IRB/EC] , 
• [Insert name of local and/or national regulatory authority as appropriate], 
• Any regulatory agency that reviews clinical trials, 
• The Dale and Betty Bumpers Vaccine Research Center and people who work 
for them, 
• The HVTN, HPTN and people who work for them,  
• The US National Institute of Allergy and Infectious Diseases Data and Safety 
Monitoring Board, and 
• The US Office for Human Research Protections. 
All reviewers will take steps to keep your records private. 
We cannot guarantee absolute privacy. If you are found to have a medical 
condition that we are required to report by law, then some of your information 
may be shared. At this clinic, we have to report the following information:  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 111 of 153 
Site: Include any public health or legal reporting requirements. Bulleted examples 
should include all appropriate cases (reportable communicable disease, risk of harm 
to self or others, etc.). If your site does not have public health or legal reporting 
requirements, you may delete the last sentence in the paragraph above, along with 
the bullets below. 
• [Item 1] 
• [Item 2] 
• [Item 3] 
The results of this study may be published. No publication will use your name or 
identify you personally. 
We may share information from the study with other researchers. We will not 
share your name or information that can identify you. 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov. This website will not include information that can 
identify you. At most, the website will include a summary of the results. You can 
search this website at any time. 
18. We may take you out of the study even if you want to stay in it.  
This may happen if: 
• You move away from the study site and transferring to another study site is 
not possible, 
• Clinic staff cannot contact you, 
• We think, or your primary HIV care provider thinks, that staying in the study 
might harm you, 
• You do not follow study instructions, 
• You enroll in a different research study where you get a study product,  
• You become pregnant or are breastfeeding,  
• You tell us you intend to get pregnant or begin breastfeeding while you are 
not taking your HIV treatment, or 
• The study is stopped for any reason. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 112 of 153 
Risks 
19. There are risks to being in this study. 
This study is designed to minimize the risks of interrupting your HIV treatment. 
This depends on you following the instructions from the clinic staff and attending 
all your study visits. 
This section describes the risks we know about. There may also be risks we don’t 
know about, even serious ones. We will tell you if we learn anything new that 
may affect your willingness to stay in the study. 
Risks of interrupting your HIV treatment 
Staying off HIV treatment is not recommended for routine healthcare for people 
living with HIV. Interrupting HIV treatment is an experimental procedure. It can 
increase the risk of serious health complications, including death. This section 
describes the risks we know about. There may also be risks we don’t know about, 
even serious ones.  
High viral load 
At some point after you interrupt your HIV treatment, your viral load will 
probably rise. During this time, you probably will not have any symptoms. 
However, it is possible that you could have symptoms of what is called “acute 
retroviral syndrome.” We think that having this syndrome is rare because you 
started taking HIV treatment soon after your HIV diagnosis. The symptoms could 
include: 
• Fever, 
• Weight loss, 
• Sore throat, 
• Swollen lymph nodes, 
• Headache, 
• Body or joint aches, 
• Tiredness, 
• Night sweats, 
• Oral yeast infection, 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 113 of 153 
• Diarrhea, or 
• Rash. 
If you have any of these symptoms, tell the study staff right away. These 
symptoms should go away or become less severe once you restart your HIV 
treatment. 
If your viral load increases, this could lead to inflammation. High levels of 
inflammation over many years are associated with heart disease and other medical 
conditions. Starting your HIV treatment again should reduce inflammation. 
Low CD4 count 
If your viral load rises, your CD4 count could drop. This could increase your risk 
for other HIV-related illnesses. In about 60 people studied to date, there has not 
been a significant difference in CD4 counts before and 6-12 months after 
interrupting HIV treatment. However, it is possible that your CD4 count might not 
return to its original level, even after you restart taking your HIV treatment.  
Transmitting HIV to your partner(s) 
While your viral load is controlled, the risk that you could transmit HIV to a 
sexual partner is very low, known as U = U (undetectable = untransmittable). 
Once you interrupt HIV treatment that risk gets higher.  
That is why you must use condoms for all sexual activity during the time that you 
are not taking your HIV treatment. 
If your sexual partners do not have HIV, they should get regular HIV testing until 
you have restarted your HIV treatment and we have confirmed that your viral load 
has returned to very low or undetectable levels. Testing for your partners is not 
part of this study.  
Site: Adjust the next sentence as appropriate for your site. 
If your partners are interested, we can tell you about a program we have for 
providing pre-exposure prophylaxis (PrEP) to them during the time that you are in 
the study. You are also welcome to bring partners to the clinic for education and 
risk reduction counseling. 
Transmitting HIV to your baby 
If you become pregnant, the risk of transmitting HIV to your baby gets higher if 
you are not taking your HIV treatment. That is why you must keep using 
contraception during the time when you are not taking HIV treatment until you 
restart treatment and your viral load returns to very low or undetectable. If you 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 114 of 153 
become pregnant, it is extremely important to take your HIV treatment throughout 
the entire pregnancy. 
Developing HIV drug resistance 
As we described in Section 7 above, when you interrupt HIV treatment, the HIV 
in your body might mutate in ways that make it resistant to the HIV treatment you 
have been taking. This means the treatment you were taking may not control your 
HIV when you start taking it again. To make this less likely, we may ask you to 
switch to a different HIV treatment before beginning the study. 
After you restart your HIV treatment, you will have very frequent viral load tests. 
If your viral load is not returning to its original level within 8-12 weeks of 
restarting your HIV treatment, we will test to see if the HIV is resistant to your 
HIV treatment regimen. If resistance is found, we will recommend more effective 
HIV treatment to you and your primary healthcare worker. 
Side effects from new HIV treatment or non-study medications: 
If you need to switch your HIV treatment, there may be some new side effects 
from the new HIV treatment. We or your primary healthcare worker can explain 
those side effects to you. 
There may also be a risk of serious or even life-threatening side effects from non-
study medications taken during the study. For your safety, tell the study doctor or 
nurse at the study clinic about all medications you are taking before you start the 
study, and also before starting using any new medications during the study.  
Routine medical procedures: 
In this study, we will take blood. This can cause bruising, pain, fainting, soreness, 
redness, swelling, itching, a sore, bleeding, and (rarely) muscle damage or 
infection where the needle was inserted. In some people, taking blood can cause a 
low blood cell count (anemia), making you feel tired. 
Risks of disclosure of your personal information: 
We will take several steps to protect your personal information. Although the risk 
is very low, it is possible that your personal information could be given to 
someone who should not have it. If that happened, you could face discrimination, 
stress, and embarrassment. We can tell you more about how we will protect your 
personal information if you would like. 
Risks of other people learning your HIV status: 
We will keep your participation in this study and your HIV status confidential. 
However, if others learn that you are in a study for people living with HIV, you 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 115 of 153 
could face discrimination, stress, embarrassment, stigma, or intimate partner 
violence.  
Risk of limitations to research participation: 
As a result of being in this study, you may not be eligible to participate in other 
HIV treatment or cure studies that require you to have an undetectable viral load 
for a period of time. After you restart taking your HIV treatment and your viral 
load becomes undetectable again, this limitation will go away over time. 
Risks of genetic testing: 
It is unlikely, but the genetic tests that might be done on your samples could show 
you may be at risk for certain diseases. If others found out, it could lead to 
discrimination or other problems. However, it is almost impossible for you or 
others to know your test results from the genetic testing. The results are not part 
of your study records and are not given to you. 
Benefits 
20. We do not expect the study to benefit you directly. 
However, information learned from this study may help others who have HIV and 
being in the study might still help you in some ways. The lab tests and physical 
exams that you get while in this study might detect health problems you don’t yet 
know about. You may also learn whether you are one of the rare people who can 
control HIV without using HIV treatment. This study may help in the search for a 
vaccine or other ways to prevent HIV. 
Your rights and responsibilities 
21. If you join the study, you have rights and responsibilities. 
You have many rights that we will respect. You also have responsibilities. We list 
these in the Participant’s Bill of Rights and Responsibilities. We will give you a 
copy of it. 
Leaving the study 
22. Tell us if you decide to leave the study.  
You are free to leave the study at any time and for any reason. Your care at this 
clinic and your legal rights will not be affected, but it is important for you to let us 
know.  
We will ask you to come back to the clinic one last time for a physical exam, and 
we may ask to take some blood and urine samples. We will also ask about any 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 116 of 153 
personal problems or benefits you have experienced from being in the study. We 
will counsel you about the importance of taking your HIV treatment and 
following up with your primary healthcare worker. We believe these steps are 
important to protecting your health, but it is up to you whether to complete them.  
Injuries 
Sites: Approval from HVTN Regulatory Affairs (at vtn.core.reg@hvtn.org) is needed 
for any change (other than those that the instructions specifically request or those 
previously approved by HVTN Regulatory Affairs) to the boxed text 
23. If you get sick or injured during the study, contact us immediately. 
Your health is important to us. (Sites: adjust the following 2 sentences if 
applicable to the care available at your site) We will tell you about the care that 
we can give here. For the care that we cannot provide, we will explain how we 
will help you get care elsewhere. 
If you become sick or injured in this study, the HVTN has a process to decide if it 
is related to the procedures. If it is, we call it a study-related injury. There are 
funds to pay for treatment of study-related injuries if certain conditions are met. 
Sites: adjust the language in this paragraph so it is applicable to your site. Note 
that the ABPI guidelines apply to South Africa only. In this study, our clinic has 
insurance to cover your medical treatment in the case of a study-related injury. 
We will follow the Association of the British Pharmaceutical Industry guidelines 
for payment of study-related injury. We can give you a copy of these guidelines. 
In rare cases, the insurance funds may not be enough.  
Some injuries are not physical. For example, you might be harmed emotionally by 
being in a study where you interrupt your HIV treatment. Or you might lose 
wages because you cannot go to work. However, there are no funds to pay for 
these kinds of injuries, even if they are study related. 
You may disagree with the decision about whether your injury is study related. If 
you wish, the HVTN will ask independent experts to review the decision. You 
always have the right to use the court system if you are not satisfied. 
Questions  
24. If you have questions or problems at any time during your participation in 
this study, use the following important contacts. 
If you have questions about this study, contact 
[name or title and telephone number of the investigator or other study staff]. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 117 of 153 
If you have any symptoms that you think may be related to this study, contact 
[name or title and telephone number of the investigator or other study staff]. 
This study has been reviewed and approved by a committee called the 
[name of local IRB/EC]. If you have questions about your rights as a research 
participant, or problems or concerns about how you are being treated in this study, 
contact [name or title and telephone number of person on IRB/EC] , at the 
committee. 
Paragraph for South African sites. The study has been structured in accordance 
with the Declaration of Helsinki (last updated October 2013) which deals with the 
recommendations guiding doctors in biomedical research involving human 
participants, the Ethics in Health Research: Principles, Structures and Processes 
Second Edition 2015, and Guidelines for Good Practice in the Conduct of Clinical 
Trials in Human Participants in South Africa. We can provide you with copies of 
these guidelines if you wish to review them. 
If you want to leave this study, contact 
[name or title and telephone number of the investigator or other study staff]. 
Remainder of section for South African sites only.  
You can reach a study staff member 24 hours a day at [telephone number]. 
If you have questions about this trial you should first discuss them with your 
doctor or the ethics committee (contact details as provided on this form). After 
you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the South 
African Healthcare Products Regulatory Authority (SAHPRA) at: 
The Acting Chief Executive Officer 
South African Health Products Regulatory Authority 
Private Bag X828 
PRETORIA 
0001 
Tel: (012) 842 7582/3 
e-mail: portia.nkambule@sahpra.org.za 
Your permissions and signature  
25. In Section 15 of this form, we told you about possible other uses of your extra 
samples and information, outside this study. Please choose only one of the 
options below and write your initials or make your mark in the box next to it. 
Whatever you choose, the HVTN keeps track of your decision about how 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 118 of 153 
your samples and information can be used. You can change your mind after 
signing this form. 
 
 
I allow my extra samples and information to be used for other studies related to HIV, 
vaccines, monoclonal antibodies, the immune system, and other diseases. This may 
include genetic testing and keeping my cells growing over time.  
OR 
 
 
I agree to the option above and also to allow my extra samples and information to be 
used in genome wide studies. 
OR 
 
 
I do not allow my extra samples to be used in any other studies. This includes not 
allowing genetic testing, growing more of my cells, or genome wide studies.  
 
26. If you agree to join this study, you will need to sign or make your mark 
below. Before you sign or make your mark on this consent form, make sure 
of the following: 
• You have read this consent form, or someone has read it to you. 
• You feel that you understand what the study is about and what will happen to 
you if you join. You understand what the possible risks and benefits are. 
• You have had your questions answered and know that you can ask more. 
• You agree to join this study. 
You will not be giving up any of your rights by signing this consent form. 
 
 
 
 
 
 
 
Participant’s name (print) 
 
Participant’s signature or mark 
 
Date 
 
Time 
 
 
 
 
 
 
 
Clinic staff conducting consent 
discussion (print) 
 
Clinic staff signature 
 
Date 
 
Time 
For participants who are unable to read or write, a witness should complete the 
signature block below: 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 119 of 153 
 
 
 
 
 
 
 
Witness’s name (print) 
 
Witness’s signature  
 
Date 
 
Time 
*Witness is impartial and was present for the entire discussion of this consent form. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 120 of 153 
Appendix B 
Approved birth control methods (for sample 
informed consent form) 
If you can become pregnant, you must agree to use effective contraception from 
21 days before interrupting your HIV treatment until you start taking HIV 
treatment again and your viral load drops to undetectable. 
You must use condoms every time you have sex to prevent HIV transmission to 
your partner. Yyou must also use one of the following contraceptive methods: 
• Birth control drugs that prevent pregnancy—such as pills, patches, vaginal 
rings, injectables, or an implant under the skin; or 
• Intrauterine device (IUD). 
You do not have to use birth control if: 
• You have been diagnosed with early menopause, with no menstrual periods 
for one year; 
• You have had a hysterectomy (your uterus removed); 
• You have had your ovaries removed; 
• You have a tubal ligation (your “tubes tied”) or confirmed successful 
placement of a product that blocks the fallopian tubes. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 121 of 153 
Appendix C 
Sample consent form for use of samples and 
information in other studies 
Title: Antiretroviral analytical treatment interruption (ATI) to assess immunologic 
and virologic responses in participants who initiated ART in early HIV infection 
after having received VRC01 or placebo in HVTN 703/HPTN 081 
Protocol number: HVTN 805/HPTN 093 
Site: [Insert site name] 
When samples are no longer needed for this study, the study sponsors want to 
keep them for use in other studies by HVTN, HPTN, or other researchers. We will 
call these “extra samples.” 
This form gives you information so you can decide if you want your extra 
samples and information used in other studies. You will mark your decision at the 
end of the form. If you have any questions, please ask. 
Key information 
These are some of the things you should know about the use of your samples and 
information for other studies: 
• The extra samples will be labeled with a code number and some personal 
information. They will not be labeled with your name. The extra samples are 
stored in a secure place. At your request, the HVTN and HPTN will destroy 
all your extra samples. You can still join the main study even if you do not 
agree to the use of your extra samples in other studies. 
• Researchers may do genetic testing on your samples, which could include 
genome wide studies. It is unlikely, but these tests could show you may be at 
risk for certain diseases. In the very unlikely event that others found out, this 
could lead to discrimination or other problems.  
• You will not be paid or otherwise benefit from allowing your extra samples to 
be used in other studies.  
The rest of this form gives more information about use of your extra samples for 
other studies. Please read it carefully. 
1. Do I have to agree? 
No. You are free to say yes or no, or to change your mind after you sign this form. 
At your request, the HVTN and HPTN will destroy all extra samples that they 
have. Your decision will not affect your being in this study or have any negative 
consequences here. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 122 of 153 
2. Where are the samples stored? 
Extra samples are stored in a secure central place called a repository. Your 
samples will be stored in the HVTN repository in South Africa. 
3. How long will the samples be stored? 
There is no limit on how long your extra samples will be stored. [Site: Revise the 
previous sentence to insert limits if your regulatory authority imposes them.] 
4. Will I benefit from allowing my samples to be used in other studies? 
We do not expect this to benefit you directly. Results from these other studies are 
not given to you, this clinic, or your doctor. They are not part of your medical 
record. The studies are only being done for research purposes. 
5. Will I be paid for the use of my samples? 
No. Also, a researcher may make a new scientific discovery or product based on 
the use of your samples. If this happens, there is no plan to share any money with 
you. The researcher is not likely to ever know who you are. 
6. Will the HVTN or HPTN sell my samples and information? 
No, but the HVTN and HPTN may share your samples with other researchers. 
Once we share your samples and information, we may not be able to get them 
back. 
7. How do other researchers get my samples and information? 
When a researcher wants to use your samples and information, their research plan 
must be approved by the HVTN and HPTN. Also, the researcher’s institutional 
review board (IRB) or ethics committee (EC) will review their plan. [Site: If 
review by your institution’s IRB/EC/RE is also required, insert a sentence stating 
this.] IRBs/ECs protect the rights and well-being of people in research. If the 
research plan is approved, the HVTN and HPTN will send your samples to the 
researcher’s location. 
8. What information is shared with HVTN, HPTN, or other researchers?  
The samples and information will be labeled with a code number. The key to the 
code will stay at this clinic. It will not be shared with the HVTN, other 
researchers or with anyone else who does not need to know your name. Your 
name will not be part of the information. However, some information that the 
HVTN and HPTN share may be personal, such as your race, ethnicity, gender, 
health information from the study, and HIV status. The HVTN and HPTN may 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 123 of 153 
share information about the study product you received and how your body 
responded to the AMP study product. 
9. What kind of studies might be done with my extra samples and information? 
The studies will be related to HIV, vaccines, monoclonal antibodies, the immune 
system, and other diseases. 
Researchers may also do genetic testing on your samples. 
In some cases, researchers may take cells from your samples and grow more of 
them over time, so that they can continue to contribute to this study.  
If you agree, your samples could also be used for genome wide studies. In these 
studies, researchers will look at all of your genes (your genome). The researchers 
compare the genomes of many people, looking for common patterns of genes that 
could help them understand diseases. The researchers may put the information 
from the genome-wide studies into a protected database so that other researchers 
can access it, but your name and other personal information will not be included. 
Usually, no one would be able to look at your genome and link it to you as a 
person. However, if another database exists that also has information on your 
genome and your name, someone might be able to compare the databases and 
identify you. If others found out, it could lead to discrimination or other problems. 
The risk of this is very small.  
10. What are the risks of genetic testing? 
It is unlikely, but the genetic tests done on your samples could show you may be 
at risk for certain diseases. If others found out, it could lead to discrimination or 
other problems. However, it is almost impossible for you or others to know your 
test results from the genetic testing. The results are not part of your study records 
and are not given to you. 
11. Who will have access to my information in studies using my extra samples? 
People who may see your information are: 
• Researchers who use your extra samples and information for other research 
• Government agencies that fund or monitor the research using your extra 
samples and information 
• Any regulatory agency that reviews clinical trials 
• The researcher’s Institutional Review Board or Ethics Committee 
• The people who work with the researcher 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 124 of 153 
All of these people will do their best to protect your information. The results of 
any new studies that use your extra samples and information may be published. 
No publication will use your name or identify you personally. 
Questions  
12. If you have questions or problems about allowing your samples and 
information to be used in other studies, use the following important contacts. 
If you have questions about the use of your samples or information or if you want 
to change your mind about their use, contact 
[name or title and telephone number of the investigator or other study staff]. 
If you think you may have been harmed because of studies using your samples or 
information, contact 
[name or title and telephone number of the investigator or other study staff]. 
If you have questions about your rights as a research participant, contact 
[name or title and telephone number of person on IRB/EC . 
Paragraph for South African sites. The study has been structured in accordance 
with the Declaration of Helsinki (last updated October 2013) which deals with the 
recommendations guiding doctors in biomedical research involving human 
participants, the Ethics in Health Research: Principles, Structures and Processes 
Second Edition 2015, and Guidelines for Good Practice in the Conduct of Clinical 
Trials in Human Participants in South Africa. We can provide you with copies of 
these guidelines if you wish to review them. 
Remainder of section for South African sites only.  
You can reach a study staff member 24 hours a day at [telephone number]. 
If you have questions about this trial you should first discuss them with your 
doctor or the ethics committee (contact details as provided on this form). After 
you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the South 
African Healthcare Products Regulatory Authority (SAHPRA) at: 
The Acting Chief Executive Officer 
South African Health Products Regulatory Authority 
Private Bag X828 
PRETORIA 
0001 
Tel: (012) 842 7582/3 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 125 of 153 
e-mail: portia.nkambule@sahpra.org.za  
13. Please choose only one of the options below and write your initials or make 
your mark in the box next to it. Whatever you choose, the HVTN and HPTN 
keep track of your decision about how your samples and information can be 
used. You can change your mind after signing this form. 
 
 
I allow my extra samples and information to be used for other studies related to HIV, 
vaccines, monoclonal antibodies,, the immune system, and other diseases. This may 
include genetic testing and keeping my cells growing over time. 
OR 
 
 
I agree to the option above and also to allow my extra samples and information to be 
used in genome wide studies. 
 
OR 
 
 
I do not allow my extra samples to be used in any other studies. This includes not 
allowing genetic testing, growing more of my cells, or genome wide studies.  
 
 
 
 
 
 
 
 
 
 
Participant’s name (print) 
 
Participant’s signature or mark 
 
Date 
 
Time 
 
 
 
 
 
 
 
Clinic staff conducting consent 
discussion (print) 
 
Clinic staff signature 
 
Date 
 
Time 
For participants who are unable to read or write, a witness should complete the 
signature block below: 
 
 
 
 
 
 
 
Witness’s name (print) 
 
Witness’s signature  
 
Date 
 
Time 
*Witness is impartial and was present for the entire discussion of this consent form. 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 126 of 153 
Appendix D 
Tables of procedures for sample informed consent form 
Table of procedures for Part 1: Screening and interrupting your HIV treatment 
 
 
HIV treatment  
switcha 
Pre-interruption visit 
about 4 weeks later 
Time after interrupting  HIV treatment 
 
Screening 
Day 0 
Week 1 
Week 2 
Week 3 
~1 month 
Week 5 
Week 6 
Week 7 
~2 months 
Week 10 
~3 months 
Week 14 
~4 months 
Week 18 
~5 months 
Week 22 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV treatment switch (if required) 
 
✓ 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
✓ 
 
 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brief physical exam  
 
✓ 
✓ 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Pregnancy test and contraception reviewb 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Interview/questionnaire 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
STI testing (blood, urine, cervical/vaginal swabs)c 
✓ 
 
 
✓ 
 
 
 
✓ 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
TB test 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood drawn 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Procedures in gray only for participants switching HIV treatments. 
a We will contact you about 2 weeks after you start the new HIV treatment to check to see if you have had any side effects or have other concerns. 
b Participants who have reached menopause or who had a hysterectomy, oophorectomy, or tubal ligation verified by medical records are not required to have a pregnancy test or 
contraception review. 
c In addition to STI testing at the checked visits, we will test at other visits if you show symptoms of an STI. 
d Extra visits every 3 months for people do not meet criteria for moving to Part 2 or Part 3.  
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 127 of 153 
Table of procedures for Part 1: Screening and interruptings your HIV treatment (continued) 
 
Time after interrupting HIV treatment 
 
~6 months 
Week 28 
Week 32 
Week 36 
~ 9 months 
Week 44 
Week 48 
1 year 
Extra visitsd 
Study procedures 
 
 
 
 
 
 
 
 
 
HIV treatment switch (if required) 
 
 
 
 
 
 
 
 
 
Medical history 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
Brief physical exam 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Pregnancy test and contraception reviewb 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Interview/questionnaire 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
STI testing (blood, urine, cervical/vaginal swabs)c 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
TB test 
 
 
 
 
 
 
 
 
 
Blood Drawn 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
a We will contact you about 2 weeks after you start the new HIV treatment to check to see if you have had any side effects or have other concerns. 
b Participants who have reached menopause or who had a hysterectomy, oophorectomy, or tubal ligation verified by medical records are not required to have a pregnancy test or 
contraception review. 
c In addition to STI testing at the checked visits, we will test at other visits if you show symptoms of an STI. 
d Extra visits every 3 months for people do not meet criteria for moving to Part 2 or Part 3.  
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 128 of 153 
Table of procedures for Part 2: Monitoring your health and your HIV 
 
Time after starting Part 2 
 
Day 0 
Week 1 
Week 2 
Week 3 
~1 month 
Week 5 
Week 6 
Week 7 
~2 months 
Week 10 
~3 months 
Week 14 
~4 months 
Week 18 
~5 months 
Week 22 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brief physical exam  
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Pregnancy test and contraception reviewa 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Interview/questionnaire 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
STI testing (blood, urine, cervical/vaginal swabs)b 
✓ 
 
 
 
✓ 
 
 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
Blood drawn 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
a Participants who have reached menopause or who had a hysterectomy, oophorectomy, or tubal ligation verified by medical records are not required to have a pregnancy test or 
contraception review. 
b In addition to STI testing at the checked visits, we will test at other visits if you show symptoms of an STI. 
c Extra visits every 3 months for people do not meet criteria for moving to Part 3.  
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 129 of 153 
Table of procedures for Part 2: Monitoring your health and your HIV (continued) 
 
Time after starting Part 2 
 
Week 24 
6 months 
Week 28 
Week 30 
Week 32 
Week 34 
Week 36 
~9 months 
Week 44 
Week 48 
1 year 
Extra visitsc 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
 
 
 
Brief physical exam  
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Pregnancy test and contraception reviewa 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Interview/questionnaire 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
STI testing (blood, urine, cervical/vaginal swabs)b 
✓ 
 
✓ 
 
✓ 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Blood drawn 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
a Participants who have reached menopause or who had a hysterectomy, oophorectomy, or tubal ligation verified by medical records are not required to have a pregnancy test or 
contraception review. 
b In addition to STI testing at the checked visits, we will test if you show symptoms of an STI. 
c Extra visits every 3 months for people do not meet criteria for moving to Part 3.  
 
 
 
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 130 of 153 
Table of procedures for Part 3: Restart HIV treatment  
 
Time after restarting HIV treatment 
 
Week 0 
Week 2 
~1 month 
Week 6 
~2 months 
Week 10 
Week 12 
~4 months 
Week 20 
~6 months 
Week 28 
~9 months 
1 year 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
 
 
 
✓ 
Brief physical exam 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
 
Pregnancy test & contraception reviewa 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
Interview/Questionnaire 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
STI testing (blood, urine, cervical/vaginal swabs)b 
✓ 
 
✓ 
 
✓ 
 
✓ 
✓c 
✓c 
✓ 
✓c 
✓ 
 
Blood Drawn 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
a Participants who have reached menopause or who had a hysterectomy, oophorectomy, or tubal ligation verified by medical records are not required to have a pregnancy test or 
contraception review. Pregnancy test and contraceptive review are not required once viral load drops to undetectable after restarting HIV treatment. 
b In addition to STI testing at the checked visits, we will test if you show symptoms of an STI.  
c STI testing is not required at this visit if viral load has returned to undetectable. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 131 of 153 
Appendix E 
Laboratory procedures—Schedule 1: Monitoring ATI  
Visit:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Days on ATI:
D0
D7
D14
D21
D28
D35
D42
D49
D56
D70
D84
D98
D112
D126
D140
D154
Weeks on ATI:
W0
W1
W2
W3
W4
W5
W6
W7
W8
W10
W12
W14
W16
W18
W20
W22
Procedure
Ship to1 
Assay location1,2
Tube Type3
Tube size
(vol. capacity)3
ATI
BLOOD COLLECTION
Screening or diagnostic assays
HIV PCR viral load13
Local labs
Local labs
EDTA
6mL
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
CD4+/CD8+ T-cell count14
Local labs
Local labs
EDTA
4mL
4
4
4
4
—
4
—
4
—
4
—
4
—
4
—
4
—
4
—
HBsAg/anti-HCV4
Local labs
Local labs
SST
5mL
10
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
QuantiFERON TB testing5
Local labs
Local labs
QFT Gold/Gold-Plus
1mL
4
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Safety labs
Hgb / ANC / PLT
Local labs
Local labs
EDTA
4mL
4
4
4
4
—
—
—
4
—
—
—
4
—
4
—
4
—
4
—
ALT / direct bilirubin / eGFR
Local labs
Local labs
SST
5mL
5
5
5
5
—
—
—
5
—
—
—
5
—
5
—
5
—
5
—
Syphilis10
Local labs
Local labs
SST
5mL
5
—
—
5
—
—
—
5
—
—
—
5
—
5
—
5
—
5
—
Hormone Levels
Hormone panel
Local labs
Local labs
SST
5mL
—
—
—
w
—
—
—
w
—
—
—
w
—
w
—
w
—
—
—
Drug levels/detection
ARV detection by dry blood spot
CSR
HVTN labs
EDTA
2mL
—
—
—
—
—
—
—
2
—
—
—
2
—
2
—
2
—
2
—
Immunogenicity & Virologic Assays
Cellular assays
ICS
CSR
HVTN labs
ACD
8.5mL
—
—
—
42.5
—
—
—
42.5
—
—
—
42.5
—
42.5
—
42.5
—
42.5
—
Phenotyping
CSR
HVTN labs
ACD
8.5mL
—
—
—
z
—
—
—
z
—
—
—
z
—
z
—
z
—
z
—
Humoral assays
Neutralizing antibody
CSR
HVTN labs
SST
8.5mL
—
—
—
8.5
—
—
—
8.5
—
—
—
8.5
—
8.5
—
8.5
—
8.5
—
FcR-mediated effector functions6
CSR
HVTN labs
SST
8.5mL
—
—
—
y
—
—
—
y
—
—
—
y
—
y
—
y
—
y
—
HIV reservoir assays
CSR
TBD
ACD
8.5mL
—
—
—
51
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Storage
Serum
CSR
SST
8.5mL
—
—
—
8.5
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Plasma
CSR
EDTA
10mL
—
—
—
—
—
—
—
—
—
—
—
10
—
10
—
10
—
10
—
PBMC
CSR
ACD
8.5mL
—
—
—
—
—
—
—
—
—
—
—
17
—
17
—
17
—
17
—
Visit total
38
19
19
134.5
6
10
6
77
6
10
6
104
6
104
6
104
6
104
6
56-Day total
38
57
76
210.5
216.5
226.5
232.5
309.5
315.5
325.5
331.5
397.5
225
313
236
324
226
324
226
URINE COLLECTION
Pregnancy Test16
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Chlamydia/gonorrhea7
Local labs
Local labs
X
—
—
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
CERVICAL/VAGINAL SWAB COLLECTION
Chlamydia/gonorrhea7
Local labs
Local labs
X
—
—
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
Trichomonas vaginalis7
Local labs
Local labs
X
—
—
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
ART 
Switch8
Screening 
visit15
ATI 
qualification 9
 
1 CSR = central specimen repository. 
2 HVTN Laboratories include: Fred Hutchinson Cancer Research Center (Seattle, Washington, USA); Duke University Medical Center (Durham, North Carolina, USA); South African Immunology 
Laboratory-National Institute for Communicable Diseases (SAIL-NICD, Johannesburg, South Africa); University of Cape Town (Cape Town, South Africa); Cape Town HVTN Immunology 
Laboratory (CHIL, Cape Town, South Africa). 
Non-HVTN laboratories: TBD. 
3 Local labs may assign appropriate alternative tube types for locally performed tests.  
4 HCV RNA PCR testing will be performed as a reflex test if indicated by anti-HCV antibody results and may require an additional blood collection. 
5 Tuberculin skin test (TST) will be performed if QuantiFERON TB testing is not available. See Procedures at CRS (Appendix H). 
6 FcR-mediated effector function assays may include ADCC, virion capture, and phagocytosis assays. 
7 Chlamydia/gonorrhea testing will be done on EITHER urine OR a cervical/vaginal swab; Trichomonas testing will be done on cervical/vaginal swab. In addition to STI testing at the marked visits, 
STI testing may occur at any visit if clinically indicated. In addition to the listed specimen types (ie., cervical/vaginal swabs), chlamydia/gonorrhea testing may occur on rectal swabs if clinically 
indicated (see HVTN 805/HPTN 093 SSP for details). 
8 The "ART switch" phase will only be performed for participants on NNRTIs. These participants will be considered enrolled on the first day of the new ART medication. 
9 The ATI Qualification visit specimens must be obtained at least 28 days after ART switch. If needed, VL retesting may continue until viral suppression has been achieved (up to 84 days after ART 
switch). The last ATI qualification procedures must take place no more than 14 days prior to visit 4 (see HVTN 805/HPTN 093 SSP for more information). 
10 In addition to syphilis testing at the marked visits, syphilis testing may occur at any visit if clinically indicated. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 132 of 153 
11 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 27 continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met criteria to transition to Schedule 2 or Schedule 3 (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
12 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 27 continuing up to 3 years of this schedule, and then every 3 months thereafter. This follow-up visit 
may be performed for participants who have not met criteria to transition to Schedule 2 or Schedule 3 (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
13 A confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) following the first VL result ≥ 200 copies/mL (see Protocol Section 3.3.1 and HVTN 805/HPTN 093 SSP 
for details). 
14 A confirmatory sample should be at the next visit (within approximately 1-2 weeks) following the first CD4+ T-cell count  < 350 cells/mm3 (see Protocol Section 3.3.2 and HVTN 805/HPTN 093 
SSP for details). 
15 Screening visit specimens for participants not undergoing an NNRTI switch should be obtained no later than 2 weeks before Visit 4 (see HVTN 805/HPTN 093 SSP for more information). 
16 For persons capable of becoming pregnant, pregnancy test may be performed on urine or blood specimens. 
17 At an early termination visit for a withdrawn or terminated participant (see Protocol Section 6.5), blood should be drawn as shown for Extended follow-up visit type A (see HVTN 805/HPTN 093 
SSP for more information).  
w = SST blood collected for syphilis testing will also cover specimen needs for HBsAg and anti-HCV screening testing. Hormone panel is defined in Protocol Sections 6.1 (Schedule 1: Monitoring 
ATI) and 6.2 (Schedule 2: Monitoring ATI with viremia). 
y = SST blood collected for neutralizing antibody will also cover specimen needs for FcR-mediated effector functions; no separate blood draw is needed. 
z = PBMC blood collected for ICS will also cover specimen needs for phenotyping; no separate blood draw is needed.  
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 133 of 153 
Laboratory procedures—Schedule 1: Monitoring ATI (continued) 
 
Visit:
20
21
22
23
24
25
26
27
Days on ATI:
D168
D196
D224
D252
D280
D308
D336
D364
Weeks on ATI:
W24
W28
W32
W36
W40
W44
W48
W52
Procedure
Ship to1 
Assay location1,2
Tube Type3
Tube size
(vol. capacity)3
Total
BLOOD COLLECTION
Screening or diagnostic assays
HIV PCR viral load13
Local labs
Local labs
EDTA
6mL
6
6
6
6
6
6
6
6
6
6
174
CD4+/CD8+ T-cell count14
Local labs
Local labs
EDTA
4mL
4
4
4
4
—
4
—
4
4
4
76
HBsAg/anti-HCV
Local labs
Local labs
SST
5mL
—
—
—
—
—
—
—
—
—
—
10
QuantiFERON TB testing5
Local labs
Local labs
QFT Gold/Gold-Plus
1mL
—
—
—
—
—
—
—
—
—
—
4
Safety labs
Hgb / ANC / PLT
Local labs
Local labs
EDTA
4mL
4
4
4
4
—
4
—
4
4
4
68
ALT / direct bilirubin / eGFR
Local labs
Local labs
SST
5mL
5
5
5
5
—
5
—
5
5
5
85
Syphilis10
Local labs
Local labs
SST
5mL
5
5
5
5
5
5
5
5
5
5
85
Hormone Levels
Hormone panel
Local labs
Local labs
SST
5mL
—
—
—
w
—
—
—
—
—
—
0
Drug levels/detection
ARV detection by dry blood spot
CSR
HVTN labs
EDTA
2mL
2
2
2
2
2
2
2
2
2
2
30
Immunogenicity & Virologic Assays
Cellular assays
ICS
CSR
HVTN labs
ACD
8.5mL
42.5
42.5
42.5
42.5
42.5
42.5
42.5
42.5
—
—
595
Phenotyping
CSR
HVTN labs
ACD
8.5mL
z
z
z
z
z
z
z
z
—
—
0
Humoral assays
Neutralizing antibody
CSR
HVTN labs
SST
8.5mL
8.5
8.5
8.5
8.5
8.5
8.5
8.5
8.5
—
—
119
FcR-mediated effector functions6
CSR
HVTN labs
SST
8.5mL
y
y
y
y
y
y
y
y
—
—
0
HIV reservoir assays
CSR
TBD
ACD
8.5mL
—
—
—
—
—
—
—
—
—
—
51
Storage
Serum
CSR
SST
8.5mL
—
—
—
—
—
—
—
—
8.5
—
17
Plasma
CSR
EDTA
10mL
10
10
10
10
10
10
10
10
10
—
130
PBMC
CSR
ACD
8.5mL
17
17
17
17
17
17
17
17
59.5
—
263.5
Visit total
104
104
104
104
91
104
91
104
104
26
56-Day total
324
318
312
312
299
299
286
299
104
26
URINE COLLECTION
Pregnancy Test16
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
Chlamydia/gonorrhea7
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
CERVICAL/VAGINAL SWAB COLLECTION
Chlamydia/gonorrhea7
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
Trichomonas vaginalis7
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
Visit Type 
A11,17
Visit Type 
B12
 
1 CSR = central specimen repository. 
2 HVTN Laboratories include: Fred Hutchinson Cancer Research Center (Seattle, Washington, USA); Duke University Medical Center (Durham, North Carolina, USA); South African Immunology 
Laboratory-National Institute for Communicable Diseases (SAIL-NICD, Johannesburg, South Africa); University of Cape Town (Cape Town, South Africa); Cape Town HVTN Immunology 
Laboratory (CHIL, Cape Town, South Africa). 
Non-HVTN laboratories: TBD. 
3 Local labs may assign appropriate alternative tube types for locally performed tests.  
4 HCV RNA PCR testing will be performed as a reflex test if indicated by anti-HCV antibody results and may require an additional blood collection.. 
5 Tuberculin skin test (TST) will be performed if QuantiFERON TB testing is not available. See Procedures at CRS (Appendix H). 
6 FcR-mediated effector function assays may include ADCC, virion capture, and phagocytosis assays. 
7 Chlamydia/gonorrhea testing will be done on EITHER urine OR a cervical/vaginal swab; Trichomonas testing will be done on cervical/vaginal swab. In addition to STI testing at the marked visits, 
STI testing may occur at any visit if clinically indicated. In addition to the listed specimen types (ie., cervical/vaginal swabs), chlamydia/gonorrhea testing may occur on rectal swabs if clinically 
indicated (see HVTN 805/HPTN 093 SSP for details). 
8 The "ART switch" phase will only be performed for participants on NNRTIs. These participants will be considered enrolled on the first day of the new ART medication. 
9 The ATI Qualification visit specimens must be obtained at least 28 days after ART switch. If needed, VL retesting may continue until viral suppression has been achieved (up to 84 days after ART 
switch). The last ATI qualification procedures must take place no more than 14 days prior to visit 4 (see HVTN 805/HPTN 093 SSP for more information). 
10 In addition to syphilis testing at the marked visits, syphilis testing may occur at any visit if clinically indicated. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 134 of 153 
11 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 27 continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met criteria to transition to Schedule 2 or Schedule 3 (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
12 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 27 continuing up to 3 years of this schedule, and then every 3 months thereafter. This follow-up visit 
may be performed for participants who have not met criteria to transition to Schedule 2 or Schedule 3 (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
13 A confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) following the first VL result ≥ 200 copies/mL (see Protocol Section 3.3.1 and HVTN 805/HPTN 093 SSP 
for details). 
14 A confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) following the first CD4+ T-cell count  < 350 cells/mm3 (see Protocol Section 3.3.2 and HVTN 805/HPTN 
093 SSP for details). 
15 Screening visit specimens for participants not undergoing an NNRTI switch should be obtained no later than 2 weeks before Visit 4 (see HVTN 805/HPTN 093 SSP for more information). 
16 For persons capable of becoming pregnant, pregnancy test may be performed on urine or blood specimens. 
17 At an early termination visit for a withdrawn or terminated participant (see Protocol Section 6.5), blood should be drawn as shown for Extended follow-up visit type A (see HVTN 805/HPTN 093 
SSP for more information).  
w = SST blood collected for syphilis testing will also cover specimen needs for HBsAg and anti-HCV screening testing. Hormone panel is defined in Protocol Sections 6.1 (Schedule 1: Monitoring 
ATI) and 6.2 (Schedule 2: Monitoring ATI with viremia). 
y = SST blood collected for neutralizing antibody will also cover specimen needs for FcR-mediated effector functions; no separate blood draw is needed. 
z = PBMC blood collected for ICS will also cover specimen needs for phenotyping; no separate blood draw is needed.  

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 135 of 153 
Appendix F 
Laboratory procedures—Schedule 2: Monitoring ATI with viremia 
Visit:
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
D0
D7
D14
D21
D28
D35
D42
D49
D56
D70
D84
D98
D112
D126
D140
D154
W0
W1
W2
W3
W4
W5
W6
W7
W8
W10
W12
W14
W16
W18
W20
W22
Procedure
Ship to1 
Assay location1,2
Tube Type3
Tube size
(vol. capacity)3
BLOOD COLLECTION
Screening or diagnostic assays
HIV PCR viral load10
Local labs
Local labs
EDTA
6mL
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
CD4+/CD8+ T-cell count11
Local labs
Local labs
EDTA
4mL
4
—
4
—
4
—
4
—
4
—
4
—
4
—
4
—
Safety labs
Hgb / ANC / PLT
Local labs
Local labs
EDTA
4mL
4
—
—
—
4
—
—
—
4
—
4
—
4
—
4
—
ALT / direct bilirubin / eGFR
Local labs
Local labs
SST
5mL
5
—
—
—
5
—
—
—
5
—
5
—
5
—
5
—
Syphilis7
Local labs
Local labs
SST
5mL
5
—
—
—
5
—
—
—
5
—
5
—
5
—
5
—
Hormone Levels
Hormone panel
Local labs
Local labs
SST
5mL
w
—
—
—
w
—
—
—
w
—
w
—
w
—
—
—
Drug levels/detection
ARV detection by dry blood spot
CSR
HVTN labs
EDTA
2mL
—
—
—
—
2
—
—
—
2
—
2
—
2
—
2
—
Immunogenicity & Virologic Assays
Cellular assays
ICS
CSR
HVTN labs
ACD
8.5mL
42.5
—
42.5
—
42.5
—
—
—
42.5
—
42.5
—
42.5
—
42.5
—
Phenotyping
CSR
HVTN labs
ACD
8.5mL
z
—
z
—
z
—
—
—
z
—
z
—
z
—
z
—
Humoral assays
Neutralizing antibody
CSR
HVTN labs
SST
8.5mL
8.5
—
8.5
—
8.5
—
—
—
8.5
—
8.5
—
8.5
—
8.5
—
FcR-mediated effector functions4
CSR
HVTN labs
SST
8.5mL
y
—
y
—
y
—
—
—
y
—
y
—
y
—
y
—
Storage
Serum
CSR
SST
8.5mL
8.5
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Plasma
CSR
EDTA
10mL
10
—
—
—
—
—
—
—
10
—
10
—
10
—
10
—
PBMC
CSR
ACD
8.5mL
—
—
—
—
—
—
—
—
17
—
17
—
17
—
17
—
Visit total
93.5
6
61
6
77
6
10
6
104
6
104
6
104
6
104
6
56-Day total6,10,11
93.5
99.5
160.5
166.5
243.5
249.5
259.5
265.5
369.5
276
313
236
324
226
324
226
URINE COLLECTION
Pregnancy Test12
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Chlamydia/gonorrhea5
Local labs
Local labs
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
CERVICAL/VAGINAL SWAB COLLECTION
Chlamydia/gonorrhea5
Local labs
Local labs
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
Trichomonas vaginalis5
Local labs
Local labs
X
—
—
—
X
—
—
—
X
—
X
—
X
—
X
—
Days on  ATI with viremia
Weeks on  ATI with viremia
 
1 CSR = central specimen repository. 
2 HVTN Laboratories include: Fred Hutchinson Cancer Research Center (Seattle, Washington, USA); Duke University Medical Center (Durham, North Carolina, USA); South African Immunology 
Laboratory-National Institute for Communicable Diseases (SAIL-NICD, Johannesburg, South Africa); University of Cape Town (Cape Town, South Africa); Cape Town HVTN Immunology 
Laboratory (CHIL, Cape Town, South Africa). 
Non-HVTN laboratories: TBD. 
3 Local labs may assign appropriate alternative tube types for locally performed tests.  
4 FcR-mediated effector function assays may include ADCC, virion capture, and phagocytosis assays. 
5 Chlamydia/gonorrhea testing will be done on EITHER urine OR a cervical/vaginal swab; Trichomonas testing will be done on cervical/vaginal swab. In addition to STI testing at the marked visits, 
STI testing may occur at any visit if clinically indicated. In addition to the listed specimen types (ie., cervical/vaginal swabs), chlamydia/gonorrhea testing may occur on rectal swabs if clinically 
indicated (see HVTN 805/HPTN 093 SSP for details). 
6 The 56-day blood draw limit does not include visits from Schedule 1; please see HVTN 805/HPTN 093 SSP for details on prioritizing collections to avoid exceeding the 56-day limit. 
7 In addition to syphilis testing at the marked visits, syphilis testing may occur at any visit if clinically indicated. 
8 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 66, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 136 of 153 
9 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 66, continuing up to 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
10 Additional weekly viral load monitoring may be required between weeks 8 and 24; after week 24, a confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) 
following the first VL result ≥ 200 copies/mL (see Protocol Section 3.3.3 and HVTN 805/HPTN 093 SSP for details). The 56-day blood draw limit does not include up to 10mL blood collected per 
visit for this additional monitoring; however, the 56-day limit is not exceeded at any visit by these collections. 
11 A confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) following the first CD4+ T-cell count  < 350 cells/mm3 (see Protocol Section 3.3.3 and HVTN 805/HPTN 
093 SSP for details). 
12 For persons capable of becoming pregnant, pregnancy test may be performed on urine or blood specimens. 
13 At an early termination visit for a withdrawn or terminated participant (see Protocol Section 6.5), blood should be drawn as shown for Extended follow-up visit type A (see HVTN 805/HPTN 093 
SSP for more information). 
w = SST blood collected for syphilis testing will also cover specimen needs for HBsAg and anti-HCV screening testing. Hormone panel is defined in Protocol Sections 6.1 (Schedule 1: Monitoring 
ATI) and 6.2 (Schedule 2: Monitoring ATI with viremia). 
y = SST blood collected for neutralizing antibody will also cover specimen needs for FcR-mediated effector functions; no separate blood draw is needed. 
z = PBMC blood collected for ICS will also cover specimen needs for phenotyping; no separate blood draw is needed. 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 137 of 153 
Laboratory procedures—Schedule 2: Monitoring ATI with viremia (continued) 
Visit:
56
57
58
59
60
61
62
63
64
65
66
D168
D182
D196
D210
D224
D238
D252
D280
D308
D336
D364
W24
W26
W28
W30
W32
W34
W36
W40
W44
W48
W52
Procedure
Ship to1 
Assay location1,2
Tube Type3
Tube size
(vol. capacity)3
Total
BLOOD COLLECTION
Screening or diagnostic assays
HIV PCR viral load10
Local labs
Local labs
EDTA
6mL
6
6
6
6
6
6
6
6
6
6
6
6
6
174
CD4+/CD8+ T-cell count11
Local labs
Local labs
EDTA
4mL
4
—
4
—
4
—
4
—
4
—
4
4
4
64
Safety labs
Hgb / ANC / PLT
Local labs
Local labs
EDTA
4mL
4
—
4
—
4
—
4
—
4
—
4
4
4
56
ALT / direct bilirubin / eGFR
Local labs
Local labs
SST
5mL
5
—
5
—
5
—
5
—
5
—
5
5
5
70
Syphilis7
Local labs
Local labs
SST
5mL
5
—
5
—
5
—
5
5
5
5
5
5
5
80
Hormone Levels
Hormone panel
Local labs
Local labs
SST
5mL
—
—
—
—
—
—
w
—
—
—
—
—
—
0
Drug levels/detection
ARV detection by dry blood spot
CSR
HVTN labs
EDTA
2mL
2
—
2
—
2
—
2
2
2
2
2
2
2
30
Immunogenicity & Virologic Assays
Cellular assays
ICS
CSR
HVTN labs
ACD
8.5mL
42.5
—
42.5
—
42.5
—
42.5
42.5
42.5
42.5
42.5
—
—
637.5
Phenotyping
CSR
HVTN labs
ACD
8.5mL
z
—
z
—
z
—
z
z
z
z
z
—
—
0
Humoral assays
Neutralizing antibody
CSR
HVTN labs
SST
8.5mL
8.5
—
8.5
—
8.5
—
8.5
8.5
8.5
8.5
8.5
—
—
127.5
FcR-mediated effector functions4
CSR
HVTN labs
SST
8.5mL
y
—
y
—
y
—
y
y
y
y
y
—
—
0
Storage
Serum
CSR
SST
8.5mL
—
—
—
—
—
—
—
—
—
—
—
8.5
—
17
Plasma
CSR
EDTA
10mL
10
—
10
—
10
—
10
10
10
10
10
10
—
140
PBMC
CSR
ACD
8.5mL
17
—
17
—
17
—
17
17
17
17
17
59.5
—
263.5
Visit total
104
6
104
6
104
6
104
91
104
91
104
104
26
56-Day total6,10,11
324
226
324
226
324
226
324
305
299
286
299
104
26
URINE COLLECTION
Pregnancy Test12
Local labs
Local labs
X
X
X
X
X
X
X
X
X
X
X
X
X
Chlamydia/gonorrhea5
Local labs
Local labs
X
—
X
—
X
—
X
X
X
X
X
X
X
CERVICAL/VAGINAL SWAB COLLECTION
Chlamydia/gonorrhea5
Local labs
Local labs
X
—
X
—
X
—
X
X
X
X
X
X
X
Trichomonas vaginalis5
Local labs
Local labs
X
—
X
—
X
—
X
X
X
X
X
X
X
Days on  ATI with viremia
Weeks on  ATI with viremia
Visit Type 
A8,13
Visit type 
B9
 
1 CSR = central specimen repository. 
2 HVTN Laboratories include: Fred Hutchinson Cancer Research Center (Seattle, Washington, USA); Duke University Medical Center (Durham, North Carolina, USA); South African Immunology 
Laboratory-National Institute for Communicable Diseases (SAIL-NICD, Johannesburg, South Africa); University of Cape Town (Cape Town, South Africa); Cape Town HVTN Immunology 
Laboratory (CHIL, Cape Town, South Africa). 
Non-HVTN laboratories: TBD. 
3 Local labs may assign appropriate alternative tube types for locally performed tests.  
4 FcR-mediated effector function assays may include ADCC, virion capture, and phagocytosis assays. 
5 Chlamydia/gonorrhea testing will be done on EITHER urine OR a cervical/vaginal swab; Trichomonas testing will be done on cervical/vaginal swab. In addition to STI testing at the marked visits, 
STI testing may occur at any visit if clinically indicated. In addition to the listed specimen types (ie., cervical/vaginal swabs), chlamydia/gonorrhea testing may occur on rectal swabs if clinically 
indicated (see HVTN 805/HPTN 093 SSP for details). 
6 The 56-day blood draw limit does not include visits from Schedule 1; please see HVTN 805/HPTN 093 SSP for details on prioritizing collections to avoid exceeding the 56-day limit. 
7 In addition to syphilis testing at the marked visits, syphilis testing may occur at any visit if clinically indicated. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 138 of 153 
8 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 66, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
9 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 66, continuing up to 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
10 Additional weekly viral load monitoring may be required between weeks 8 and 24; after week 24, a confirmatory sample should be drawn as soon as possible following the first VL result ≥ 200 
copies/mL (see Protocol Section 3.3.3 for details). The 56-day blood draw limit does not include up to 10mL blood collected per visit for this additional monitoring; however, the 56-day limit is not 
exceeded at any visit by these collections. 
11 A confirmatory sample should be drawn at the next visit (within approximately 1-2 weeks) following the first CD4+ T-cell count  < 350 cells/mm3 (see Protocol Section 3.3.3 and HVTN 805/HPTN 
093 SSP for details). 
12 For persons capable of becoming pregnant, pregnancy test may be performed on urine or blood specimens. 
13 At an early termination visit for a withdrawn or terminated participant (see Protocol Section 6.5), blood should be drawn as shown for Extended follow-up visit type A (see HVTN 805/HPTN 093 
SSP for more information). 
w = SST blood collected for syphilis testing will also cover specimen needs for HBsAg and anti-HCV screening testing. Hormone panel is defined in Protocol Sections 6.1 (Schedule 1: Monitoring 
ATI) and 6.2 (Schedule 2: Monitoring ATI with viremia). 
y = SST blood collected for neutralizing antibody will also cover specimen needs for FcR-mediated effector functions; no separate blood draw is needed. 
z = PBMC blood collected for ICS will also cover specimen needs for phenotyping; no separate blood draw is needed. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 139 of 153 
Appendix G 
Laboratory procedures—Schedule 3: Follow-up on ART 
Visit:
807
81
82
83
84
85
86
87
88
89
90
9112
92
D0
D14
D28
D42
D56
D70
D84
D112
D140
D168
D196
D280
D364
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W40
W52
Procedure
Ship to1 
Tube Type3
Total
BLOOD COLLECTION
Screening or diagnostic assays
HIV PCR viral load
Local labs
Local labs
EDTA
6mL
6
6
6
6
6
6
6
6
6
6
6
6
6
78
CD4+/CD8+ T-cell count
Local labs
Local labs
EDTA
4mL
4
—
4
—
4
—
4
—
4
—
4
4
4
32
Safety labs
Hgb / ANC / PLT
Local labs
Local labs
EDTA
4mL
—
—
4
—
4
—
4
—
—
4
—
4
—
20
ALT / direct bilirubin / eGFR
Local labs
Local labs
SST
5mL
—
—
5
—
5
—
5
—
—
5
—
5
—
25
Syphilis9
Local labs
Local labs
SST
5mL
5
—
5
—
5
—
5
513
513
5
513
5
—
45
HIV genotypic antiretroviral resistance8
CSR
HVTN Labs
EDTA
6mL
—
—
—
—
12
—
—
—
—
—
—
—
—
12
Immunogenicity & Virologic Assays
Viral isolation/sequencing
CSR
HVTN Labs
EDTA
10mL
10
10
—
—
—
—
10
—
—
10
—
10
10
60
   Cellular assays
ICS
CSR
HVTN Labs
ACD
8.5mL
—
—
—
—
—
—
42.5
—
—
42.5
—
42.5
42.5
170
Phenotyping
CSR
HVTN Labs
ACD
8.5mL
—
—
—
—
—
—
z
—
—
z
—
z
z
0
    Humoral assays
Neutralizing antibody
CSR
HVTN Labs
SST
8.5mL
—
—
—
—
—
—
8.5
—
—
8.5
—
8.5
8.5
34
FcR-mediated effector functions4
CSR
HVTN Labs
SST
8.5mL
—
—
—
—
—
—
y
—
—
y
—
y
y
0
HIV reservoir assays
CSR
TBD
ACD
8.5mL
34
—
—
—
—
—
—
—
—
51
—
51
51
187
Storage
Serum
CSR
SST
8.5mL
8.5
—
—
—
—
—
8.5
—
—
8.5
—
8.5
8.5
42.5
Plasma
CSR
EDTA
10mL
—
—
—
—
—
—
10
—
—
10
—
10
10
40
PBMC
CSR
ACD
8.5mL
42.5
—
—
—
—
—
102
—
—
51
—
51
51
297.5
Visit total
110
16
24
6
36
6
205.5
11
15
201.5
15
205.5
191.5
56-Day total5
126
150
156
192
88
277.5
258.5
231.5
227.5
231.5
205.5
191.5
URINE COLLECTION
Pregnancy Test11
Local labs
Local labs
X
X10
X10
X10
X10
X10
X
X10
X10
X
X10
X
X
Chlamydia/gonorrhea6
Local labs
Local labs
X
—
X
—
X
—
X
X13
X13
X
X13
X
—
CERVICAL/VAGINAL SWAB COLLECTION
Chlamydia/gonorrhea6
Local labs
Local labs
X
—
X
—
X
—
X
X13
X13
X
X13
X
—
Trichomonas vaginalis6
Local labs
Local labs
X
—
X
—
X
—
X
X13
X13
X
X13
X
—
Weeks post ART re-initiation:
Days post ART re-initiation
Tube size
(vol. capacity)3
Assay location1,2
ART re-
initiation visit
 
1 CSR = central specimen repository. 
2 HVTN Laboratories include: Fred Hutchinson Cancer Research Center (Seattle, Washington, USA); Duke University Medical Center (Durham, North Carolina, USA); South African Immunology 
Laboratory-National Institute for Communicable Diseases (SAIL-NICD, Johannesburg, South Africa); University of Cape Town (Cape Town, South Africa); Cape Town HVTN Immunology 
Laboratory (CHIL, Cape Town, South Africa). 
Non-HVTN laboratories: TBD. 
3 Local labs may assign appropriate alternative tube types for locally performed tests.  
4 FcR-mediated effector function assays may include ADCC, virion capture, and phagocytosis assays. 
5 56-day totals do not include visit totals from Schedule 1 or 2. See HVTN 805/HPTN 093 SSP for details on prioritizing collections to avoid exceeding the 56-day limit. 
6 Chlamydia/gonorrhea testing will be done on EITHER urine OR a cervical/vaginal swab; Trichomonas testing will be done on cervical/vaginal swab. In addition to STI testing at the marked visits, 
STI testing may occur at any visit if clinically indicated. In addition to the listed specimen types (ie., cervical/vaginal swabs), chlamydia/gonorrhea testing may occur on rectal swabs if clinically 
indicated (see HVTN 805/HPTN 093 SSP for details). 
7 Samples for visit 80 should be collected after ART re-initiation criteria have been met, but prior to ART re-initiation.  
8 HIV antiretroviral resistance testing will be performed only if indicated by viral load results (see HVTN 805/HPTN 093 SSP). 
9 In addition to syphilis testing at the marked visits, syphilis testing may occur at any visit if clinically indicated. 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 140 of 153 
10 Pregnancy testing is not required if viral load has returned to undetectable. 
11 For persons capable of becoming pregnant, pregnancy test may be performed on urine or blood specimens. 
12 At an early termination visit for a withdrawn or terminated participant (see Protocol Section 6.5), blood should be drawn as shown for Visit 91 (see HVTN 805/HPTN 093 SSP for more 
information). 
13 Syphilis, chlamydia and gonorrhea testing is not required at this visit if viral load has returned to undetectable. 
y = SST blood collected for neutralizing antibody will also cover specimen needs for FcR-mediated effector functions; no separate blood draw is needed. 
z = PBMC blood collected for ICS will also cover specimen needs for phenotyping; no separate blood draw is needed. 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 141 of 153 
Appendix H 
Procedures at CRS—Schedule 1: Monitoring ATI 
Visit: 
011 
02 
03 
043 
05 
06 
07 
08 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Days on ATI: 
Screening 
ART  
Switch2 
ATI 
qualification 
D0 
D7 
D14 
D21 
D28 
D35 
D42 
D49 
D56 
D70 
D84 
D98 
D112 
D126 
D140 
D154 
Weeks on ATI: 
W0 
W1 
W2 
W3 
W4 
W5 
W6 
W7 
W8 
W10 
W12 
W14 
W16 
W18 
W20 
W22 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening consent (if used) 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol consent 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of understanding 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
✓ 
 
 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam4 
 
✓ 
✓ 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Concomitant medications4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Intercurrent illness/adverse experience4 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
ART re-initiation assessment4 
 
 
 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Contraception status assessment5 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Decision aid 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decision-making assessment 
 
✓ 
 
✓ 
 
 
 
 
 
 
 
 
 
✓ 
 
 
 
 
 
Psychosocial assessment 
 
✓ 
 
✓ 
 
 
 
 
 
 
 
 
 
✓ 
 
 
 
 
 
Social impact assessment4 
 
 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Social impact assessment questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
✓ 
 
 
 
 
 
QuantiFERON tuberculosis test 6 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm eligibility 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specimen collection7 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
1 Screening may occur over the course of several contacts/visits up to and including the day of enrollment as defined in Section 6.1.2.  
2 For participants undergoing switch from NNRTI-based to protease- or integrase-based ART regimen. Participants undergoing an “ART switch” will be considered enrolled on first day of the new 
ART medication. The "ART switch" phase will not be performed for participants not on NNRTIs. For procedure timing during the “ART switch,” see Section 6.1.3 and HVTN 805/HPTN 093 SSP. 
3 Enrollment visit for participants who do not undergo ART switch. 
4 Procedure to be performed at interim visits held to draw confirmatory viral load samples or confirmatory samples for CD4+ T cell counts (see Sections 3.3.1, 3.3.2, and 3.3.3). 
5 Contraception status assessment is required only for participants who can become pregnant (does not include those persons not of reproductive potential due to having undergone hysterectomy or 
bilateral oophorectomy [verified by medical records]). 
6 If QuantiFERON TB testing cannot be performed, a tuberculin skin test (TST) should be conducted. Additional risk/clinical/diagnostic assessment may be performed at the discretion of the clinician 
to meet institutional standard of care for evaluation and treatment of latent TB.  
7 For specimen collection requirements, see Appendix E. 
8 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 27, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 142 of 153 
9 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 27, continuing up 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
10 At an early termination visit for a withdrawn or terminated participant, CRS staff should consider performing procedures specified for Extended follow-up visit Type A (see Section 6.5 and HVTN 
805/HPTN 093 SSP for details). 
 
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 143 of 153 
Procedures at CRS—Schedule 1: Monitoring ATI (continued) 
Visit: 
20 
21 
22 
23 
24 
25 
26 
27 
Visit 
Type 
A8, 10 
Visit 
Type 
B9 
Days on ATI: 
D168 
D196 
D224 
D252 
D280 
D308 
D336 
D364 
Weeks on ATI: 
W24 
W28 
W32 
W36 
W40 
W44 
W48 
W52 
Study procedures 
 
 
 
 
 
 
 
 
 
 
Screening consent (if used) 
 
 
 
 
 
 
 
 
 
 
Protocol consent 
 
 
 
 
 
 
 
 
 
 
Assessment of understanding 
 
 
 
 
 
 
 
 
 
 
Medical history 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Concomitant medications4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Intercurrent illness/adverse experience4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
ART re-initiation assessment4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction 
counseling4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Contraception status assessment5 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Decision aid 
 
 
 
 
 
 
 
 
 
 
Decision-making assessment 
✓ 
 
 
✓ 
 
 
 
✓ 
 
✓ 
Psychosocial assessment 
✓ 
 
 
✓ 
 
 
 
✓ 
 
✓ 
Social impact assessment4 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Social impact assessment questionnaire 
✓ 
 
 
✓ 
 
 
 
✓ 
 
✓ 
QuantiFERON tuberculosis test 6 
 
 
 
 
 
 
 
 
 
 
Confirm eligibility 
 
 
 
 
 
 
 
 
 
 
Specimen collection7 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
1 Screening may occur over the course of several contacts/visits up to and including the day of enrollment as defined in Section 6.1.2.  
2 For participants undergoing switch from NNRTI-based to protease- or integrase-based ART regimen. Participants undergoing an “ART switch” will be considered enrolled on first day of the new 
ART medication. The "ART switch" phase will not be performed for participants not on NNRTIs. For procedure timing during the “ART switch,” see Section 6.1.3 and HVTN 805/HPTN 093 SSP. 
3 Enrollment visit for participants who do not undergo ART switch. 
4 Procedure to be performed at interim visits held to draw confirmatory viral load samples or confirmatory samples for CD4+ T cell counts (see Sections 3.3.1, 3.3.2, and 3.3.3). 
5 Contraception status assessment is required only for participants who can become pregnant (does not include those persons not of reproductive potential due to having undergone hysterectomy or 
bilateral oophorectomy [verified by medical records]). 
6 If QuantiFERON TB testing cannot be performed (see Appendix E), TST should be conducted. Additional risk/clinical/diagnostic assessment may be performed at the discretion of the clinician to 
meet institutional standard of care for treatment of latent TB. 
7 For specimen collection requirements, see Appendix E. 
8 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 27, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 144 of 153 
9 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 27, continuing up 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
10 At an early termination visit for a withdrawn or terminated participant, CRS staff should consider performing procedures specified for Extended follow-up visit Type A (see Section 6.5 and HVTN 
805/HPTN 093 SSP for details). 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 145 of 153 
Appendix I 
Procedures at CRS—Schedule 2: Monitoring ATI with viremia 
Visit: 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
Days on ATI with viremia: 
D0 
D7 
D14 
D21 
D28 
D35 
D42 
D49 
D56 
D70 
D84 
D98 
D112 
D126 
D140 
D154 
Weeks on ATI with viremia: 
W0 
W1 
W2 
W3 
W4 
W5 
W6 
W7 
W8 
W10 
W12 
W14 
W16 
W18 
W20 
W22 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam1 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Concomitant medications1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Intercurrent illness/adverse experience1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
ART re-initiation assessment1 
 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Contraception status assessment2 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Decision-making assessment 
✓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychosocial assessment 
✓ 
 
 
 
 
 
 
 
 
 
✓ 
 
 
 
 
 
Social impact assessment1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Social impact assessment questionnaire 
 
 
 
 
 
 
 
 
 
 
✓ 
 
 
 
 
 
Specimen collection3 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
1 Procedure to be performed at interim visits held to draw confirmatory viral load samples or confirmatory samples for CD4+ T cell counts (see Sections 3.3.1, 3.3.2, and 3.3.3). 
2 Contraception status assessment is required only for participants who can become pregnant (does not include those persons not of reproductive potential due to having undergone hysterectomy or 
bilateral oophorectomy [verified by medical records]). 
3 For specimen collection requirements, see Appendix F. 
4 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 66, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
5 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 66, continuing up 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
10 At an early termination visit for a withdrawn or terminated participant, CRS staff should consider performing procedures specified for Extended follow-up visit Type A (see Section 6.5 and HVTN 
805/HPTN 093 SSP for details). 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 146 of 153 
Procedures at CRS—Schedule 2: Monitoring ATI with viremia (continued) 
Visit: 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
Visit 
Type 
A4, 6 
Visit 
Type 
B5 
Days on ATI with viremia: 
D168 
D182 
D196 
D210 
D224 
D238 
D252 
D280 
D308 
D336 
D364 
Weeks on ATI with viremia: 
W24 
W26 
W28 
W30 
W32 
W34 
W36 
W40 
W44 
W48 
W52 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Concomitant medications1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Intercurrent illness/adverse experience1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
ART re-initiation assessment1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction 
counseling1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Contraception status assessment2 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Decision-making assessment 
✓ 
 
 
 
 
 
✓ 
 
 
 
✓ 
 
✓ 
Psychosocial assessment 
✓ 
 
 
 
 
 
✓ 
 
 
 
✓ 
 
✓ 
Social impact assessment1 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Social impact assessment questionnaire 
✓ 
 
 
 
 
 
✓ 
 
 
 
✓ 
 
✓ 
Specimen collection3 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
1 Procedure to be performed at interim visits held to draw confirmatory viral load samples or confirmatory samples for CD4+ T cell counts (see Sections 3.3.1, 3.3.2, and 3.3.3). 
2 Contraception status assessment is required only for participants who can become pregnant (does not include those persons not of reproductive potential due to having undergone hysterectomy or 
bilateral oophorectomy [verified by medical records]). 
3 For specimen collection requirements, see Appendix F. 
4 Extended follow-up visit type A will occur every 6 months starting with 3 months after visit 66, continuing up to 3 years of this schedule. This follow-up visit may be performed for participants who 
have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
5 Extended follow-up visit type B will occur every 6 months starting with 6 months after visit 66, continuing up 3 years of this schedule and then every 3 months thereafter. This follow-up visit may 
be performed for participants who have not met ART re-initiation criteria (see Protocol Section 3.3 and HVTN 805/HPTN 093 SSP for details). 
6 At an early termination visit for a withdrawn or terminated participant, CRS staff should consider performing procedures specified for Extended follow-up visit Type A (see Section 6.5 and HVTN 
805/HPTN 093 SSP for details). 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 147 of 153 
Appendix J 
Procedures at CRS—Schedule 3: Follow-up on ART 
Visit: 
801 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
914 
92 
Days after ART re-initiation: 
D0 
D14 
D28 
D42 
D56 
D70 
D84 
D112 
D140 
D168 
D196 
D280 
D364 
Weeks after ART re-initiation: 
W0 
W2 
W4 
W6 
W8 
W10 
W12 
W16 
W20 
W24 
W28 
W40 
W52 
Study procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete physical exam 
 
 
 
 
 
 
 
 
 
 
 
 
✓ 
Targeted physical exam 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
 
Concomitant medications 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Intercurrent illness/adverse experience 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Transmission risk reduction counseling 
✓ 
✓ 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
Contraception status assessment2 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Decision-making assessment 
✓ 
 
 
 
 
 
✓ 
 
 
✓ 
 
 
✓ 
Psychosocial assessment 
✓ 
 
 
 
 
 
✓ 
 
 
✓ 
 
 
✓ 
Social impact assessment 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
Social impact assessment questionnaire 
 
 
 
 
 
 
✓ 
 
 
✓ 
 
 
✓ 
Specimen collection3 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
1 ART re-initiation visit. 
2 Contraception status assessment is required only for participants who can become pregnant (does not include those persons not of reproductive potential due to having undergone hysterectomy or 
bilateral oophorectomy [verified by medical records]). Contraception status assessment is not required if participant VL has returned to undetectable. 
3 For specimen collection requirements, see Appendix G. 
4 At an early termination visit for a withdrawn or terminated participant, CRS staff should consider performing procedures specified for Visit 92 (see Section 6.5 and HVTN 805/HPTN 093 SSP for 
more details).  
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 148 of 153 
Appendix K 
Visit Windows  
 
Visit Windows – Schedule 1: Monitoring ATI 
 
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window  
Lower 
Target Day 
Target Day4 
relative to 
initiation of ATI 
Upper 
Target Day 
Upper 
Allowable 
Window  
01.0¹ 
Screening 
[for participants not on 
NNRTIs] 
-56 
 
- 
- 
- 
- 
Participants on NNRTIs 
[ART Switch 
Participants] 
Screening²  
 
-140 
- 
- 
- 
- 
02.0 
ART Switch² 
 
-84 
 
-42 
 
-29 
03.0 
ATI 
Qualification², 3  
-28 
 
-14 
 
0 
04.0  
Week 0 
Initiation of ATI 
- 
- 
0 
- 
- 
05.0  
Week 1 
-3 
-2 
7 
+2 
+3 
06.0 
Week 2 
-3 
-2 
14 
+2 
+3 
07.0 
Week 3 
-3 
-2 
21 
+2 
+3 
08.0 
Week 4 
-3 
-2 
28 
+2 
+3 
09.0 
Week 5 
-3 
-2 
35 
+2 
+3 
10.0 
Week 6 
-3 
-2 
42 
+2 
+3 
11.0 
Week 7 
-3 
-2 
49 
+2 
+3 
12.0 
Week 8 
-3 
-2 
56 
+2 
+7 
13.0 
Week 10 
-6 
-4 
70 
+4 
+7 
14.0 
Week 12  
-6 
-4 
84 
+4 
+7 
15.0 
Week 14  
-6 
-4 
98 
+4 
+7 
16.0 
Week 16  
-6 
-4 
112 
+4 
+7 
17.0 
Week 18 
-6 
-4 
126 
+4 
+7 
18.0 
Week 20  
-6 
-4 
140 
+4 
+7 
19.0 
Week 22 
-6 
-4 
154 
+4 
+7 
20.0 
Week 24 
-6 
-4 
168 
+4 
+14 
21.0 
Week 28 
-13 
-8 
196 
+8 
+14 
22.0 
Week 32 
-13 
-8 
224 
+8 
+14 
23.0 
Week 36 
-13 
-8 
252 
+8 
+14 
24.0 
Week 40 
-13 
-8 
280 
+8 
+14 
25.0 
Week 44 
-13 
-8 
308 
+8 
+14 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 149 of 153 
26.0 
Week 48 
-13 
-8 
336 
+8 
+14 
27.0 
Week 52 
-13 
-8 
364 
+8 
+14 
Visit Type 
A⁵ 
Follow-up (Schedule 1: 
Visit Type A) 
-42 
-28 
Visit Type A will 
occur every 6 
months starting 
with 3 months 
after visit 27 
continuing up to 
3 years of this 
schedule 
+28 
+42 
Visit Type 
B⁵ 
Follow-up (Schedule 1: 
Visit Type B) 
-42 
-28 
Visit Type B will 
occur every 6 
months starting 
with 6 months 
after visit 27 
continuing up to 
3 years of this 
schedule, and 
then every 3 
months 
thereafter 
+28 
+42  
¹Screening may occur over the course of several contacts/visits up to and including the day of enrollment, as defined in 
Section 6.1.2. All screening assessments must be done within 56 days of enrollment; for participants on NNRTIs, all 
screening assessments must be done within 56 days of the ART Switch.  
²The ART switch phase will only be performed for participants on NNRTIs. 
3Participants must be on the new ART regimen for at least 4 weeks prior to the ATI qualification visit, see Section 6.1.3. The 
ATI Qualification visit must be at least 28 days from the ART Switch and, if needed, VL interim visits may continue until 
approximately 12 weeks or until viral suppression has been achieved.  
4Viral load sample collection should occur as close to the target day as possible and must occur at least 2 days apart (this 
applies to both scheduled visits and interim visits). See Visit Scheduling and Coding SSP for further details. 
⁵Type A and Type B visits must be at least 8 weeks apart.  
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 150 of 153 
Visit Windows – Schedule 2: Monitoring ATI with viremia 
 
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window  
Lower 
Target Day 
Target Day1  
Upper 
Target Day 
Upper 
Allowable 
Window  
40.0 
First visit after 
confirmed ATI 
VL ≥ 200 copies/mL  
- 
- 
0 
- 
- 
41.0 
Week 1 
-3 
-2 
7 
+2 
+3 
42.0 
Week 2 
-3 
-2 
14 
+2 
+3 
43.0 
Week 3 
-3 
-2 
21 
+2 
+3 
44.0 
Week 4 
-3 
-2 
28 
+2 
+3 
45.0 
Week 5 
-3 
-2 
35 
+2 
+3 
46.0 
Week 6 
-3 
-2 
42 
+2 
+3 
47.0 
Week 7 
-3 
-2 
49 
+2 
+3 
48.0 
Week 8 
-3 
-2 
56 
+2 
+7 
49.0 
Week 10 
-6 
-4 
70 
+4 
+7 
50.0 
Week 12 
-6 
-4 
84 
+4 
+7 
51.0 
Week 14 
-6 
-4 
98 
+4 
+7 
52.0 
Week 16 
-6 
-4 
112 
+4 
+7 
53.0 
Week 18 
-6 
-4 
126 
+4 
+7 
54.0 
Week 20 
-6 
-4 
140 
+4 
+7 
55.0 
Week 22 
-6 
-4 
154 
+4 
+7 
56.0 
Week 24 
-6 
-4 
168 
+4 
+7 
57.0 
Week 26 
-6 
-4 
182 
+4 
+7 
58.0 
Week 28 
-6 
-4 
196 
+4 
+7 
59.0 
Week 30 
-6 
-4 
210 
+4 
+7 
60.0 
Week 32  
-6 
-4 
224 
+4 
+7 
61.0 
Week 34 
-6 
-4 
238 
+4 
+7 
62.0 
Week 36  
-6 
-4 
252 
+8 
+14 
63.0 
Week 40  
-13 
-8 
280 
+8 
+14 
64.0 
Week 44 
-13 
-8 
308 
+8 
+14 
65.0 
Week 48  
-13 
-8 
336 
+8 
+14 
66.0 
Week 52 
 
-13 
-8 
364 
+8 
+14 
Visit Type 
A2 
Follow-up (Schedule 2: 
Visit Type A) 
-42 
-28 
Visit Type A will 
occur every 6 
months starting 
with 3 months 
after visit 66 
continuing up to 
+28 
+42 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 151 of 153 
3 years of this 
schedule 
Visit Type 
B2 
Follow-up (Schedule 2: 
Visit Type B) 
-42 
-28 
Visit Type B will 
occur every 6 
months starting 
with 6 months 
after visit 66 
continuing up to 
3 years of this 
schedule, and 
then every 3 
months 
thereafter 
+28 
+42 
1Viral load sample collection should occur as close to the target day as possible and must occur at least 2 days apart (this 
applies to both scheduled visits and interim visits). See Visit Scheduling and Coding SSP for further details. 
2Type A and Type B visits must be at least 8 weeks apart. 
 
 
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 152 of 153 
Visit Windows – Schedule 3: Follow-up on ART 
  
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window  
Lower 
Target Day 
Target Day1 
relative to ART 
re-initiation 
Upper 
Target Day 
Upper 
Allowable 
Window  
80.0 
ART Re-initiation  
- 
- 
0 
- 
- 
81.0 
Week 2 
-6 
-4 
14 
+4 
+7 
82.0 
Week 4 
-6 
-4 
28 
+4 
+7 
83.0 
Week 6 
-6 
-4 
42 
+4 
+7 
84.0 
Week 8 
-6 
-4 
56 
+4 
+7 
85.0 
Week 10 
-6 
-4 
70 
+4 
+7 
86.0 
Week 12 
-6 
-4 
84 
+4 
+14 
87.0 
Week 16 
-13 
-8 
112 
+8 
+14 
88.0 
Week 20 
-13 
-8 
140 
+8 
+14 
89.0 
Week 24 
-13 
-8 
168 
+8 
+14 
90.0¹ 
Week 28 
-13 
-8 
196 
+8 
+14 
91.0¹ 
Week 40 
-42 
-14 
280 
+14 
+42 
92.0¹ 
Week 52 
-28 
-14 
364 
+14 
+42 
¹There must be at least 8 weeks between visits 90.0 and 91.0, and visits 91.0 and 92.0.  
 

HVTN 805/HPTN 093 Version 1.0 / April 27, 2020 
HVTN805_HPTN093_v1.0_FINAL.docx / Page 153 of 153 
Appendix L 
Protocol Signature Page 
 
Antiretroviral analytical treatment interruption (ATI) to assess immunologic and 
virologic responses in participants who initiated ART in early HIV infection after 
having received VRC01 or placebo in HVTN 703/HPTN 081 
I will conduct the study in accordance with the provisions of this protocol and all 
applicable protocol-related documents. I agree to conduct this study in compliance 
with United States (U.S.) Health and Human Service regulations (45 CFR 46); 
applicable U.S. Food and Drug Administration regulations; standards of the 
International Conference on Harmonization Guideline for Good Clinical Practice 
(E6); Institutional Review Board/Ethics Committee determinations; all applicable in-
country, state, and local laws and regulations; and other applicable requirements (eg, 
U.S. National Institutes of Health, Division of AIDS) and institutional policies 
 
 
 
 
 
 
 
 
 
Investigator of Record Name (print) 
 
Investigator of Record Signature 
 
Date 
 
 
DAIDS Protocol Number: HVTN 805/HPTN 093 
DAIDS Protocol Version: Version 1.0 
Protocol Date: April 27, 2020